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I. Abstract 
For the development of the next generation of polymeric nanomedicines, it is crucial to gain a 
fundamental understanding of their behaviour and interactions with and within biological systems. 
Moving beyond in vitro models, into in vivo models, earlier in the development process will greatly 
aid in the advancement of the next generation of nanomedicines. By moving to whole animal 
models, our understanding of these systems progresses beyond cell targeting and uptake, to 
developing mechanisms for how these materials will distribute through tissues and their 
pharmacokinetic profile. This information is important for truly assessing the performance of a 
nanomedicine. One possible set of tools for obtaining this information is molecular imaging. 
 Molecular imaging is a field of research dedicated to the real time monitoring of biological 
processes in vivo, without the use of invasive techniques such as biopsies and dissections. 
Molecular imaging has been used extensively to follow the in vivo behaviour of a labelled material. 
This is advantageous because the performance of a single material in one subject can be 
monitored and mapped against the progression of disease. It can help to provide the 
pharmacokinetic information necessary for preclinical development of nanomedicines. 
Nanomedicines can be designed to combine molecular imaging with targeting molecules and 
therapeutic agents to create a theranostic, which can be used for simultaneous imaging and 
treatment of disease. 
 This thesis aims to synthesise novel multimodal molecular imaging agents based on a 
hyperbranched polymer architecture, and to gain a deeper understanding of how these materials 
behave in vivo. To achieve this, biocompatible hyperbranched polymers with defined architectures 
were synthesised using RAFT polymerisation techniques. These materials were extensively 
characterised using a wide range of spectroscopic techniques to thoroughly understand their 
physical and chemical properties. A variety of synthetic strategies were investigated for 
functionalising both the α- and ω-chain ends of these polymers with multiple imaging ligands to 
form multimodal imaging agents. Far-red and near-infrared fluorophores provided for 
fluorescence imaging and radiometal chelators allowed for positron emission tomography (PET) 
imaging. 
 These hyperbranched polymer systems were first evaluated as molecular imaging agents in 
C57 BL/6J mice using whole animal fluorescence and PET-CT imaging. It was shown that the rate of 
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excretion was dependent on the size and level of branching of the hyperbranched polymer cores. 
The larger more highly branched material showed extended circulation times, making it suitable 
for use as a passive targeting agent for cancer. It was demonstrated in a murine model for 
melanoma, that the material showed significant uptake within the tumour after 24 hours and that 
the material was not cleared from the tissue within 72 hours.  
 To gain a deeper understanding of the behaviour of these materials in vivo, PET imaging was 
combined with gadolinium contrast enhanced MRI, in order to gain both molecular and 
physiological information. Using this technique, we were able to show that while a folic acid 
targeted hyperbranched polymer did accumulate in the tumour tissue, its distribution was 
concentrated in highly vascularised areas of the tumour. This is the first time that this 
phenomenon has been demonstrated at a macroscopic level, in a living animal. This has important 
implications for using these materials as theranostics, because heterogeneous distribution of the 
nanomaterial, and therefore delivery of a therapeutic, can lead to ineffective treatment of the 
cancer and thus lead to tumour recurrence. 
 In further development of these imaging agents into theranostics, targeting of the 
hyperbranched polymers by conjugating single chain fragment antibodies (scFv) was explored. 
Two potential routes to improve efficiency of conjugation were investigated. Both approaches 
used novel bifunctional oligoethylene glycol (OEG) linkers to introduce the required chemical 
functionality to either the hyperbranched polymer or scFv. The first approach utilised a 
heterobifunctional OEG which was synthesised with a pentafluorophenol ester at one end for 
coupling with amines and an ω-azide group at the other end to allow for the copper catalysed 
Huigsen 1,3-dipolar cycloaddition reactions. This linker was first attached to the scFv via activated 
ester chemistry, to provide the necessary azide functionality for coupling of the scFv to the alkyne 
end groups of the hyperbranched polymer. The second route used an enzymatic cross coupling 
approach using the sortase enzyme. In order to achieve this, a triglycine functionalised OEG ligand 
was synthesised and attached to the hyperbranched polymer. The triglycine could then be used as 
a substrate for enzymatic cross coupling to scFvs bioengineered to possess the required 
recognition sequence (LPETG). Despite both OEG linkers being demonstrated to be able to 
undergo conjugation to both the hyperbranched polymers and scFvs independently, further 
optimisation is required to achieve conjugation of the two macromolecules. 
iii 
 
 In summary, this thesis has explored aspects of design, synthesis and characterisation of 
hyperbranched polymers as novel multimodal molecular imaging agents. A range of synthetic 
strategies have been combined for the production of hyperbranched polymers with controlled 
architecture, and for the incorporation of imaging moieties and targeting molecules. The imaging 
agents synthesised in this thesis have been used to gain significant insight into the in vivo 
biological behaviour of these hyperbranched polymer materials. All of this new knowledge will 
greatly progress the development of hyperbranched polymers as a class of materials into working 
theranostics. 
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Chapter 1. Introduction and Literature Review 
1.1. Prologue 
Nanomedicine is the application of nanotechnology approaches to the design and synthesis of 
materials for use in the monitoring, diagnosis, prevention and treatment of disease.1 The 
development and translation of a new nanomedicine is a lengthy process, which requires a 
multidisciplinary approach to succeed. This process can be divided into four major areas that need 
to be understood in order to develop a clinically relevant nanomedicine: material design, 
molecular interactions, therapeutic effects and preclinical properties (Figure 1-1). Each of these 
areas is a collection of fundamental scientific questions, which require research and 
understanding. It is not possible to address all of these areas in a single PhD. This thesis will focus 
on understanding the interplay between material design and the preclinical properties of 
nanomaterials, specifically hyperbranched polymers. Hyperbranched polymers have a unique 
combination of physical and chemical properties (reviewed in section 1.3) that make them 
promising candidates for novel nanotherapeutics, but further research is required to fully 
understand their biological behaviour. Molecular imaging is a commonly utilised tool to achieve 
this, because it allows direct visualisation of a labelled nanomaterial in a cell, animal model or 
patient. It can also be used to visualise the interaction between a nanomaterial and its biological 
environment (reviewed in section 1.2). In the area of material design this thesis aims to investigate 
how hyperbranched polymers with well defined physical properties can be synthesised, and how 
these properties can be exploited to yield highly effective imaging agents (Chapter 3). It also aims 
to develop synthetic strategies for the conjugation of these materials to single chain variable (scFv) 
fragment antibodies, to yield targeted imaging agents (Chapter 5). In assessing the preclinical 
properties of the hyperbranched polymers molecular imaging techniques will be used to examine 
their biological behaviour (such as their biodistribution and excretion), and to examine how this 
behaviour is affected by the physicochemical properties of these materials (Chapters 3 and 4). This 
research will ultimately provide insights into how these hyperbranched polymer materials can be 
developed into theranostics, which combine aspects of targeting, imaging and therapy into one 
construct. 
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Figure 1-1. The development process for a new nanomedicine divided up into four key areas of understanding and 
demonstrative research goals associated with each area. 
1.2. Molecular imaging 
Molecular imaging is dedicated to the visual representation, characterisation and quantification of 
biological processes at the cellular and sub-cellular levels within whole, living organisms.2 
Molecular imaging differs from traditional medical imaging techniques, in that it aims to identify 
and monitor specific molecular events associated with the pathology of disease. It can also be 
used to determine both spatial and temporal biodistribution of the molecule within a whole 
animal. On the other hand, traditional medical imaging relies on non-specific, macroscopic 
changes to anatomy to identify diseased tissues.3 This field of research has grown from its infancy 
over the past two decades, into a widely utilised tool in both clinical therapies and pre-clinical 
experimentation. In 2003, Massoud and Gambhir laid out seven goals for molecular imaging in 
aiding preclinical development of nanomedicine and biomedical research.2 (1) Development of 
noninvasive in vivo imaging methods for specific cellular and molecular processes; (2) monitoring 
multiple molecular events simultaneously; (3) following the trafficking and targeting of cells; (4) to 
aid in optimisation of drug and gene therapy; (5) to image the effects of drug and gene therapy; (6) 
to assess disease progression at a molecular pathological level. The final goal is to achieve all of 
these in a rapid, reproducible and quantitative manner, in which all areas of molecular imaging are 
Chemical synthesis
Material properties
Chemical characterisation
Safety
Biocompatibility
Clearance mechanisms
Targeting
Cellular entry
Cellular trafficking
Interaction with therapeutic target
Pharmacokinetics
Biodistribution
Delivery of drug payload
Improved tissue repair
Disease regression
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continually improving. Since then, there has been significant progress towards achieving these 
goals, particularly with regards to enhancing the wealth of data that can be mined from preclinical 
experiments. 
 Molecular imaging has contributed significantly to the drug discovery process, because it 
allows researchers to study the effects of a new compound in an animal model over time, mapped 
against the progression of disease. It can be used to rule out compounds that have adverse 
biodistribution and pharmacokinetic profiles, prior to human clinical trials. In this way, it has been 
useful in both accelerating and refining lead compound development.4, 5 Another significant 
advantage of molecular imaging is the ability to monitor a probe/biomarker in one animal, over 
time, using a variety of techniques. Consecutive experiments with one technique can be used to 
follow the temporal behaviour of one type of molecule, or complementary techniques can be used 
to simultaneously report on different molecules of interest, associated cellular processes or 
changes in physiology of tissues. By not having to cull subjects at each time point of interest, this 
leads to a more efficient (and therefore ethical) use of experimental animals.6 This also makes 
these approaches clinically relevant, where it may be necessary to follow one patient over the 
progression of their disease or the course of their treatment. 
 There are a wide range of molecular imaging techniques that have witnessed development 
in both the clinical and pre-clinical sphere. Table 1-1 summarises and compares some of the most 
widely utilised molecular imaging techniques. Each of these techniques will be introduced below, 
with a brief discussion of the most relevant techniques for in vivo imaging. This literature review 
does not aim to be exhaustive, but instead to highlight the strengths and limitations of these 
techniques, and some of the experimental considerations that must be made in order to 
effectively utilise them.  
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Table 1-1. Overview and comparison of commonly available molecular imaging techniques (Information adapted from  
 MRI PET SPECT Fluorescence Bioluminescence/ 
Chemiluminescence 
X-ray and X-
ray-CT 
Ultrasound Photoacoustics 
Electromagnetic 
Radiation used in 
technique 
Radiowaves High energy γ-rays Low energy γ-
rays 
UV/Visible to 
near infrared 
light 
Visible light X-rays High 
frequency 
sound waves 
Excitation: near-
infrared light 
Emission: 
soundwaves 
Resolution 25 – 100 μm  1 – 2 mm 1 – 2 mm  2 – 3 mm 2 – 3 mm 50 – 100 μm  50 – 500 μm  100 – 500 μm 
Sensitivity 10
−3
–10
−5
 M 10
−11
–10
−12
 M 10
−10
–10
−11
 M 10
−9
–10
−12
  M 10
−15
–10
−17
  M 10
-3
 M 10
-12
 M with 
microbubbles 
10
-9
-10
-12
 M 
Tissue penetration 
depth 
Isotropic Isotropic Isotropic 1 cm 1 – 2 cm Isotropic mm-cm 
(frequency 
dependent) 
mm-cm (lazer 
and US 
frequency 
dependent) 
Molecular  imaging 
agents used 
Paramagnetic 
metals (e.g., Gd, 
Eu), iron oxide 
nanoparticles, 
19
F. 
MRS endogenous 
biomolecules (e.g. 
amino acids and 
metabolites) 
Radioactive small 
molecules (e.g. H2
15
O) 
radiopharmaceuticals (e.g. 
11
C-L-methyl-methionine), 
radiolabeled: peptides, 
antibodies, nanomaterials. 
Radiolabelled 
complexes (e.g. 
99m
 Tc-DTPA), 
radiolabeled 
peptides, 
antibodies, 
nanomaterials. 
Fluorescent 
proteins, organic 
fluorophores, 
quantum dots, 
fluorescent 
polymers. 
Bioluminescent enzymes 
(e.g. Luciferase), 
chemiluminescent 
molecules (e.g. luminol), 
radiopharmaceuticals 
Barium salts, 
iodine salts, 
iodinated 
nanoparticles, 
gold 
nanoparticles. 
Microbubbles, 
nanobubbles.  
Organic 
fluorophores, 
quantum dots, 
haemoglobin, 
lipids, nanotubes. 
Multiplexed signals Yes No Yes Yes Yes No No Yes 
Amount of probe 
required 
Micrograms - 
milligrams 
Nanograms Nanograms Micrograms - 
milligrams 
Micrograms - 
milligrams 
Milligrams Micrograms - 
milligrams 
Micrograms 
Cost of 
instrumentation 
(millions AUD) 
0.8-1.4 0.8-1.2 0.8-1.2 0.1-0.6 0.1-0.6 0.3-0.6 0.3-0.5 0.5-0.9 
Clinical relevance Commonly used Commonly used Commonly used Limited 
applications 
No clinical applications Commonly 
used 
Commonly 
used 
Early clinical 
development 
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1.2.1. Nuclear tomographic imaging 
Nuclear tomographic imaging encompasses two major imaging techniques; Positron Emission 
Tomography (PET) and Single Photon Emission Computer Tomography (SPECT). Both of these 
techniques allow for detection of a radionuclide labelled pharmaceutical or material, but differ in 
the underlying physical process of detection. These differences in detection give rise to significant 
differences in the capabilities of both techniques. 
Positron Emission Tomography (PET) 
PET imaging utilises radioisotopes that decay via positron emission (β+ decay). These isotopes are 
unstable due to an excess of protons in their nuclei, which is stabilised by transforming a proton 
into a neutron, positron and neutrino. The positron is ejected from the nucleus and interacts with 
the electron clouds of surrounding atoms, until it has lost almost all of its kinetic energy, collides 
with an electron and annihilates. Conservation of energy and momentum result in the energy of 
this annihilation event to be released as two photons, each with energy of 511 keV, travelling in 
opposite directions (~180°). These two photons are highly energetic, and they fall within the 
gamma radiation (γ-rays) region of the electromagnetic spectrum. This high energy radiation 
(compared to other forms of electromagnetic radiation typically utilised in molecular imaging) 
gives these photons a high chance of leaving the body and being detected without being absorbed 
by biological tissue. This makes PET an isotropic technique, with no limitation due to tissue 
depth.7, 8 
PET detectors are closed rings of scintillation detectors, which detect the emitted photons 
and convert them into an electrical signal. The PET ring detects the coincident pair of gamma rays 
by recording temporal pairs (photons that arrive within nanoseconds of each other) and rejecting 
all other events. This pair generates a line of response, which can be used to determine the origin 
of the photons. The electrical signal of the scintillator is converted into a sinogram that can be 
reconstructed into tomographic images after application of dead time, scatter and attenuation 
corrections, detector normalisation and subtraction of random coincidences. The isotropic nature 
of this technique and the application of these corrections allow PET to produce quantitative data, 
which is one of the major strengths of PET.8 
 PET radioisotopes are usually generated with a cyclotron (Summary Table 1-2), though there 
are exceptions, which are produced from a generator source (e.g. 68Ga).  There is a wide range of 
PET radioisotopes available, with varying radioactive half-lives. The commonly used clinical 
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isotopes are short lived (minutes: 11C, 18F), but there are longer lived isotopes (hours-days: 64Cu, 
89Zr), which are being developed for preclinical applications.9-11 The small size of many PET 
isotopes, allows for the direct labelling of small molecule targets, generally without perturbing the 
biological behaviour of the labelled target.12 This makes PET particularly well suited to the 
assessment of small molecule pharmaceuticals and metabolites. The limiting factor for many 
isotopes is their relatively short radioactive half-lives (e.g. 18F: 110 min, 15O: 20 min), which means 
that imaging must occur in close proximity to the source of the isotope (generally a cyclotron).  
Table 1-2. Overview of the commonly used radioisotopes for PET and SPECT imaging 
Isotope Radioactive half-life 
(t1/2) 
Production 
source 
Energy of emitted photons 
PET Isotopes    
Carbon-11 20.3 minutes Cyclotron 
Pair of 511 keV photons from positron 
annihilation 
Fluorine-18 109 minutes Cyclotron 
Gallium-68 68 minutes Generator 
Copper-64 12.7 hours Cyclotron 
Iodine-124 4.2 days Cyclotron 
Zirconium-89 78.41 hours Cyclotron 
SPECT Isotopes    
Technetium-
99m 
6 hours Generator 140.5 
Indium-111 2.8 days Cyclotron 171.3, 245.4 
Iodine-123 13.2 hours Cyclotron 159.0 
Thallium-201 12.2 days Cyclotron 135, 167 
Lutetium-177 6.7 days Reactor 113, 120 
 
 Single Photon Emission Computed Tomography (SPECT) 
SPECT imaging utilises radioisotopes that undergo gamma decay, which directly emit a gamma 
photon at a defined energy level. The energy of this emitted photon will vary, depending on the 
isotope utilised (Table 1-2). SPECT uses a gamma camera, which is rotated around the patient (as 
opposed to a scintillator ring in PET). Due to the nature of the decay of the nuclides in this 
technique, the detection events do not contain enough information for the direct determination 
of the origin of the photon. Instead a collimator is used, which excludes all diagonally incident 
photons. By only using photons travelling perpendicular to the detector, a line of response can be 
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generated. Unfortunately collimation leads to rejection of most of the photons being ejected from 
the nuclide, thus decreasing the sensitivity of SPECT, compared to PET. This has a secondary effect 
on the temporal resolution of SPECT, as longer acquisition frames are required compared to PET. 
Multi-pinhole SPECT is one technique that is being developed to enhance the resolution of SPECT, 
without sacrificing sensitivity.13 
 SPECT isotopes are generally longer lived and larger than those commonly used for PET. 
They can be produced in a cyclotron (eg. 123I, 111In) or from a generator (eg. 99mTc). The longer half-
life allows for imaging to be performed further away from the source of the isotope. The downside 
of many of the SPECT isotopes are their large size and/or metallic nature, which relies on 
conjugation via chelators. This can impact the biological behaviour of the labelled molecule, 
particularly small molecule pharmaceuticals and metabolites. Therefore the large majority of 
clinically available SPECT pharmaceuticals do not provide specific biochemical information, but 
there have been recent developments in using SPECT isotopes for labelling macromolecules such 
as peptides and antibodies.14, 15 
 PET and SPECT as tools for molecular imaging 
The most critical advantage of both PET and SPECT are their much greater sensitivity compared to 
many other techniques (Table 1-1), being able to detect sub microgram level of imaging probe. 
Both modalities offer limited anatomical information though, and so are generally combined with 
CT or MRI for anatomical reference of detected signal. PET imaging allows for quantitation of the 
radioisotope (after attenuation correction), which makes it very useful for studying biodistribution 
and pharmacokinetics of labelled materials.16 SPECT data cannot be quantified, but due to each 
isotope producing its own individual γ-ray, it offers the possibility of multiplexing of different 
imaging targets simultaneously.17, 18 This is not possible using PET since all radioisotopes generate 
the same two 511 keV photons due to positron annihilation. There are some recent pre-clinical 
developments in attempting to multiplex PET radiopharmaceuticals via differences in their 
pharmacokinetics, and the radioactive half-lives of the isotopes, but these techniques require 
complex deconvolution algorithms and are not yet in clinical practice. 19-22  
 Another important point for consideration with nuclear imaging are the safety concerns 
arising from the use of ionising radiation. This factor is compounded when these techniques are 
combined with CT, which adds additional radiation burden to the subject (discussed below). This 
can limit the number of scans which can be performed on a single patient. To minimise this, the 
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minimum dose of radioisotope is used in experiments. Also by moving towards PET-MRI 
multimodal imaging, the dose from the CT component can be removed as MRI uses no ionising 
radiation. 
1.2.2. Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a very powerful imaging technique, being able to provide 
information about both anatomical structure and physiological state of tissues of interest. 
Magnetic resonance (MR) relies on atoms which have an uneven number of protons and neutrons, 
which leads to them possessing a specific angular momentum. These nuclei can also produce a 
small magnetic field and the ratio of these two parameters is termed the gyromagnetic ratio. This 
value is unique to all MR active nuclei and will affect their imaging properties.  
 During an MRI experiment, a large, external magnetic field is applied to the subject. The MR 
active nuclei will align either parallel or anti-parallel to this field. There is a small net difference in 
the number of nuclei that align parallel vs anti-parallel, as described by the Boltzmann distribution. 
(Equation 1-1) The difference between these two populations is dependent upon the temperature, 
and the energy difference between the two states (determined by the applied magnetic field). This 
small difference leads to a magnetic moment for each nuclei, and the average across all nuclei in a 
voxel is the net magnetisation vector (M0), which aligns parallel to the external magnetic field. This 
signal is very small (order of µTesla), but is detectable.23, 24 The intensity of the MR signal is 
dependent on: (1) polarisation (applied field strength), (2) gyromagnetic ratio of nuclei of interest, 
and (3) concentration of nuclei of interest (including natural abundance of MR active isotope, e.g. 
1% carbon exists naturally as MR active 13C). These factors lead to weak signal and poor sensitivity 
for MRI imaging in comparison to nuclear and optical techniques. (Table 1-1) 
Equation 1-1. Ratio of protons in the spin up and spin down state as given by the Boltzmann distribution. (E: energy difference 
between spin states, kB: Boltzmann constant, T: temperature) 
   
     
         
 During image acquisition, a radio frequency (RF) pulse is applied to the aligned nuclei. This 
“tips” the magnetisation vector into the xy (transverse) plane, which can be detected by receivers 
in this plane. The nuclei return to equilibrium, undergoing two forms of relaxation; spin-lattice 
(longitudinal) or spin-spin (transverse) relaxation. Each tissue will have a specific time it takes to 
undergo longitudinal (T1) or transverse (T2) relaxation. By tuning the timing of the RF pulses (pulse 
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sequence), contrast can be introduced into the image by preferentially sensitising the image to 
differences in these relaxation values. For example in a T1 weighted image the image is sensitized 
for differences in T1 between tissues, with fluids appearing dark, water-based tissues grey and 
fatty tissues white.23 
 Besides T1 and T2 weighted images there are numerous other MRI techniques that have been 
developed to study the anatomy and physiology of tissues (e.g. diffusion weighted MRI: DW-MRI, 
blood oxygen level dependent MRI: BOLD-MRI). Dynamic contrast enhanced MRI (DCE-MRI) 
utilises images acquired before and after injection of a contrast agent into the blood stream (see 
below for explanation of contrast agents), and is used to study the vasculature and blood flow into 
tissues.25 Molecular imaging based MRI techniques have been developed by targeting these 
materials to specific molecular targets in vivo. Concentration of the agent at the target site will 
cause a localised change in contrast of the image. The other commonly utilised molecular imaging 
technique is magnetic resonance spectroscopy (MRS), where a MR spectrum is recorded within a 
voxel. This can be used to probe biological processes that are naturally occurring within the body, 
by monitoring changes in the spectrum, or concentration of a certain biochemical species. Both of 
these molecular imaging techniques will be discussed in more detail below. 
MR for in vivo molecular imaging: MRI 
A proton MR image is generated from the nuclear spins of hydrogen atoms within water, due to 
the high concentration of water within the body, the close to 100% natural abundance of the 1H 
isotope (99.985%) and that 1H possesses the highest gyromagnetic ratio of all MR active nuclei 
(42.5774MHz.T-1).26 Relaxation based MRI contrast agents are paramagnetic species that can 
influence the nuclear spins of nearby water protons, changing their relaxation times (either T1 or 
T2) and thus producing image contrast. There are two significant classes of relaxation-based MRI 
contrast agents; (1) chelates of paramagnetic transition metals, of which the most clinically 
significant is Gadolinium(III), and (2) superparamagnetic iron oxide nanoparticles (SPION). 
 Paramagnetic transition metals have at least one unpaired electron and thus possess a 
permanent magnetic moment. This strong magnetic moment can interact with the much smaller 
magnetic moment of nearby water molecules. Small fluctuations in these interactions, due to 
random molecular motion, cause a reduction in both T1 and T2 of these water molecules. 
27 At low 
concentrations, the effect is greater on T1 shortening, leading to positive contrast in a T1 weighted 
image. While the most clinically utilised paramagnetic species is Gd(III),28 there are also limited 
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examples of Manganese(II) complexes in clinical use.29-31 Stabilised free radical systems (e.g. 
nitroxides) are also being developed as novel contrast agents.32, 33 
 By attaching a Gd(III) chelate to a molecule capable of targeting a specific molecular target, it 
is possible to convert these non-specific contrast agents into MR molecular imaging agents. There 
are significant challenges to utilising these materials as molecular imaging agents. These include, 
maintaining the relaxivity of the Gd(III) within the construct, and getting a large enough increase in 
local concentration to gain measureable contrast enhancement, due to the low sensitivity of 
MRI.34 Despite these limitations, there are examples in the literature of Gd(III) based molecular 
agents. Small molecule systems, such as boronic acids35 or porphyrins36 have been used to target 
epitopes presented on the cell surface. More specific agents have been generated by conjugation 
to antibodies or peptides. Antibody probes targeting the αvβ3 integrin receptor, a marker for 
angiogenesis,37 and peptides targeting fibronectin38 are examples which show significant image 
enhancement of tumour tissue.  
 Superparamagnetic iron oxide nanoparticles (SPION) form the other major group of 
relaxation based MRI contrast agents. Changes in relaxation of nearby water molecules can be 
explained by the outer-sphere relaxation theory, whereby the relaxation rates of water protons 
are affected by the unpaired electrons of the iron nanoparticle.39 The enhancement of either T1 or 
T2 by SPIONs, is dependent on the size of the particles.
27 The original SPIONs developed were 
efficient T2 agents, due to susceptibility differences producing variations in the local magnetic 
field, thus generating negative contrast in an MR image.40 Recently, the development of ultra-
small SPIONs (<10 nm diameter) have a much larger effect on enhancing T1, and so will produce a 
bright spot in a T1 weighted image.
41, 42 To ensure stability of the nanoparticles and their 
biocompatibility, their surfaces are generally functionalised with a polymer coating. This provides 
additional chemical functionality that can be exploited for attachment of biologically active 
molecules, which can target specific receptors or other molecular species. This allows for imaging 
of diseases such as cancer, where SPIONs have been functionalised with folic acid that enhances 
uptake in a range of cancer cell lines,43 or with Annexin-5 which is an apoptotic specific marker.44, 
45 Cardiovascular disease is another well-developed field for MRI molecular imaging agents, with 
one example being nanoparticles functionalised with antibodies46 and peptides47 that recognise 
the vascular cell adhesion molecule-1 (VCAM-1) as reporters on early stages of endothelial 
inflammation. 
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 A new class of contrast agents that do not rely on changes in relaxation to generate image 
contrast has also been developed. Chemical exchange saturation transfer (CEST) contrast agents 
are molecules that possess protons that exchange slowly (NMR timescale) with bulk water. This 
gives these protons a unique chemical shift to the signal from water. It is then possible to apply 
radio frequency pulses to saturate these exchangeable protons, which will then exchange with 
bulk water protons, reducing its magnetisation vector and therefore signal intensity.48 While CEST 
agents do possess unique chemical shift frequencies to water, the differences are often quite 
small, which can lead to ineffective contrast.27 It is possible to use paramagnetic metal complexes 
with a coordinated water molecule, which undergoes slow exchange, to greatly enhance this 
difference. This is termed PARACEST and has been demonstrated for lanthanide (III) complexes 
like Europium(III).49, 50  Most typical CEST and PARACEST agents have detection limits in the 
millimolar concentration range, which limits their use as molecular imaging agents. One approach 
to overcome this issue is to entrap a large concentration of CEST agents within a liposomal carrier 
(LIPOCEST), which allows for detection down to the nanomolar level.51 A novel approach produced 
highly sensitive PARACEST lipid nanoparticles, with bifunctional DOTA-lipids. The particles 
possessed an Eu3+ concentration of 2.1 mM and a saturation transfer effect at 52 ppm. These 
nanoparticles were targeted towards fibrin and were used to visualise unstable, atherosclerotic 
plaques.52 
The final class of exogenous imaging agents are probes which contain a high content of MR 
active nuclei other than 1H, and so are directly detectable. A popular nuclei for this purpose is 19F, 
due to its high gyromagnetic ratio (40.0776), 100% natural abundance of the isotope and 
undetectable levels of naturally occurring nuclei in vivo, giving rise to high signal to noise ratio 
(SNR).26, 53 It is also possible to use compounds that have been artificially enriched with higher 
concentrations of an MR active nuclei, such as [1-13C]glucose.54 Even with these enriched 
compounds image acquisition time is still long and spatial resolution is still low, leading to limited 
implementation in the clinic. One technique that has been developed to greatly improve the 
sensitivity of these nuclei is hyperpolarisation. This involves artificially producing nuclei with non-
equilibrium distributions of spin states, external to the MRI scanner, then introducing them to the 
subject. This gives these nuclei an enhanced polarisation compared to the thermal distribution (up 
to 100,000 fold enhancement).55 This hyperpolarisation will decay back to thermal equilibrium via 
longitudinal relaxation processes, so imaging must be completed within 5 times the length of the 
longitudinal relaxation time (T1). While this limits the available time frame for imaging, the 
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enhancement in sensitivity has allowed for imaging of fast biological processes, the most 
successful example being [1-13C]pyruvate.56, 57 
MR for in vivo molecular spectroscopy: MRS 
As discussed earlier, MR can be used to probe endogenous biomolecules for both physiological 
assessments at the tissue level (e.g. DW-MRI), or for probing individual molecular species (MRS). 
MRS is analogous to the chemical technique Nuclear Magnetic Resonance (NMR), where a 
chemical spectrum of MR active nuclei is recorded, only MRS is performed in a specific voxel 
within an animal or patient. These spectra can be used to probe the concentration/distribution of 
a biomolecule,58 or to follow a biological process, such as metabolism of a substrate.59 
It is possible to perform MRS imaging, by visually mapping changes in the spectrum of a 
particular molecule onto 1H MRI images, for anatomical context. 60  MRS of 1H suffers from low 
SNR due to the low concentration of biomolecule protons relative to water (~1,000 fold excess 
water protons). MRS of other nuclei suffers further from the low natural abundance of 
magnetically active nuclei (e.g. ~1% carbon exists as 13C). These factors can lead to prohibitively 
long acquisition times and can require large voxel volumes (~1 cm3), leading to low resolution of 
the image. Techniques such as hyperpolarisation (discussed above) are being used to improve the 
sensitivity and thus the acquisition time and resolution of MRS.61 
1.2.3. Optical Imaging 
Optical imaging techniques are the most widely utilised techniques for pre-clinical molecular 
imaging, due to their relatively low cost, broad availability and because they are relatively safe 
through the use of non-ionising radiation. Fluorescence microscopy has revolutionised cellular 
biology, providing understanding of molecular events on the cellular level, such as protein 
interactions, gene delivery and RNA knockdown.62 During this time there has been a concomitant 
development of macroscopic optical imaging techniques, capable of visualising events in small 
animals (e.g. bioluminescence) and in whole organs of larger subjects (e.g. intraoperative 
fluorescence imaging). These techniques share a number of key strengths and weaknesses, which 
will be discussed below. 
 The first requirement for all optical imaging techniques is detection of low intensity light in 
the visible to near infrared (NIR) region. Charge coupled devices (CCD) are silicon semi-conductor 
materials, which are highly sensitive devices for detecting light in this spectral region. The devices 
detect photons with energy of just 2-3 eV and convert them into an electrical signal, which is 
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equivalent to the intensity of incoming light. Cooled CCD detectors are now used, as they have a 
much higher signal to noise ratio than older devices. This is due to a reduction in thermal noise 
(dark noise), where thermal energy within the device is leading to a constant release of electrons. 
This noise is reduced by a factor of 10 for each 20 °C reduction in temperature. 63 Highly sensitive 
CCD detectors have revolutionised the development of optical imaging systems.  
 The major limitation for macroscopic optical imaging is tissue penetration depth. While 
optical imaging is inherently sensitive and can achieve high resolution, these factors fall off with 
increasing tissue depth of molecular imaging probe due to absorbance (~factor of 10/cm of tissue) 
and scattering events.64 There are numerous naturally occurring biomolecules which absorb light, 
such as deoxy/haemoglobin, cytochromes and melanin. The different concentration of these 
molecules, in various tissues, leads to differing levels of absorption. For example, highly 
vascularised organs such as the liver have very low levels of transmission, compared to skin and 
muscle. This issue can be overcome by increasing the wavelength of light used, though this is 
limited by the increasing absorbance of water by infrared light. This leads to a narrow window in 
the near infrared region that is suitable for in vivo optical imaging, where tissue auto fluorescence 
and absorbance by biomolecules and water are minimised. (Figure 1-2).65, 66 
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Figure 1-2. Plots showing the absorption coefficient of native tissues across the visible-near infrared range, demonstrating the 
narrow window in the NIR range suitable for in vivo optical imaging. The bottom panel demonstrates this by the difference in 
transmission of red light (532 nm) and deep red light (670 nm) through the thoracic cavity of a mouse.
67
 
 Optical imaging can be divided into two major classes, depending on the source of the light. 
Luminescence imaging generally refers to techniques that rely on the endogenous production of 
light through biological or chemical processes, whereas fluorescence imaging techniques rely on 
an externally applied source of light being converted to an emitted light of higher wavelength. 
Both of these two classes will be discussed in further detail below. 
Luminescence Imaging 
Luminescence imaging can be achieved using several sources of energy for light emission. The 
most commonly utilised technique is bioluminescence imaging (BLI), which relies on the oxidation 
of a specific chemical substrate by a corresponding enzyme, to produce light (Figure 1-3.b). 
Bioluminescence is a specific form of chemiluminescence, which describes more generally any 
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chemical reaction which produces light, though these two classes are generally referred to 
separately when discussing molecular imaging. Chemiluminescence imaging has been used to 
detect directly reactive oxygen species (ROS)68-71 and the activity of peroxidase enzymes.72 The 
third and final form of luminescence, which has seen development for whole animal imaging, is 
Cerenkov radiation. Cerenkov radiation occurs when a charged particles passes through a 
dielectric medium at a velocity exceeding that of light in that medium. It causes light emission in 
the UV-blue range of the spectrum, which can then be detected with a CCD detector.73 This 
section will focus on bioluminescence, since it is much more widely utilised in pre-clinical animal 
imaging than the other two techniques, though many of the technical considerations are common 
across all classes. 
 
Figure 1-3. a) The bioluminescent reporter is engineered as a transgene, under the control of a desired endogenous reporter. b) 
Illustration of the Firefly Luciferase system for the production of bioluminescent light. 
 Luciferase isolated from the North American firefly is the most commonly utilised BLI 
system, although enzymes have been isolated from a range of animals and bacteria. Each 
individual luciferase has a characteristic emission profile and requires a specific substrate and 
sometimes additional co-factors.74 BLI requires genetic engineering to introduce the luciferase 
gene into the cell or tissue of interest, under the control of a selected gene promoter (Figure 
1-3.a).75 North American firefly luciferase (Fluc) requires the benzothiazoyl-benzothiazole luciferin 
substrate, with ATP, O2 and Mg
2+ as cofactors to produce a broad band emission that peaks at 562 
nm (530-640 nm range).(Figure 1-3.b) Emission in this range of the spectrum allows for imaging up 
to several centimetres in depth, making this luciferase useful for in vivo applications.76 Fluc has 
been used to monitor and study infectious diseases,77-79 as well as aspects of cancer biology, such 
as tumour growth,80-82 onset of metastases,82-84 and efficacy of treatment.80, 85  
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 The strengths of bioluminescence imaging are that it does not require an external light 
source and that vertebrate tissues do not undergo bioluminescence, leading to very low levels of 
background signal and thus high SNR compared to conventional fluorescence techniques (see 
below). BLI is also a very cost effective technique, compared to other molecular imaging 
techniques, with relatively cheap instruments with low running costs and short acquisition times. 
The technique is relatively simple without the use of ionising radiation and without the need for 
extensive and specialised training, which makes it very accessible for a wide range of users. The 
promoter gene for the luciferase enzyme can be selected to be the same promoter for a gene of 
interest. This allows for the monitoring of gene expression, by measuring the amount of light 
produced.75 One example of this is the production of transgenic mice with the vascular endothelial 
growth factor receptor-2 (VEGFR-2) promoter fused with the Fluc gene, to monitor angiogenesis 
during wound healing.86 
 As discussed above the major drawback to BLI are tissue penetration depth, due to 
absorption and scattering by tissues. This limits quantification, due to surface weighting of the 
detected signal. Development of tomographic techniques, similar to those developed for 
fluorescence imaging (see below), provide solutions to overcome these drawbacks.87 The reaction 
also requires the complex interaction of a number of molecules, including the enzyme, substrate 
and co-factors. Differences in the availability of these molecules across tissues can mean that the 
level of light emitted may not be a true representation of the activity of luciferase.76 BLI is also 
limited by the need to genetically engineer the luciferase gene into cells and tissues of interest, 
which has greatly limited the translation of this technique to the clinic. Despite these issues, it still 
remains one of the most widely utilised pre-clinical modalities. 
Fluorescence Imaging 
The photochemical process of fluorescence occurs due to the excitation of an electron in a 
fluorophore to a higher quantum state (S1), which then emits light (hvem) as it relaxes back down 
to its ground state (S0) (Equation 1-2). Due to loss of some of the energy non-radiatively as heat, 
the emitted photon generally has a longer wavelength than the excitation photon. Two-photon 
absorption is an exception to this, but will not be discussed in this review, due to its limited scope 
of use in whole animal imaging. 
Equation 1-2. The physical processes involved in excitation of a fluorescent molecule and its subsequent relaxation by emission 
of light and heat. 
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Fluorescence molecular imaging involves irradiating a subject with light from the UV to NIR 
spectrum (395 nm-900 nm), and detecting the red shifted (longer wavelength) light that is emitted 
by a fluorescent probe.88 There are a wide range of fluorescent probes available for use in 
molecular imaging, which include fluorescent proteins, organic dyes, inorganic quantum dots and 
lanthanide complexes. Generally these probes are introduced exogenously prior to imaging, with 
the one exception being genetically encoded fluorescent proteins. These materials can rely on 
their unique physicochemical properties, to passively target and image a biological process, but it 
is much more common to ligate these materials to a biologically recognised ligand or substrate 
(e.g. peptide, antibody, RNA).89 The combination of a variety of probes with an even broader range 
of biological targeting molecules has been utilised in many pre-clinical applications.90-92 
As with luminescence imaging, the widely recognised strengths of fluorescence imaging is 
its relative low cost, ease of use and versatility for a wide range of animal and disease models. One 
of great strength, which is specific to fluorescence imaging, is its ability to use activatable probes 
that can report on specific molecular events as they occur. This occurs through an energy transfer 
mechanism to another molecule. If the energy is transferred from one fluorophore to a second 
fluorophore, which then emits the light at an even longer wavelength, this is known as Förster 
Resonance Energy Transfer (FRET, Figure 1-4).93-95 If the energy is transferred to another molecule 
that undergoes “non-radiative” relaxation back to the ground state (energy is lost as heat rather 
than light, Equation 1-2), then this is known as quenching (Figure 1-4).96 This quenching can occur 
with another photo-active probe, such as an organic quencher.97 By using these activatable 
techniques, a wide range of molecular events have been monitored and measured in vivo, with a 
range of microscopy techniques.98-100 One example, which instead utilised FRET in combination 
with a whole animal imaging system, monitored the presence of matrix metalloproteinase in an 
osteoarthritis model.97 There is work reported in the literature looking at using fluorescence 
molecular tomography (see below) to visualise in 3D and quantify FRET, deep within tissues.101, 102 
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Figure 1-4. Schematic representations of single fluorophore fluorescence and energy transfer mechanisms to either a second 
fluorophore or a quencher. (* represents excited state) 
Tissue depth penetration, as discussed with bioluminescence imaging, is the major 
limitation for in vivo fluorescence imaging. Fluorescence imaging can be further complicated by 
auto-fluorescence of native tissues, dramatically increasing background signal. Again this 
phenomenon is greatly reduced in the NIR region of the spectrum (Figure 1-5).91 Quantification of 
fluorescence imaging data is also heavily surface weighted, but these issues have been overcome 
by the advent of fluorescence molecular tomography (FMT), which can allow for high resolution 
imaging and quantification of fluorescence down to the femtomolar concentration range and up 
to a depth of multiple centimetres.103 The issues of tissue penetration depth, historically, have 
hindered the use of fluorescence based imaging techniques in a clinical setting. In recent years, 
through the use of NIR probes and live intra-operative imaging techniques, fluorescence imaging 
has been utilised in a clinical setting, some examples of which include the detection and surgical 
resection of cancerous nodes104 and liver cancers105 and the detection of dysplastic colonocytes106. 
The continued development of novel fluorescence imaging probes and improving the translation 
of these techniques to the clinic will continue to drive the development of this modality. 
Dye 1 + Dye 2
Dye + Q
Fluorescence
Quenching
Dye Dye* Dye
Excitation Fluorescence
Dye + Q*Dye* + Q
No
Fluorescence
Energy
Transfer
hvex hvem
FRET
Dye 1 + Dye 2*Dye 1* + Dye 2
Fluorescence at 
longer wavelength
Energy
Transfer
hvem
Δ
19 
 
 
Figure 1-5. Demonstration of autofluorescence in mouse tissues in the visible light range, utilising different filter sets. a) white 
light photograph, b) blue-green filter set (used for fluorescein or GFP) c) green-red filter set (used for rhodamine or DsRed), d) 
near-infrared filter set (used for Cy7 or iRFP). In the near-infrared range, no autofluorescence can be seen.
91
 
1.2.4. Ultrasound and photoacoustics 
Ultrasound (US) is the most widely utilised imaging modality in the clinic, due to its low cost and 
safety due to absence of ionising radiation. US images are generated by the reflection of incident 
high frequency sound waves off the interfaces of different organs and tissues. In US imaging, there 
is a trade-off between resolution and depth of detection. High resolution images can be generated 
by using high frequency sound waves, but the penetration depth is limited by the short 
wavelengths, which leads to higher energy loss to surrounding media.107 
Gas filled-lipid or polymer coated microbubbles have been used as contrast agents for US to 
improve blood to tissue contrast. Detection of these agents is highly sensitive, with single 
molecule detection possible.108 These microbubbles have been functionalised with targeting 
agents such as aptamers and antibodies, to translate them into molecular imaging agents.109-111 
Due to the micron size of these contrast agents, they are unable to extravasate from the blood 
stream, and so they are limited to molecular targets inside the vasculature. These agents are also 
limited by the fact that the bubbles are damaged by the high frequency sound waves used to 
detect them.109 Despite this, ultrasound microbubbles have seen early development in clinical 
applications as contrast agents.111 
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Photoacoustic imaging combines principles from both ultrasound and fluorescence imaging 
into one modality. A pulsed laser beam is applied to the subject, which is selectively absorbed by a 
molecule of interest. This light energy is converted to an acoustic signal via the photoacoustic 
effect, which can then be detected by an ultrasound transducer.112 This technique combines the 
strengths of both modalities to offset their corresponding drawbacks. The absorption of the 
incident light is dependent on the spectral properties of the molecule of interest and is 
characteristic of that molecule. This allows for multispectral images to be generated, which is not 
possible in US.113 By detecting an acoustic signal, rather than an optical signal allows for much 
deeper imaging (up to 5 cm), as the longer wavelength sound waves are attenuated less by tissues 
in the body (3 orders of magnitude less/unit path length).114 
All of the same imaging agents from fluorescence imaging can be used in photoacoustic 
imaging (e.g. organic dyes, quantum dots), but there is a wider range of molecules available since 
they only need to absorb the optical signal and do not need to fluoresce. Of particular interest are 
native biomolecules present in tissues. A common application in photoacoustics is the 
measurement of blood oxygenation, based on the differing spectral properties of oxy- and de-
oxyhaemoglobin in the NIR spectral window.115, 116 It is also possible to spectrally unmix multiple 
exogenous agents117, or to map a tracer to tissue oxygenation levels.118 Photoacoustic imaging is 
still an emerging technology, in early stages of pre-clinical development, but development of this 
technique for imaging of human subjects has begun.119 
1.2.5. X-ray Computed Tomography  
X-ray computed tomography (CT) is a widely utilised clinical imaging technique. This is partly due 
to the fact that it was one of the earliest forms of 3D medical imaging to be developed. It also 
produces very high resolution anatomical images, of an entire patient, at a much lower cost 
compared to MRI. As such CT has seen widespread use in pre-clinical development as well.120 The 
image signal in CT is produced by the different absorption levels of X-rays by various tissues in the 
body, identical to a standard 2D X-ray image. In CT imaging the X-ray source and detector are 
rotated around the subject in tandem (the subject can be rotated, but not usually used for live 
subjects) to build up volumetric data and to produce 3D tomographic images.121  
 Due to the relatively weak attenuation of X-rays by soft tissues, there is low contrast 
between various tissues in the body (e.g. fat, muscle, organs). In order to enhance these 
differences, a contrast agent with high X-ray attenuation is used. These contrast agents generally 
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contain large mass quantities of high atomic mass atoms such as iodine, barium or gold. These 
agents are generally non-specific and are used to visualise vasculature or the digestive system.122, 
123 While historically CT has had very limited use as a molecular imaging technique, there is recent 
work that is looking to target these contrast agents to specific molecular targets. Gold 
nanoparticles have seen significant development as targeted systems, due to their longer 
circulation time and biological inertness. Gold nanoparticles have been developed for CT 
molecular imaging agents by attachment of specific targeting molecules. Examples include 
nanoparticles functionalised with monoclonal antibodies (mAb) targeting the EGFR receptor for 
targeting head and neck cancer,124 anti-HER2 mAb for breast cancer125 and bombesin peptides for 
prostate cancer.126 
There are two major limitations to the development of CT as a molecular imaging agent. The 
first is the large mass quantity of contrast agent that is required to localise at the target for 
effective contrast generation.127 The second is safety, with each CT scan delivering a relatively 
large radiation dose (one CT scan: ~0.6 Gy, 5% LD50 for a mouse).
128 This limits the repeated use of 
CT over short time periods. Modern development of scanners has led to much more sensitive 
detectors being used, which will help to lower the dose given to a subject each scan. The 
development of CT as a true molecular imaging modality is still in its infancy.  More research is 
required into increasing the sensitivity of this technique, either by improving the level of contrast 
of these agents and increasing the pay load delivered to the target site, or by developing new 
detection techniques or reconstruction algorithms that improve image contrast.129  
1.2.6. Polymeric molecular imaging agents 
Molecular imaging agents designed on polymeric materials are becoming increasingly popular, due 
to their favourable biological properties demonstrated in vivo. It is the unique chemical and 
physical properties of polymeric materials that impart these desired properties. For example, their 
large size can prevent renal clearance, and their chemical composition can prevent clearance via 
the mononuclear phagocyte system (MPS).130-133 This can lead to enhanced circulation time of 
polymeric agents, compared to small molecule agents, which can be utilised for vascular 
imaging134 or tumour imaging through the enhanced permeation and retention (EPR) effect.131 
Other advantages include multi-functionality for the introduction of a range of therapeutics and 
targeting ligands, their ability to protect biological molecules such as proteins and antibodies, and 
their ability to carry a large payload of small molecules agents.135 For a more in depth review of 
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the recent developments in the field of polymeric imaging agents, the reader is directed to 
Chapter 2: Molecular imaging with polymers.136 
One advantage of polymeric materials is that they can be designed to possess multiple chemical 
functionalities that can be used to introduce extra functionality to an imaging agent, such as 
targeting, drug delivery or multiple complementary imaging moieties. In section 1.3 
hyperbranched polymers will be introduced as advanced functional materials, with a unique 
combination of properties that make them advantageous for development as molecular imaging 
agents. 
 
1.3. Hyperbranched polymers  
Hyperbranched polymers are a class of dendritic polymer, which owing to their unique structural 
features and chemical properties have seen development as functional materials.137, 138 
Hyperbranched polymers typically contain very high branching densities, are unimolecular and 
globular in shape and are relatively large in molecular weight in comparison to linear polymers of 
similar hydrodynamic dimensions. The branched structure gives these molecules high end group 
functionality compared to linear polymers, which is useful for further chemistries. Branching also 
affects the segmental mobility and entanglement of the chains, which in turn affects the solubility 
and solution viscosity of the particles. These are just some of the reasons that branched polymers 
have seen so much attention in the last twenty years.139 
 Hyperbranched polymers differ from dendrimers in that they are prepared via a one-pot 
synthesis. This leads to heterogeneity in size and structure that is not seen in dendrimers, which 
are precisely formed branched structures, monodisperse in size. Despite this, hyperbranched 
polymers are often favoured for their simpler synthetic methodology and compatibility with a 
range of conventional polymerisation techniques.140 This has made them popular in large scale 
and industrial processes, seeing their development as resins and coatings, additives to improve 
rheology and processing of linear polymers.141 They have also been utilised in many 
nanotechnology applications, such as opto-electronics, drug delivery vehicles, catalysts and 
diagnostic tools.142-145 
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1.3.1. Chemical synthesis of hyperbranched polymers 
A wide range of synthetic strategies have been developed to produce hyperbranched polymers. 
They can be organised into three classes: step-growth, chain-growth and dendrigraft/arborescent 
polymers. Step-growth and chain-growth synthetic strategies will be discussed in further detail 
below. The third class of hyperbranched polymers are known by many names in the literature, for 
example arborescent graft polymers,146 dendritic polymers147 or hyper-Macs.148 All of these 
polymers share the common features of possessing true polymeric chains between each branching 
point. They combine aspects of chain growth and step growth techniques and are synthesised via 
an iterative branching process similar to dendrimers.148 There are numerous examples of such 
polymers and their structure varies from that typically associated with HBP and so will not be 
discussed further. Readers are directed to dedicated reviews for more information on these 
materials.149, 150 
Step-growth synthesis of hyperbranched polymers 
Step-growth polymerisation is the ‘classical’ approach to synthesise hyperbranched polymers and 
was first theorised by Flory.151 It uses monomers with an ABx (where x > 2) type functionality (or 
some derivative thereof), where A ideally reacts with B with no side reactions and the reactivity of 
all B functional groups is equal. There should also be no internal cyclisation reactions, which will 
limit the maximum achievable molar mass.140 AB2 types monomers are the most commonly used 
for the synthesis of hyperbranched polymers, though high order of B functionality (eg. B4, B6
152) 
have been used to control the branching structure of the material. 
 These step growth polymerisations are traditionally polycondensation reactions of AB2 or 
ABx + By monomers, with polyesters being the most widely utilised due to the commercial 
availability of a wide range of monomers. Almost all forms of polycondensation reactions have 
been explored for the synthesis of hyperbranched polymers, with some examples including 
polyamides,153 polyethers,154 polyphenylenes155, polycarbonates156 and polyphenylacetylenes.157 
Polyaddition reactions (do not have undergo elimination of a small molecule), have also been used 
to synthesise step-growth hyperbranched polymers. These reactions can include polyurethane 
formation 158, Michael-type addition reactions159 and cycloaddition reactions (such as 1,3-dipolar 
cycloadditions160).  
There have also been reports of polymerisation of A2 + Bx monomers, which deviates from 
Flory’s prerequisites, because these systems gel and hyperbranched materials are achieved on the 
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path towards network formation (gelation). It is necessary to carefully control the kinetics of these 
reactions to achieve soluble branched systems by controlling the feed ratio and feed rate (slow 
monomer addition) of A and B functionalities, halting the polymerisation (precipitation or end 
capping) or by using specialised catalysts and reagents.142 The first examples of hyperbranched 
polymers from these systems were described independently for polyaromatic amides161 and 
aliphatic polyethers.162 
Chain-growth synthesis of hyperbranched polymers 
Following on from step-growth were chain-growth strategies, which became popular after the 
invention of self-condensing vinyl polymerisation (SCVP).163 Since then this area has grown to 
include self-condensing ring opening polymerisation (SCROP), proton transfer polymerisations and 
radical polymerisations combined with multifunctional crosslinkers.139, 140  
 SCVP involves the use of a vinyl monomer which possess a pendant initiating group, known 
as an inimer (initiator + monomer, Figure 1-6.a). Inimers have been synthesised for cationic 
polymerisation, 163 group transfer polymerisation (GTP),164, 165 atom transfer radical polymerisation 
(ATRP)166-168 and nitroxide mediated polymerisation (NMP).169 Similarly, related vinyl 
functionalised molecules have been synthesised from iniferters (pendant group is an initiator, 
transfer and terminating agent)170-172 and RAFT agents (pendant group is a transfer agent).173-175 
(Figure 1-6.a) In these methods the vinyl group represents the A moiety of an AB2 type monomer. 
The initiator or transfer group is one of the B groups, where upon addition of a second monomer 
the growth site becomes the second B functionality. (Figure 1-6.b) The relative reactivity ratio of 
the initiating site (B) compared to the growth site (B*) can be controlled, which can allow for the 
control of the degree of branching away from 50% (as seen in step growth reactions).176 Each of 
these techniques discussed can be adapted to a copolymerisation method (self condensing vinyl 
copolymerisation), by inclusion of a monofunctional monomer with the bifunctional inimer. This 
provides further control over the architecture and functional properties of these materials.177, 178 A 
similar approach has been applied to inimers with heterocyclic groups, known as self-condensing 
ring opening polymerisation (SCROP) or ring-opening multibranching polymerisation (ROMBP).179 
While both of these methods allow access to a wide range of architectures, they are limited by the 
need to synthesise novel branching inimer molecules. 
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Figure 1-6.a) Bifunctional branching molecules for self condensing polymerisation techniques, for the production of 
hyperbranched polymers. b) Representation of how these bifuncitonal groups are considered AB2 type crosslinking molecules 
during polymerisation. 
Chain-growth synthesis: free radical vinyl crosslinking polymerisations 
Another recent strategy developed for the synthesis of hyperbranched polymers is to use catalysts 
in the free radical polymerisation of divinyl monomers to suppress the formation of insoluble gel 
networks. The first of these techniques to be described is known as the ‘Strathclyde’ method and 
uses large quantities of thiol chain transfer agents to suppress gelation of free radical vinyl 
polymerisation systems.180 While it is possible to produced branched polymers at high dilution, as 
precursors to gel systems, this method allows for the production of soluble products at high 
monomer concentration (40 vol.% monomers).  
The ‘Strathclyde’ method has now been extended to utilise reversible-deactivation radical 
polymerisation (RDRP) techniques, to provide greater control over the architecture of these 
materials.181 The methodology has been applied to NMP,182 ATRP,144, 183-186 and RAFT187-189 
polymerisation techniques. RDRP synthesised hyperbranched polymers are popular because they 
allow for the use of commercially available monomers and difunctional crosslinker. The RDRP 
mechanisms provide control over molecular weight, molar mass dispersity (ÐM) and end group 
functionality. Importantly, the end group functionality provides a convenient handle for 
downstream modification of the polymer. In terms of molecular weight control, the use of 
 b) 
26 
 
conventional thiol chain transfer agents allows the polymerisation to proceed via a free radical 
mechanism, yielding high molecular weight chains at low conversion, with suppression of gelation. 
For ideal RDRP all chains are initiated simultaneously, propagate at the same rate to reach a 
degree of polymerisation that is dictated by the ratio of monomer to initiator/transfer agent and is 
free of termination events. A mechanism for the polymerisation of hyperbranched polymers by 
RDRP describes the process in three stages. (Figure 1-7) During the early stages of polymerisation, 
the concentration of monomer to difunctional brancher is high and favours linear propagation of 
both molecules, giving linear polymer chains with pendant double bonds (Mn and ÐM follow 
follows ideal RDRP kinetics). As the polymerisation progresses and monomer is consumed, the 
ratio of free monomer to pendant vinyl groups decreases, and branching begins (MN and ÐM 
diverge from ideal RDRP kinetics). During the final stages of polymerisation at high conversion, the 
concentration of free monomer groups is negligible and predominantly pendant double bonds 
remain. Coupling of polymer chains is favoured at this stage and Mn and ÐM will increase 
exponentially in this regime, similar to what is seen in step growth polymerisation.183, 190 
 
Figure 1-7. Model for the evolution of branching in RDRP synthesised hyperbranched polymers. Branching is delayed until high 
conversion due to the slow controlled growth of polymer chains, leading to a high ratio of free monomer compared to pendant 
double bonds during the propagation step.
183
  
It has been shown both theoretically191-193 189 and experimentally183, 189 that the ratio of 
crosslinker and polymer chains should not exceed unity in order to produce soluble 
hyperbranched polymers; above this point macrogelation generally occurs. This is given by the 
critical condition for an infinite network, which is the point where the product of the probability 
that a primary chain contains more than one branch unit (α) and the degree of polymerisation of 
that chain (DP) is equal to one. (Equation 1-3a)  The probability at the critical point (αc) can be 
calculated using Equation 1-3b where f is the number of reactive groups on the branching 
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molecule.191, 192 In the Strathclyde method, this condition is met when every polymer chain 
incorporates at least one crosslinking group. In RDRP methods the total number of polymer chains 
is dictated by the concentration of initiator (NMP and ATRP) or chain transfer agent (RAFT), so the 
ratio of these molecules to the crosslinker must be fixed at less than one. These predictions are 
made based on the assumption that there are no intramolecular cyclisation reactions occurring, 
which for AB2 type monomers in step growth syntheses is valid.  However, it has been shown in 
crosslinking polymerisations (e.g. Strathclyde-type approaches) that this rule is not always valid 
and crosslinker ratios can be increased well above the theoretical value (Table 1-1). Molecular 
modelling suggests that this phenomenon is due to the occurrence of intramolecular cyclisation 
reactions.189, 194-196  Direct quantification of this phenomenon was first confirmed with 1H NMR 
spectroscopy.197  
Equation 1-3: (a) The critical condition for the transition from a branched polymer to an infinite, gelled network (α: probability 
that a primary chain contains more than one branch unit, DP: degree of polymerisation). (b) Determination of the critical 
probability for an infinite network (f: number of reactive functional groups on the branching molecule). 
          
      
 
   
 
It has also been shown in the literature that not only the ratio of brancher per primary 
chain, but also the initial concentration of monomer in the reaction affects the rate of both 
gelation and intramolecular cyclisation.196, 198 The RAFT and ATRP polymerisation of methyl 
methacrylate (MMA) with a reducible disulfide dimethacrylate crosslinker has been explored at an 
initial monomer concentration of 10 wt% and 40 wt%. 10 wt% was calculated to be the 
approximate critical overlap concentration (c*) for this system. It was shown that, independent of 
polymerisation technique used, at 10 wt% intramolecular cyclisation reactions were favoured and 
at 40 wt% intermolecular branching reaction were favoured. This is due to the requirement for 
efficient branching to have individual polymer chains interpenetrate each other and encounter 
propagating radicals.199 It is important to consider all of these experimental conditions when 
designing a material, and to monitor them during synthesis to maintain consistent and 
reproducible production of hyperbranched materials. 
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 Table 1-3. Summary of synthetic conditions used in the literature for the synthesis of hyperbranched polymers with RDRP 
techniques. (Adapted from Li (2008)
198
) 
Reaction 
Mechanism 
Monomer 
Type 
DP [M]  
(% w/v) 
c* 
(%) 
Final Conversion 
(%) 
Branchers per 
Chain 
ATRP
200
 HPMA 50 45 14 >99 0.95 
ATRP
183
 HPMA 50 54 14 >99 1.0 
ATRP
201
 MMA 100 bulk 6 80 0.5 
ATRP
202
 MMA 100 20 6 88 1.0 
ATRP
203
 MA 50 54 8 ∼100 0.9 
RAFT
188
 MMA 35 20 13 97 1.74 
RAFT
188
 MMA 22 20 19 96.5 1.13 
RAFT
204
 Am 81 10 5 >97 3.6 
 
1.3.2. Hyperbranched polymers from RAFT polymerisation 
Reversible addition-fragmentation chain transfer (RAFT) is a popular polymerisation technique, 
due to its relative convenience and versatility for a wide range of monomers and synthetic 
conditions.205, 206 The technique relies on the use of thiocarbonylthio [RS(Z)C=S] groups as chain 
transfer agents; the most commonly used classes of which are dithioesters [RS(R)C=S], 
trithiocarbonates [RS(RS)C=S], dithiocarbamates [RS(RN)C=S] and xanthates [RS(RO)C=S]. These 
transfer agents establish equilibria during the polymerisation process, between active propagating 
radical centres and dormant chains (Figure 1-8.d), which provides all chains an equal opportunity 
to grow and gives polymer products with narrow molecular weight distributions.206-208 It is possible 
to predict the theoretical molecular weight (Mn) of a synthesised polymer, by controlling the feed 
ratio of monomer units to chain transfer agents. (Equation 1-4) This allows for a desired polymer 
mass to be targeted, thus providing further control over the architecture of polymeric materials. 
RAFT can also be used to control the polymerisation of two (or more) different monomers, 
providing well defined copolymers. By controlling the kinetics of copolymerisation, it is possible to 
modify the polymer composition from block like, to gradient and truly statistical random 
copolymers. By providing control of molar mass, dispersity and composition, RAFT allows for the 
production of complex macromolecular architectures.209  
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Figure 1-8.Mechanism of RAFT polymerisation.
206
 
Equation 1-4. Calculating theoretical molar mass of polymer chains from a RAFT polymerisation. (Mn: number average molar 
mass of polymer, [M]: concentration of monomer, [RAFT]: concentration of transfer agent, d: is the number of chains produced 
from a radical-radical reaction, f: initiator efficiency, mM: molecular mass of individual monomer units, mRAFT: molecular mass of 
RAFT agent, kd: rate constant for initiator concentration)
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Equation 1-5. Reduced form of Equation 1-4, where the concentration of initiator is small compared to the RAFT concentration 
and the concentration of initiator chain ends can be considered negligible. (Mn: number average molar mass of polymer, [M]: 
concentration of monomer, [RAFT]: concentration of transfer agent, p:fractional monomer conversion, mM: atomic mass of 
individual monomer units, mRAFT: atomic mass of RAFT agent)  
           
      
       
          
As has been discussed above, RAFT has been utilised for the production of hyperbranched 
polymers with a variety of strategies, including SCVP and the ‘Strathclyde’ strategy described 
above.  Adaptation of the ‘Strathclyde’ method to RAFT polymerisation was first described by 
Perrier et al, utilising the bifunctional crosslinker ethylene glycol dimethacrylate (EGDMA) 
a)
b)
c)
d)
e)
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copolymerised with MMA.187, 188 It was shown that gelation was inhibited at very high conversions 
and good molecular weight control was maintained throughout the polymerisation, compared to 
previous studies with ATRP. Since then, this technique has been extended to a wide range of 
synthetic conditions for use in many applications, such as thermoresponsive materials,211-213 
imaging agents,143, 214, 215 gene delivery vectors216, 217 and photolithographic resists.218 
 RAFT polymerisation of hyperbranched polymers with difunctional crosslinkers shows 
significant non-ideal behaviour. Literature reports have shown that soluble hyperbranched 
polymers can be synthesised when the ratio of crosslinker to polymer chains (equivalent to the 
concentration of chain transfer agent) exceeds unity (up to 15:1).187, 188, 211, 214, 217 This can be 
explained by the relatively dilute conditions under which these polymerisations were performed. 
For example, in the original paper by Perrier et al, they were able to synthesise hyperbranched 
polymers with a crosslinker to RAFT ratio of 1.95:1.188 The initial methyl methacrylate 
concentration in the polymerisations was 25 w/w% in toluene. This is close to the estimated 
critical overlap concentration (c*) for PMMA30 of 20 w/w%. (c* estimated from model for 
PMMA199) As has been discussed in the previous section, at monomer concentrations equivalent 
to or less than c*, intramolecular cyclisation reactions are favoured over branching reactions.196, 
198, 199 It is important to control this reaction parameter, to synthesise materials with desired 
architectures. 
The structure and chemical reactivity of the crosslinker is also important in the formation 
of hyperbranched copolymers with the RAFT ‘Strathclyde’ method. The reactivity ratio between 
the crosslinker and other monomers will define whether the primary chains will contain pendant 
vinyl groups that are randomly distributed along the backbone, or concentrated in one region of 
the polymer. It has been demonstrated that by changing this reactivity (and thus distribution) it is 
possible to go from a classic hyperbranched polymer architecture to a ‘star-like’ structure, with a 
branched core.214 The length and flexibility of the crosslinker has been shown to affect the ratio of 
intra- and inter-molecular crosslinks. Bulkier and more rigid crosslinkers showed a high propensity 
for intermolecular crosslinking, compared to shorter and more flexible linkers.194 Crosslinkers have 
also been designed with asymmetrical functionality, with one vinyl group being less reactive 
towards radical propagation. This allows for a high concentration of crosslinker to be incorporated 
into the primary chains, while minimising inter- and intra-molecular reactions and preventing 
gelation.219, 220 This will leave a high concentration of pendant vinyl groups at the end of the 
reaction, which can be used for further functionalisation.221  
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Beyond providing control over polymer architecture, another advantage of using RAFT is for 
providing end functional polymers. This is important for developing polymers into advanced 
materials, because it can allow for a wide range of post-polymerisation modifications to occur, 
including the formation of conjugates and bioconjugates, self-assembly into higher order 
structures and the modification of material surfaces with polymers. The thiocarbonylthio end 
groups of the polymers are inherently reactive and have been utilised for a wide range of post-
polymerisation reactions (overview given in Figure 1-9).222  It is also possible to design and 
synthesise RAFT agents with additional functionality built into their R and Z groups.223 A wide 
range of different functional moieties have been incorporated into polymeric end groups in this 
fashion, but of particular attention in recent years has been the incorporation of ligation 
chemistries to allow for the conjugation of polymers to other materials. Some examples of these 
include activated esters,224, 225 alkynes and azides for copper catalysed cycloaddition reactions,226, 
227 maleimides,228 boronic esters,229 dienes and dienophiles.230, 231 These ligation chemistries have 
allowed for the conjugation of polymeric chains to other polymeric chains for block copolymer 
synthesis, proteins and antibodies forming bioconjugates, or for coating inorganic nanoparticles 
and surfaces. By modifying both the Z and R groups of the RAFT agent it is possible to synthesise 
hetero-telechelic polymers, with different functionality at both chain ends, greatly expanding the 
ability to build multi-functionality into these materials.232, 233 The use of conjugation strategies 
such as these, for the formation of polymer-protein bioconjugates will be explored in Chapter 5. 
 
Figure 1-9. Overview of thiocarbonylthio end group modifications (M': radical, [H]: hydrogen donor, M: monomer)
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1.4. Hyperbranched polymers in molecular imaging 
The synthesis of hyperbranched polymers and their unique properties have been described in the 
previous section. These properties include their globular and unimolecular structure, high levels of 
chemical functionality, branched architecture, and their relatively small size compared to other 
nano-particulate systems.234 These properties make them especially well suited for use as 
molecular imaging agents, which will be discussed in more detail below. 
It has been discussed previously that hyperbranched polymers possess high levels of 
reactive functional groups within their structure, compared to linear polymers of similar 
hydrodynamic volume and chemical composition. This allows for the incorporation of high 
concentrations of imaging ligands, providing materials with high SNR. A specific example of this 
was shown by Hayashi et al, who functionalised hyperbranched poly(4-bromomethyl styrene) with 
tertiary amine bearing TEMPO derivatives.235 They were able to measure approximately 20 TEMPO 
radicals per hyperbranched polymer with electron spin resonance spectroscopy. These showed 
comparable relaxivities to the clinically used Gd3+-DTPA (Magnevist®). A similar approach was used 
to graft approximately 17 Gd3+-DTPA chelates to a Boltorn® based hyperbranched polyester core, 
which led to a threefold increase in relaxivity over free Gd3+-DTPA.236 This idea has been utilised in 
other imaging modalities beyond MRI, including optical fluorescence,237 PET238 and SPECT 
imaging.239 
The high level of chemical functionality can also be utilised to develop multipurpose 
nanomaterials. By incorporating both an imaging and targeting ligand, along with a therapeutic 
drug, it is possible to develop a theranostic agent. Theranostics are able to detect and visualise a 
disease, deliver a therapeutic and monitor the treatment, all in one material.240 Xiao et al were 
able to attach the chemotherapeutic doxorubicin to the pendant groups of their polymers, and the 
copper-64 chelator NOTA and a cyclic RGD peptide for targeting to their end groups.238 They were 
able to show that the targeted conjugate with attached doxorubicin was more toxic to U87MG 
cells in vitro than the non-targeted control. Using PET they demonstrated that the targeted system 
also showed an increased up take in vivo, and that this uptake was decreased when a blocking 
dose of free cyclic RGD was co-injected. The potential of using hyperbranched polymers to 
develop multifunctional materials, is a very powerful tool for molecular imaging and theranostics. 
The size and three dimensional shape of nanomaterial based imaging agents are well known to 
affect their biodistribution and pharmacokinetics.241, 242 The branched architecture of 
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hyperbranched polymers generally gives them a compact and globular structure. Their 
hydrodynamic diameters (Dh) are much smaller than their linear analogues of the same molecular 
weight. This smaller diameter compared to linear polymers would suggest more rapid excretion, 
but this is not what has been reported in the literature. Once a minimum size threshold is reached, 
where the size of the nanoparticles is larger than the size of glomerular pores, then the number of 
branches affects their rate of filtration. This is due to the decreased ability for branched polymers 
to deform and reptate through the pores (Figure 1-10).243 These results match the theoretical 
predictions, for the energy barriers to the entry of a hyperbranched polymer into nanopores.244, 245 
The opposite is true when comparing branched polymers to solid nanoparticles of a similar Dh, 
where their flexible nature allows them to deform through a pore that a hard sphere cannot. 
These properties are advantageous for molecular imaging because it can greatly increase their 
vascular circulation time. This phenomenon has been exploited to develop agents for vascular 
imaging.246  
 
Figure 1-10. Diagrammatic examples of the effect that nanoparticle architecture has on the rate of passage through a pore of 
approximately equivalent hydrodynamic volume.
243
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Hyperbranched polymers can be used to form the core of an amphiphilic core-shell system. 
This gives a micellar-like structure with the advantage of stability, due to their intrinsically cross 
linked nature. This amphiphilic structure can provide a hydrophobic core which can be used for 
encapsulation of hydrophobic imaging agents and drugs.247 The cavities within the core of 
hyperbranched polymers have been exploited for the in-situ synthesis of fluorescent quantum 
dots.248-250 The cationic core of hyperbranched poly(amido-amine)-b-PEG polymer could 
spontaneously sequester cadmium(II) ions from aqueous solution, which upon reaction with 
sulfide ions formed CdS quantum dots. The inclusion of acylhydrazone bonds in the 
hyperbranched structure provided pH-sensitive materials, where the fluorescence intensity 
increased upon degradation of these labile moieties below pH 5.5.251 Hyperbranched π-conjugated 
polymers have been shown to possess improved fluorescence properties over linear polymers, 
because the branched structure can prevent both hydrophobic and π-π* stacking.252, 253 By 
forming amphiphilic core-shell structures with these materials, it is possible to make them 
soluble/dispersible in aqueous solutions and therefore can be used as molecular imaging agents. 
254-256 
The branched nature of hyperbranched polymers has also been used to improve the 
imaging properties of fluorinated polymers for 19F MRI. The desirable properties of 19F MRI has 
been discussed previously in section 1.1.2 of this chapter. In order to realise these properties, the 
materials require a high concentration of chemically identical 19F atoms. Inclusion of large 
quantities of these moieties in an amphiphilic material, dispersed in aqueous media, can require 
long image acquisition times (hours).257, 258 It has been shown that the T2 relaxation time of these 
fluorinated species is a good indicator of imaging performance, and that longer T2 times were 
achieved by maintaining high mobility and flexibility of fluorinated groups.259-261 By copolymerising 
fluorinated monomers into a hyperbranched polymer with a water soluble monomer 
(dimethylaminomethyl methacrylate), the association of the fluorinated groups was frustrated and 
imaging times decreased dramatically (< 10 minutes).143 The multifunctional nature of the 
hyperbranched polymers has also been exploited, to include optical dyes and targeting ligands, to 
provide targeted multimodal imaging of melanoma in a murine model.215 
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1.5. Project Outline and Objectives 
As discussed in section 1.2, molecular imaging is an extremely powerful tool for preclinical 
experimentation, but more work is needed in designing new materials with specific properties that 
enhance the performance of the imaging agent. Hyperbranched polymers are proposed as 
materials that can be used for this task, owing to their unique structural and chemical properties, 
as discussed in section 0. Alongside the development of hyperbranched polymers as imaging 
agents, molecular imaging can be used as a tool to evaluate the performance of these materials as 
nanomedicines. Imaging is well suited for preclinical experiments involving in vivo animal models 
and allows for a greater understanding about the interplay between the physicochemical 
properties of hyperbranched polymers and their biological behaviour. This thesis aims to explore 
two major goals: 1) the development of hyperbranched polymers as molecular imaging agents, 
and 2) to use molecular imaging to gain a better understanding of how the materials properties 
affect their performance in vivo. Ultimately, this will aid in the development of these materials as 
naomedicines and theranostics. To achieve these goals a number of specific objectives have been 
defined: 
Objective 1: To design and synthesise hyperbranched polymers, for use as 
multimodal molecular imaging agents. 
Multimodal molecular imaging agents, which are able to incorporate multiple imaging modalities 
into one construct, are tools with obvious advantages due to their ability to provide 
complementary information about the behaviour of a material in an in vivo model. Polymeric 
materials are good candidates for multimodal agents due to their ability to carry appropriate pay-
loads of imaging moieties, and to tune the pharmacokinetics of these molecules for a required 
application. The incorporation of multiple imaging modalities into a single construct is relatively 
well established in the literature, but there are limitations to reported approaches in their ability 
to be translated into clinical systems. Firstly, the imaging modalities incorporated into the 
nanomaterial must be detectable in preclinical animal models, and ultimately within a patient. 
Secondly is designing these materials to impart a number of favourable properties to the device 
which will improve image quality, such as tuning the blood circulation time to accumulation at the 
targeted site, or to increase contrast by decreasing uptake in non-target organs.  This thesis aims 
to use hyperbranched polymers to develop multimodal molecular imaging agents suitable for 
preclinical molecular imaging. To achieve these goals, materials were synthesised to conform to 
the following specific design criteria: 
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 Polymers must be biocompatible and safe for use in vivo. 
 Polymers must contain multiple, orthogonal chemistries for facile attachment of imaging and 
targeting ligands. 
 Attached imaging moieties must be suitable for use with in vivo preclinical imaging 
experiments. 
 Chapter 3 describes the synthesis of hyperbranched polymer structures, which fulfil these 
criteria. The hyperbranched polymers were synthesised via RAFT polymerisation and were 
rendered biocompatible by incorporating poly(ethylene glycol) methyl ether methacrylate as a 
major component of the feed. RAFT polymerisation was chosen because it is a robust technique 
for producing hyperbranched polymers. It can provide good control over molecular weight and 
branching, and also provides functional end groups that can be used for post-polymerisation 
modification. The chemical and physical properties of these systems were fully characterised using 
techniques such as NMR spectroscopy, UV-Vis spectroscopy, SEC-MALLS and DLS. This 
characterisation was critical for understanding the relationship between the physicochemical 
properties of the hyperbranched polymers (e.g. hydrodynamic size) and their biological behaviour 
(e.g. time retained within the body).  
 All imaging molecules used in this work were selected for their proven compatibility with 
pre-clinical imaging, specifically with in vivo models. Commercially available NIR fluorophores were 
used to allow for whole animal fluorescence imaging. NOTA and Desferrioxamine B were selected 
as chelators for copper-64 and zirconium-89 respectively, which have been proven to be effective 
ligands for in vivo imaging experiments. These isotopes have radioactive half lives that more 
closely match the biological half lives of polymeric materials circulating in animals. This allows for 
longer experiments to be performed, providing more information about the ultimate fate of the 
polymeric materials in vivo. Attachment of these imaging ligands was achieved through coupling to 
the functional end groups of the hyperbranched polymers. 
Objective 2: To study the properties of hyperbranched polymers, in vivo, utilising 
the complementary information provided by multimodal molecular imaging 
techniques  
This thesis will use molecular imaging as a tool to inform on the interplay between the 
physicochemical properties of hyperbranched polymers and their performance in vivo. This will 
ultimately provide insight into how to better design these materials to enhance their use as 
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nanomedicines. PET and fluorescence imaging techniques were selected as the primary imaging 
modalities for exploring the behaviour of the hyperbranched polymers in vivo. This is due to their 
unique strengths, which provide different but complementary information on the behaviour of 
nanomaterials in vivo. Fluorescence imaging is a rapid technique that can relatively simply be used 
to economically image large cohorts of mice. The signal from the fluorophores is generally stable 
over long periods of time, which allows for long term studies looking at the behaviour of materials 
to be performed easily. PET imaging is more complex, but can provide much more detailed and 
quantifiable information about the biodistribution of the polymers. This is because the PET signal 
is not attenuated when passing through the tissues of the animal. The radioactive decay of the 
isotopes reduces the amount of detectable signal over time, which limits the timescale of PET 
experiments.  
 Chapter 3 and Chapter 4 describe how these two molecular imaging techniques, combined 
with anatomical imaging techniques (x-ray, CT, MRI), were used to investigate the in vivo biological 
behaviour of hyperbranched polymers. In Chapter 3, the relationship between the physical 
properties of these hyperbranched polymers (size and branching), to their biodistribution and rate 
of excretion were explored. This leads into an investigation looking at the ability of these 
materials, to passively target a tumour model, due to their long circulation times. In Chapter 4 
PET-MRI is used to probe not just the whole animal biodistribution, but also the distribution of 
these materials in a single tissue. These experiments provide insight into the role of irregular 
tissue vascularisation on the heterogeneous distribution of the polymers across a tumour. This 
phenomenon is important to overcome, in developing these materials as drug delivery vehicles, to 
ensure that the therapeutic payload is delivered to all areas of the tumour and thus preventing 
relapse and resistance. 
Objective 3: To develop novel strategies for conjugation of polymeric molecular 
imaging agents and biomolecules for use as targeted systems. 
In order to enhance the effectiveness of hyperbranched polymers as molecular imaging agents 
and ultimately nanomedicines, it is important to direct them to molecular targets of a desired 
tissue or cell type. Generally these targets are specific for a disease state, so that the materials can 
be used as therapeutics. A common approach for generating materials that possess a high affinity 
for their target is to conjugate them to antibodies, peptides, aptamers or other biological 
molecules. In order to achieve this, highly specific and facile chemistries are required for these 
bioconjugation reactions. In chapter 5, two different approaches will be explored for the 
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conjugation of hyperbranched polymers to single chain variable fragments bioengineered from an 
antibody (scFvs): 1) copper catalysed Huigsen 1,3-dipolar cycloadditions (CuAAC), and 2) enzyme 
catalysed cross coupling by the sortase enzyme. 
 In order to achieve this, two different heterobifunctional oligo(ethylene glycol) (OEG) ligands 
were synthesised, to introduce the necessary functionality for conjugation, on either the 
hyperbranched polymer or the scFv. Both OEG linkers possessed an azide functionality at one end, 
to allow attachment to the alkyne end groups of the hyperbranched polymers. CuAAC is a widely 
utilised technique for the formation of conjugates, but requires the necessary chemical 
functionality (alkyne and azide) to be present on both materials. Hence, the first linker was 
designed with a terminal activated ester, which allows for attachment to lysine residues on any 
protein based targeting molecule. This will then provide the necessary azide functionality on these 
materials, allowing for CuAAC coupling to the alkyne functionality of the hyperbranched polymers. 
 The second OEG linker synthesised possessed azide functionality and a short triglycine 
peptide sequence. This triglycine motif is recognised as a substrate by the sortase enzyme, which 
can couple it to another short peptide motif that has been incorporated into the sequence of an 
scFv to form a covalent linkage. This approach is promising, because it requires only mild reaction 
conditions, has been shown to be relatively rapid and can be used to conjugate any expressed 
protein sequence that has been modified with the recognition motif. The development of these 
hyperbranched polymers into targeted therapeutics and theranostics will be greatly enhanced by 
the generation of these new methodologies, which can easily generate a wide range of polymer-
scFv bioconjugates. 
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Chapter 2. Polymers for molecular imaging 
2.1. Introduction 
The field of molecular imaging was introduced in Chapter 1, which highlighted the different 
opportunities that arise through utilisation of the most common techniques. The concept of using 
polymers for developing molecular imaging agents was briefly introduced, along with some of the 
key strengths of these materials. In this chapter, the synthesis and applications of polymeric 
materials as molecular imaging agents will be discussed further. The current state of the literature 
has been reviewed to highlight the latest developments, focusing on materials that have been 
designed for use in vivo or that show significant improvement on current technologies.  
2.2. Polymers for molecular imaging: mini review 
Begins on next page. 
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2.3. Conclusions 
The unique combination of physical properties that polymers posses, present novel opportunities 
for the development of advanced molecular imaging agents. They can be used to alter the 
pharmacokinetics of a probe, for example the circulation time of a small molecule imaging probe 
can be increased, thus can allowing for use as blood pool imaging agents in contrast enhanced 1H 
MRI.1 Polymers can be used to make multifunctional materials that possess multiple imaging 
molecules, or combining additional functionality such as targeting ligands or therapeutics.2, 3 
Finally the concentration of imaging molecule attached to or contained within the polymeric 
structure can be tuned to the necessary application. For example with a low sensitivity modality 
such as 19F MRI, a high number of imaging molecules (in this case 19F nuclei) can be incorporated 
as pendant side chains.4 Alternatively molecules for highly sensitive modalities, such as PET, can be 
incorporated at lower concentrations on the end groups.5 . In order to fully realise the potential of 
polymeric molecular imaging agents, more research is required into the synthetic strategies 
required for their production, and a better understanding of their behaviour in complex biological 
systems. These concepts will be explored further in the following chapters.  The design and 
synthesis of highly functional hyperbranched polymers as molecular imaging agents is described in 
Chapters 3 and 5. Molecular imaging will then be used as a tool to understand the relationship 
between the physicochemical properties of these materials and their behaviour in vivo. For 
example the relationship between their size and their rate of clearance is explored in Chapter 3. 
This is investigated more thoroughly in Chapter 4, where the heterogeneous distribution of the 
hyperbranched polymers across a tumour is visualised, which is caused by the limited penetration 
of the large polymers into the tissue from the vasculature. 
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Chapter 3. Synthesis of a multimodal molecular 
imaging probe based on a hyperbranched polymer 
architecture. 
3.1. Introduction 
In molecular imaging, no single technique can provide all the necessary information about a 
biochemical process, and each individual technique possesses its own strengths and weaknesses. 
By combining modalities into a single experiment, it is possible to gain complementary information 
from different techniques and to offset the weakness of one technique with the strengths of 
another. Modalities that provide molecular information (e.g. optical, PET) are often combined with 
an anatomical imaging technique (such as CT, MRI). The molecular modality can provide 
information about the probe of interest, which can be complemented by the anatomical and 
physiological information from the second modality.1 Recently, multiple molecular modalities have 
been investigated to provide complementary molecular information on a system or process of 
interest.2 This can be done by looking at separate probes/molecules with multiple techniques; 
combining the information from each molecules helps to build up a more complete understanding 
of the system as a whole. Alternatively one molecule can be constructed, which has the necessary 
functionalities for multiple modalities. This allows for various modalities to be used to follow the 
one molecule of interest, utilising the differing strengths of each technique to offset limitations of 
the others. 
 By using individual, chemically distinct imaging probes, it is possible to monitor how 
different biological processes relate to a single physiological response.  As an example, Manning et 
al used two NIR fluorescent probes and the tumour proliferation marker [18F]FLT (3′-[18F]fluoro-3′-
deoxythymidine).3 One of the fluorescent probes was used to visualise expression of the 
endothelial growth factor receptor (EGFR), and the second was an Annexin V conjugate, which was 
used as a marker for apoptosis. They were able to show that after treatment with Cetuximab, 
despite decreased level of EGFR expression and increased levels of apoptosis, there was no 
reduction in measured tumour proliferation. The main limitation of these multi-agent approaches 
is controlling the pharmacokinetics of the different molecules, to gain temporally-matched 
information.  
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 The combination of multiple modalities onto one construct removes the issue of matching 
the pharmacokinetics of the various probes, since they are intrinsically matched to that of the 
carrier. This can also lead to shorter imaging times and reduce the burden on the subject’s 
excretion system, an issue that arises through administering multiple agents.4 Most examples of 
multimodal imaging probes have been related to nanoparticles, due to the availability of a high 
concentration of functional groups for attachment of multiple molecules,5 though there are also 
examples of proteins,6 peptides7 and small molecule systems.8 In order for a material to be 
developed into a multimodal molecular imaging agent, it must contain an appropriate payload of 
complementary imaging molecules, depending on the sensitivity of the technique. It is also 
favourable if it can improve the biocompatibility of the imaging molecules, and be able to target a 
specific biological target.  
 As discussed in Chapter 1, hyperbranched polymers are particularly suited to use as 
molecular imaging agents, due to their unique combination of physicochemical properties, 
including their globular and unimolecular structure, high level of chemical functionality, branched 
architecture and their relatively small size compared to other nano-particulate systems.9 In 
particular, the high level of chemical functionality makes them particularly suited for use in 
developing multimodal imaging agents, because they provide multiple attachment points for for a 
variety of imaging moieties. 
 In this chapter, the ’Strathclyde’ approach using RAFT polymerisation methodologies, 
described in Chapter 1, will be utilised to produce biocompatible hyperbranched polymers with 
well defined physical properties and architectures. These polymers will provide the framework for 
producing novel multimodal molecular imaging agents, capable of both fluorescence and PET 
imaging. This will be achieved by functionalising the end groups with the bifunctional macrocyclic 
chelator NOTA-isothiocyanate, which will bind the radioactive PET tracer copper-64, and either the 
far-red dye Alexafluor-647 or the near-infrared fluorophore IrDye®-750. Once it has been 
demonstrated that these materials are suitable for preclinical molecular imaging in a mouse 
model, these imaging techniques will be used to probe the relationship between the physical size 
and level of branching of these materials, and how they are excreted. The possibility of using these 
materials to visualise tumours will also be investigated, with a murine model for melanoma. It will 
be demonstrated how preclinical imaging techniques can provide critical information for 
understanding the performance of hyperbranched polymers as nanomedicines. 
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3.2. Synthesis of a multimodal molecular imaging probe based on 
a hyperbranched polymer architecture. 
Begins on next page.
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3.3. Conclusions 
This chapter described the synthesis and characterisation of two series of hyperbranched 
polymers, with controlled size and architecture. The first series had a molar mass of 31 kDa, 3.8 
branch points and a hydrodynamic diameter of 5.1 nm. A second larger series was synthesised 
with a molar mass of 53 kDa, 6 branch points and a hydrodynamic diameter of 11.6 nm. These 
materials were modified and functionalised to introduce NIR fluorophores and copper chelators to 
produce multimodal molecular imaging agents, capable of in vivo fluorescence and PET imaging. 
These materials were observed to be effective multimodal imaging agents, with in vivo 
visualisation of both fluorescence and PET modalities possible. This provided a mechanism to 
study the behaviour of the hyperbranched polymers under physiological conditions in living 
subjects. By utilising the quantifiable nature of PET, it was shown that the larger, more highly 
branched polymer was retained in the mouse for much longer than the smaller, less branched 
material, which underwent a period of rapid excretion in the first 5 hours post injection. This was 
hypothesised to be due to the renal clearance of the smaller hyperbranched polymer. Both 
imaging modalities showed that the material was taken up into the tissue of a solid melanoma 
that was developed using a subcutaneous model, but fluorescence imaging provided longitudinal 
studies up to minimum 72 hours, showing that the material had not been cleared from the tumour 
over the time-frame of the experiment. While the whole animal biodistribution of the polymeric 
materials has been visualised, the distribution of the polymer in individual tissues is also an 
important phenomenon that needs to be measured. This is especially important in cancerous 
tissue, because heterogeneous distribution of therapeutic materials can lead to ineffective 
treatment of the disease. While this can be achieved by using ex vivo fluorescence imaging, it 
would be preferable to be able to visualise this phenomenon in a live mouse. It would also be 
preferable to use a technique where the signal is less attenuated by the physiological properties of 
the tissues, such as was seen with melanin expression in the melanoma tumours. This will be 
explored in Chapter 4, by combining the molecular information gained from PET imaging, with the 
anatomical information gained from CT and MRI.  
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“Synthesis of a multimodal molecular imaging probe based on a hyperbranched 
polymer architecture.” 
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3.5.2. Model reactions for the conjugation and characterisation of isothiocyanate 
functionalised bifunctional chelates. 
 
Figure 3-1. Chemical structure of NOTA-NCS used in the paper above, and the model compound DOTA-NCS. The green oval 
highlights the reactive isothiocyanate chemistry used for conjugation to primary amine. 
The commercially available bifunctional chelate 2-(p-isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA-Bn-NCS) is widely used for 64Cu-PET imaging. This is 
due to its high selectivity for Cu2+ over other metal ions, low exchange rate at physiological pH and 
high in vivo stability.10-12 The isothiocyanate group allows for facile attachment to primary amines. 
Characterisation of reactions involving the end groups of polymers can be difficult, due to the 
relatively low concentration of these chemical groups in comparison to the polymer repeat units. 
As such a small molecule model reaction was performed between the isothiocyanate of DOTA (an 
analogue for NOTA, see Figure 3-1) and the amine of the azide functionalised PEG spacer. 
Characterisation of this reaction on the hyperbranched polymers was further hindered by the 
relevant peaks in 1H NMR being obstructed by peaks representing PEGMA in the polymers. As such 
this model reaction proved highly effective for validating the reaction conditions for attaching 
NOTA-NCS to the hyperbranched polymers. 
 Firstly each of the starting materials was characterised with 1H NMR and 1H-1H correlation 
spectroscopy (COSY). 1H-1H COSY is a 2D NMR technique, which can detect proton spins that are 
scalar coupled to one another, registering a correlation between protons on adjacent carbons.13 
Figure 3-2.A shows the proton spectrum of the 11-azido-3,6,9-trioxaundecan-1-amine PEG spacer. 
There is a collection of overlapping multiplets between 3.45-3.60 ppm. These peaks are assigned 
as the four methylene groups (f-i) in the middle of the PEG spacer, as they are the most chemically 
similar species. The methylene group adjacent to the primary amine should be shifted furthest 
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upfield, due to the lower electronegativity of amine groups in comparison to oxygen atoms; 
therefore this group is assigned to the triplet at 2.63 ppm (d). 1H-1H COSY spectrum shows a 
coupling between this peak with the triplet at 3.35 ppm (e), suggesting this peak represents the β-
methylene to the primary amine (Figure 3-3). Finally the triplets at 3.40 (k) and 3.60 ppm (j) show 
a cross correlation in the COSY spectrum, and are assigned as the last two chemically distinct 
methylenes α- (3.60 ppm) and β- (3.40 ppm) to the azide group.  
 
Figure 3-2. 
1
H NMR characterisation of model reaction between DOTA-Bn-NCS and azido-PEG-NH2. A) 
1
H NMR spectrum of 11-
azido-3,6,9-trioxaundecan-1-amine. B) 
1
H NMR spectrum of NOTA-NCS. C) 
1
H NMR spectrum of PEG functionalised DOTA 
 Upon reaction with DOTA-Bn-NCS, the triplets at 2.63 ppm (d) and 3.35 ppm (e) disappear 
and two new peaks appear at 2.80 ppm (d’) and 3.52 ppm (e’) (Figure 3-2.C), which correlate 
together in COSY experiments (Figure 3-4). This shift to lower field is due to conversion of the 
amine to a thiourea species. There is no change in the chemical shift of the methylene groups 
closest to the azide, as would be expected. As further evidence to formation of the thiourea, there 
is a change in coupling pattern of the protons on the aromatic ring of DOTA-Bn-NCS. On the free 
ligand, these protons appear as a doublet of doublets, as would be expected for a para substituted 
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aromatic ring (Figure 3-2.B).14 Upon coupling these peak now appear as three peaks, a singlet (a’ 
7.4 ppm) and two doublets shifted upfield (b’ and c’, 7.10 and 7.20 ppm), which each integrate to 
half the intensity of the singlet (Figure 3-2.C). This suggests that these peaks represent the two 
protons on the aromatic ring ortho to the thioamide group, as this group is less electronegative 
than the isothiocyanate. In the COSY spectrum the two doublets both couple to the singlet, but do 
not couple to each other (Figure 3-5). These two protons do not appear equivalent, as would be 
expected. This could be due to the flat rigid nature of the thiourea group and decreased rotational 
freedom due to attachment of the large DOTA and PEG species. This could generate slightly 
different chemical environments for the ortho protons, making them inequivalent, and also 
causing them to each split into doublets.   
 Once formation of a bond between the isothiocyanate of NOTA and the amine of the PEG 
spacer was confirmed with the model reaction, these reaction conditions could be used for 
attachment of the ligand to the modified hyperbranched polymer cores, as reported in the paper 
above. 
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Figure 3-3. 
1
H-
1
H COSY spectrum of 11-azido-3,6,9-trioxaundecan-1-amine 
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Figure 3-4. 
1
H-
1
H COSY spectrum of PEG functionalised DOTA (expansion of region from 2.5-3.7 ppm) 
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Figure 3-5. 
1
H-
1
H COSY spectrum of PEG functionalised DOTA (expansion of region from 6.7-8.2 ppm) 
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Chapter 4. Imaging tumour distribution of a 
polymeric drug delivery platform in vivo by PET-
MRI 
4.1. Introduction 
Polymer-based nanomedicines have seen extensive development over the last three decades, with 
researchers attempting to achieve improved delivery and therefore a reduction in side effects of 
small molecule pharmaceuticals and biological therapeutics.1, 2 While there has been significant 
development of these polymeric materials into clinical products,3 there are still significant 
limitations to the effectiveness of such therapies, the causes of which must be investigated and 
overcome. As has been discussed previously, molecular imaging can be employed as an insightful 
tool for investigating the cause of these limitations and thus improve the preclinical development 
of these devices. 
 When molecular imaging is combined with a therapeutic agent, this new class of molecules 
are termed ‘theranostics’. These materials allow for the simultaneous treatment of a disease, as 
well as visualisation of the diseased tissue, visualisation of the therapeutic release, or monitoring 
of the disease progression with treatment.4 Molecular imaging allows for the direct in vivo 
visualisation and measurement of the uptake of therapeutics by the tissue or even cells of interest, 
off-target effects, clearance of the material and the efficacy of the therapy.5 Rapid improvements 
in preclinical molecular imaging technologies are allowing researchers to probe the behaviour of 
nanomedicines more thoroughly. In particular, unique information is provided by the use of 
techniques that are isotropic, quantitative and able to visualise in three dimensions, such as PET 
and MRI. 
Cancer treatment is one area where polymer based theranostics are being developed. Solid 
tumours posses many unique physiological features that distinguish them from healthy tissues. 
Leaky blood vessels and poor lymphatic drainage are commonly targeted by nanotherapeutics, to 
enhance delivery and accumulation into cancerous tissue.6, 7 Once the nanomaterials enter the 
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tissue, there are significant barriers to these nanoparticles penetrating homogenously throughout 
the tumour mass. These include necrotic regions where diffusion may be low, the high interstitial 
pressure observed in tumour tissue and the stiff extracellular matrix. These properties have been 
shown to severely limit the penetration of both small molecule drugs8, 9 and nanotherapeutics.10, 11  
This heterogeneity in tissue distribution has long been recognised as being responsible for the 
variation in therapeutic outcomes between patients.12-14 While these phenomena have been 
widely studied, experiments have mostly been limited to sophisticated in vitro models (such as 
spheroids), or the analysis of ex vivo tissues. 15 There are examples of in vivo imaging being 
performed through the use of intravital microscopy, but this is an invasive procedure which poses 
risks of infection and complications caused by physiological responses to the surgery.16 Preclinical 
molecular imaging provides for a non-invasive way to investigate these effects, thus allowing the 
behaviour of the theranostic to be examined in vivo. 
In this chapter, the hyperbranched polymers described previously were modified to 
synthesise model theranostic agents. To do this the hyperbranched polymers were functionalised 
with folic acid. Our group has demonstrated previously that folic acid is an effective targeting 
ligand for these hyperbranched polymers systems towards melanoma tumours.17 NOTA was again 
incorporated into the chemical structure as a chelator for copper-64, allowing PET imaging. In 
order to develop a fundamental understanding of how the nanomaterial behaves in the in vivo 
model, the simplest system was chosen for this study. Thus, the therapeutic component was not 
included in the structure to minimise both synthetic and analytical complexity. Firstly two imaging 
systems were compared, preclinical PET-CT and PET-MRI, to look at the different physiological 
information that could be attained from CT and MRI to complement the PET modality. Using PET 
we were able to investigate how the hyperbranched polymers were distributed within the tumour 
tissue. MRI was able to provide additional information about how this distribution related to the 
tumour physiology, which was not available from CT. These finding will provide crucial information 
about how these materials could perform as theranostics in the future. 
4.2. Imaging tumour distribution of a polymeric drug delivery 
platform in vivo by PET-MRI 
Begins on next page. 
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4.3. Conclusions 
In this chapter a hyperbranched polymer was synthesised to mimic the behaviour of a theranostic 
agent in tumour targeting. The hyperbranched polymer contained a chelator to allow for copper-
64 PET imaging and folic acid as a targeting ligand against the folate receptor that is over 
expressed in melanoma. The material was radiolabeled and administered to a mouse that had 
previously developed a subcutaneous melanoma tumour. The tumour showed significant 
accumulation of the polymer. The information acquired from preclinical PET-CT and PET-MRI was 
compared, and it was shown that MRI was able to provide more detailed information about the 
physiology of the tumour tissue than CT. It was also shown that by combining this information 
with the information from the PET modality, the distribution of the theranostic was constrained 
within the well vascularised regions of the tumour. Areas further away from the vasculature 
showed much lower copper-64 signal, indicating poor penetration of the theranostic into these 
regions. This is one of the first examples of using whole animal imaging to visualise this 
phenomenon in a live animal. This information has ramifications for the development of these 
hyperbranched polymer systems into drug delivery vehicles and theranostics. If the 
hyperbranched polymers cannot penetrate the whole tumour mass, then this could lead to 
ineffective treatment and continued tumour progression or relapse of drug resistance. While this 
chapter utilised folic acid as a targeting ligand, more specific targeting molecules are required for 
effective theranostics.18, 19 Targeting ligands with much higher specificities will be investigated in 
Chapter 5.  
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Chapter 5. Investigating highly efficient conjugation 
strategies for production of targeted molecular 
imaging agents 
5.1. Introduction 
The incorporation of a targeting moiety into the overall design of a nanomedicine is important for 
increasing the therapeutic effect of the material to diseased cells, and thus reducing the effect on 
healthy tissues.1 This can prevent unwanted therapeutic side effects, which often limit the 
maximum safe dose of a therapeutic and limit its efficacy for treating the disease.  Targeting can 
also provide a mechanism for monitoring disease progression through utilisation of molecular 
imaging techniques.2 Ultimately, the combination of molecular imaging and therapy onto a single 
targeted construct creates a theranostic agent, and this provides a facile means to simultaneously 
treat and monitor a disease. Nanomaterials can be targeted towards certain tissues by attaching a 
molecule that is recognised specifically by a certain cell type or other antigen. A range of 
biomolecules have been explored in the literature: from relatively simple small molecule species, 
such as folic acid,3 saccharides,4 or oligopeptides,5 through to large proteins such as antibodies.6, 7 
Antibodies have been demonstrated to be particularly effective targeting molecules for 
nanomaterials.8-10 
 Antibodies (or immunoglobulins) are a class of glycoproteins that play a crucial role in the 
immune system of vertebrate animals. All immunoglobulins share similar structural properties 
(Figure 5-1.b), with two identical antigen binding domains (Fab), each connected to an identical 
effector region (Fc). These regions are constructed from heavy and light chains, with variable and 
constant regions. The variable heavy (VH) and variable light (VL) chains are involved in antigen 
binding, giving the antibody its specificity. The number of constant heavy chain domains defines 
the isotype of the antibody (Figure 5-1.a).11 IgG is the most abundant isotype found in human 
blood and is the most commonly utilised for molecular targeting of therapeutics. Production of 
antibodies is achieved through either the in vitro or in vivo culture of hybridoma cells, which are 
fusions of antibody expressing B-lymphocytes (harvested from an inoculated animal) with 
immortalised myeloma cells.12 This leads to cell lines that can indefinitely produce IgG, which are 
now termed monoclonal antibodies (mAbs). MAbs have revolutionised the field of targeted 
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therapeutics, with a number of significant clinical therapies now available on the market, including 
mAb-PEG conjugates.13 Yet, there are significant difficulties in using them as targeting molecules 
for functional nanomaterials; materials which can provide other advantages beyond just extending 
circulation time.14 The greatest issue is their large size and complex structure. This can make 
expression of enough antibody for use as a therapeutic dose in a patient very inefficient and thus 
expensive. 15, 16 Targeted nanomaterials can be made smaller and comparatively simpler by 
instead using functional fragments of immunoglobulins. 
 
Figure 5-1.a) Schematics representations of the five major isotypes of mammalian immunoglobulins. b) Detailed structure of IgG, 
highlighting the Fac and Fc regions, the heavy and light chains, and the constant and variable regions. The complimentarity 
determining regions (CDR’s) hypervariable region is responsible for antigen binding.
17
 
 Fragment antibodies are smaller than their IgG derived parent molecules (20-50 kDa), but 
still retain most of their binding ability. They also lack the Fc region and so no longer have a 
mechanism for specifically activating an immune response.18, 19 The two classes most widely 
explored for nanoparticle conjugation are antigen binding fragments (Fab) and single chain 
variable fragments (scFv). (Figure 5-2) Third generation classes of molecules that involve either 
single domains,20 or multivalent structures of these two classes of molecules21-24 are also being 
developed (Figure 5-2). ScFvs are comprised of the smallest functional domains of an antibody 
that necessitate high affinity binding (i.e. the VH and VL regions). They are covalently linked by an 
oligopeptide chain of 10-25 amino acids, which prevents dissociation of the two domains in vivo.25 
They can be expressed in vitro in a range of hosts, including bacteria, yeast, plant, insect or 
mammalian cell lines. This is done in high density cell fermentation, which can produce high yields, 
leading to relatively efficient production costs.26 Due to the monovalent nature and small size of 
scFvs, there are limitations to their use, including instability in solution and low functional affinity 
combined with a short in vivo half life.27 Attempts at overcoming these limitations have included 
designing third generation antibodies that possess multivalent structures, but another approach is 
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to conjugate scFvs to nanomaterials to improve their pharmacokinetic profiles. An additional 
benefit of this strategy is that the polymer can be designed to provide additional functionality, 
such as carrying imaging or therapeutic molecules. This approach will be investigated in this 
chapter.  
 
Figure 5-2. Schematic representation of different antibody formats. a) An intact IgG highlighting the variable heavy and light 
chains. b) Classical antibody fragments. c) "Third generation” antibody fragment classes
28
 
 In order to produce polymer-scFv conjugates, it is crucial to have chemistries that are facile, 
highly chemoselective and efficient. These requirements ensure for the production of chemically 
homogeneous products, which are not hindered by side reactions with the various functional 
groups available on the scFv and can also prevent degradation or loss of activity of the scFv. There 
exists a vast array of chemical reactions that have been demonstrated as suitable for polymer-
protein conjugation; in this thesis, only two approaches will be explored. The first involves 
conjugation through copper catalysed azide-alkyne Huisgen 1,3-dipolar cycloaddition (CuAAC), 
which has been widely utilised and proven to possess high chemical selectively.29-31 The second 
technique is enzyme catalysed conjugation using the sortase enzyme, which is a technique that is 
much less well developed but offers some unique solutions to issues associated with chemical 
conjugations. While only these two techniques will be discussed here in detail, there are many 
more conjugation strategies described in the literature. This field is too broad to review in this 
chapter alone and the reader is directed towards dedicated reviews on the topic.32-35 
 While Huisgen 1,4-dipolar cycloaddition reactions had been known for many years,36-38 it 
wasn’t until the reaction (typically between an azide and alkyne) was found to be catalysed by 
a b
c
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copper(I) ions under mild reaction conditions, that it began to see widespread use.39, 40 A 
simplified description of the mechanism is highlighted in Figure 5-3, where the copper(I) ion first 
coordinates to the terminal alkyne group forming the Cu(I)-acetylide, and then to the nucleophilic 
nitrogen of the azide. The key bond forming step then occurs by reaction of the β-carbon (which 
has nucleophilic properties) of the copper acetylide to the terminal nitrogen (which has 
electrophilic properties) of the azide. Reduction and protonation will eventually lead to the 
organic triazole species and return of Cu(I) to the catalytic cycle.30, 41 Due to its relatively simple 
and robust reaction conditions, as well as high selectivity towards its substrates, CuAAC has 
proven popular in a range of scientific fields, including small molecule synthesis,31 organic 
macromolecular chemistry,42 nanoparticle functionalisation,43 and finally in protein conjugation.44 
Since proteins do not naturally contain alkyne or azide functionality, these groups must be 
introduced into the structure. One popular method for introducing the necessary functionality is 
by using a bifunctional molecule, which possesses either an alkyne or an azide along with a group 
that is highly reactive towards common protein functional groups (eg. amines, thiols, carboxylic 
acids).45 These small molecule linkers are generally employed in excess and purification of 
unreacted linker is relatively simple. This can then allow for the much more specific and efficient 
CuAAC to link the polymeric material with the desired protein in near-quantitative yield. While 
CuAAC has been proven to be highly efficient, there are limitations to its use, such as the fact that 
they generally require additional synthetic steps to introduce the necessary alkyne or azide 
functionality. Depending on the chemistry used for this modification, it can lead to non-site 
specific functionalisation of the protein.  Enzyme catalysed reactions offer one possible solution to 
overcome these difficulties. 
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Figure 5-3. Simplified mechanism for copper catalysed alkyne-azide cycloaddition.
30
 
 Enzyme catalysed conjugations of proteins has been proposed as a mild alternative to 
chemical conjugation that is amenable to the sensitive nature of proteins, with the additional 
benefit of site specific conjugation. One of the earliest examples of an enzyme that could be used 
in this way is transglutaminase (TGase).46 TGase catalyses the reaction between an alkylamine 
donor and the amide of glutamine, within a specific peptide acceptor sequence. This technique 
has proven useful for the conjugation of both small molecules,47 and polymers46, 48, 49 to proteins. 
A range of other enzyme based conjugation systems have also been explored,50-52 but the most 
widely utilised in the literature is the transpeptidase enzyme sortase.53  The reasons for its 
popularity will be discussed in more detail in the following sections.  
 Sortase is expressed by many Gram-positive bacteria, where it is involved in the anchoring of 
proteins to the cell wall and construction of pili, both of which are important in bacterial 
pathogenesis.54, 55 Sortase A recognises proteins bearing a “sorting” peptide sequence (LPXTG, for 
Staph. A.), where it cleaves the bond between threonine and glycine and forms a new bond to the 
N-terminus of an oligopeptide nucleophile (oligoglycine for Staph. A.) (Figure 5-4).53 Conjugation 
can be achieved at either the C- or N-terminus, depending on whether the sorting (C-terminal 
labelling) or oligoglycine (N-terminal labelling) sequence is recombinantly expressed on the 
protein (Figure 5-4). Generally, C-terminal labelling is preferred, because the simpler oligoglycine 
motif is more easily incorporated chemically onto the non-protein substrate. It is also possible to 
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combine both strategies to dual conjugate a protein, by using two different sortase enzymes that 
recognise different sorting sequences and nucleophiles.56 Since Sortase A is natively involved in 
the anchoring of a wide array of proteins to the cell wall of bacteria, it has the ability to accept a 
wide range of nucleophilic acceptors (including alkylamines), to conjugate large macromolecules 
and to conjugate onto surfaces.57-60 It is this wide applicability, while still maintaining substrate 
and site specificity, which makes sortase coupling a popular method in the field. 
 
Figure 5-4. Schematic of the two approaches for using the sortase enzyme for either C- or N-terminal labelling of a protein 
substrate (green) with a functional tag of choice (red). 
53
 
 In this chapter the formation of polymer conjugates as targeted molecular imaging agents 
that combine an scFv and hyperbranched polymer will be investigated. The scFv selected for this 
work binds to the epidermal growth factor receptor (EGFR). EGFR is a transmembrane protein, 
which upon binding of peptide growth factors promotes cell proliferation and differentiation.61 
EGFR has been shown to play a central role in the pathogenesis of a number of carcinomas and is 
often over expressed in diseased tissues.62 Two different approaches will be compared, chemical 
conjugation by CuAAC and enzymatic conjugation by Sortase A. CuAAC provides a technique that is 
applicable to a wide range of protein and polymer substrates, but generally requires additional 
synthetic steps to introduce the required alkyne or azide functionality. This will be compared to 
sortase conjugation, where conjugation is performed directly on the bioengineered scFv.   
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 In order to investigate these coupling methodologies, two heterobifunctional linkers will be 
designed and synthesised to provide the necessary functionality for coupling. The first linker 
contains an α-terminal azide and an ω-terminal activated ester. This will allow for conjugation to 
the lysine side chains of the scFv, providing azide functionality for CuAAC coupling to alkyne chain 
ends on the hyperbranched polymer imaging agent. The second linker will also possess an azide 
group for chemical attachment to the hyperbranched polymer. The other end of this linker will 
bear the oligopeptide triglycine, which will facilitate site specific Sortase A conjugation of the 
imaging agent to the  anti-EGFR scFv, which bears the sortase recognition sequence LPETG.  
 The design of the multimodal imaging agent used in this work has been adapted from that 
which was used in Chapter 3. A similar hyperbranched polymer core was synthesised using RAFT 
polymerisation, with exclusion of the FEA monomer because it was unwarranted as it added 
unnecessary complexity to the synthesis of the materials. The near-infrared fluorophore was 
replaced with the far-red dye Cy5, to allow for both in vitro and in vivo imaging. The NOTA chelator 
was also replaced with desferrioxamine-B (DFO), which binds the PET isotope Zirconium-89. The 
use of 89Zr, which has a radioactive half-life of 78 hours, will allow for the time frame for PET 
studies to be increased from the maximum three days achievable with 64Cu, up to two weeks. This 
will allow for longer term monitoring of these larger constructs in which the biological half-life is 
expected to be in the order of several days to weeks.63-66  In order to achieve simpler and more 
efficient incorporation of these imaging molecules, a new approach using radical initiators 
functionalised with activated esters was also investigated. 
5.2. Materials and methods 
5.2.1. Materials 
Unless otherwise stated, all reagents and solvents were purchased from Sigma Aldrich at the 
highest available purity and used as received. All monomers were passed through a short plug of 
basic alumina, immediately prior to use, to remove free radical inhibitors. Tetrahydrofuran and 
dimethylformamide were purified by a MB-SPS800 solvent purification system, prior to use. Cy-5 
amine (Lumiprobe) was used as received. Ultrapure water with a resistivity of 18.2 MΩ.cm was 
obtained from an Elga ultra pure water system. The 1 prop-2-yn-1-yl 4-
(((butylthio)carbonothioyl)thio)-4-cyanopentanoate (BTCAlk) RAFT agent and ACVA-PFP were  was 
synthesised as per published methods.67-69 FITC-DBCO was synthesised by reaction of fluorescein 
isothiocyanate with dibenzocyclooctyne-amine and purified by HPLC. Two anti-EGFR scFvs were 
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supplied from the National Biologics Facility (University of Queensland), having been produced 
with mammalian cell expression (CHO cells). The first anti-EGFR scFv used for CuAAC conjugation 
reactions possessed a His-tag for purification and a terminal cysteine (sequence shown in 
Appendix 5.7.1. ). The anti-EGFR scFv also possessed a His-tag, but had been designed to include 
the sortase recognition sequence LPETG (sequence show in Appendix 5.7.1. ). 
5.3. Instrumentation and characterisation 
NMR samples were prepared in either CDCl3 or DMSO-d6 and spectra were collected on either a 
AVANCE 500MHz or 700 MHz NMR spectrometer (Bruker), using the residual solvent peak as an 
internal standard. The 500 MHz spectrometer was fitted with a 5 mm BBO probe. 1H NMR spectra 
were acquired with a 45  pulse and 3.9 s acquisition time. 19F NMR spectra were acquired with 90 
 pulse and 0.6 s acquisition time. 13C NMR spectra were acquired with a 30  pulse and 1 s 
acquisition time. The 700 MHz spectrometer was fitted with a 5 mm CPTCI cryoprobe. 1H NMR 
spectra were acquired with a 30  pulse and 3.9 s acquisition time. 19F NMR spectra were acquired 
with 90  pulse and 0.3 s acquisition time. 13C NMR spectra were acquired with a 30  pulse and 1.3 
s acquisition time. 
 UV-Vis spectroscopy was performed on a Nanodrop 2000c spectrophotometer (Thermo 
Scientific). For quantification of trithiocarbonate groups, all samples were prepared in acetonitrile, 
at a concentration that gave a maximum absorbance at 307 nm less than 1.0. Protein A280 
measurements were performed using the micro-volume pedestal and the Nanodrop 2000c 
software package (Thermo Scientific). 
 Analytical size exclusion chromatography (SEC) for analysis of polymer size was performed 
on a system consisting of a 1515 Isocratic pump (Waters), a 717 auto sampler (Waters), Styragel 
HT 6E and Styragel HT 3 columns (Waters), a 2414 differential refractive index detector (Waters) 
and a Dawn 8+ MALLS detector (Wyatt). THF was used as the mobile phase at a flow rate of 1 
mL/min. Empower 2 (Waters) and Astra (Wyatt) software was used for data collection and 
processing. For the determination of molar mass, light scattering data was used with a measured 
dn/dc value of 0.0600 mL/g. 
 Preparative SEC for purification of synthesised polymeric materials was performed on an 
AKTA Prime Plus (GE Healthcare Life Sciences) fitted with a HiTrap desalting column (GE 
Healthcare Life Sciences), UV detector monitoring at 220 nm and a conductivity meter. Purification 
 102 
 
was run with a 20 % ethanol solution in ultrapure water as the running solvent, with 0.5 mL 
fractions being collected. Analysis of fractions was achieved by UV-Vis spectroscopy. 
 Liquid chromatography-mass spectrometry (LCMS) used a Waters 2695 separations 
module with a Waters 2489 UV detector (Waters Corporation). Samples at 1 mg/mL were applied 
to a Jupiter 5 µm C4 300 Å column (Phenomenex) at a flow rate of 0.2 mL min-1, using a linear 
gradient of 10-100 % (v/v) buffer B over 45 min with absorbance of the eluate monitored at 214 
nm. Buffer A was 0.01 % (v/v) trifluoroacetic acid (TFA) and buffer B was 0.01 % (v/v) TFA in 
acetonitrile. Eluate was injected directly into a Quattro micro API tandem quadrupole system in 
positive ion mode. Mass spectra for synthesised products were collected by direct injection into 
the MS module of 0.1 mg/mL solutions prepared in methanol. 
 Preparative HPLC was performed on a Waters 600 system equipped with a 2487 UV–visible 
detector set at 220 nm and 280 nm and running Empower software (Waters Corporation). The 
samples were injected into a Sunfire reverse phase C-18 OBD column (Waters Corporation) and 
run at 5 mL/min with either a gradient from water to acetonitrile, or isocratic with acetonitrile. 
 Hyperbranched polymer particle sizes were measured in ultrapure water using a Malvern 
Zetasizer. The diameters recorded (Table 1) are number averages (and standard deviations) of 5 
experiments conducted at 25 C. Samples were filtered through 450 μm PTFE filters prior to 
measurement. 
 MALDI-TOF analysis of the molar mass of scFv and conjugates was performed on an Autoflex 
II system (Bruker Daltonics). Samples were prepared by diluting 2 μL of scFv solution into 8 μL of 
0.1% trifluoroacetic acid in 50 % acetonitrile and water. 1 μL of this solution was spotted onto a 
ground steel target plate, mixed with 1 μL of saturated sinapinic acid solution (in same 0.1% TFA, 
50% acetonitrile solution) and allowed to recrystallise at 25 C. Spectra were acquired using linear 
positive mode. 
 Polyacrylamide gel electrophoresis (PAGE) was performed on an XCell SureLock® Mini-cell 
equipped with a power supply at 200 V for 30-40 min in MES buffer. Samples were prepared in 
NuPAGE Sample Reducing Agent (Invtirogen) and heated to 95 C for five minutes. Samples were 
applied to 4-12% crosslinked NuPAGE Bis-Tris pre-cast gels and SeeBlue protein ladder was used as 
a molecular weight standard (Life Technologies). Visualisation of protein bands was achieved by 
first washing the gels with deionised water for 3 × 5 min, then staining with coomassie blue 
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(SimplyBlue SafeStain, Life Technologies) for 15 mins at 25 C, and then destaining by soaking for 2 
h in deionised water. The visualisation of gels was performed on a Chemidoc MP System (Bio-Rad). 
 Flow cytometry of cell binding was performed on a BD LSR II analyser or  an Accuri C6 Flow 
Cytometer (BD Biosciences).  Cells were analyzed using filters for detection of Cy5 (666nm 
emission: FL-4: 675/25 nm ), FITC (525nm emission: FL-1: 533/30nm) and TAMRA (575 nm 
emission: FL-2: 585/40 nm). 
5.3.1. Synthesis of hyperbranched polymer multimodal molecular imaging agent 
 
Scheme 1. Synthetic strategy for the production of a hyperbranched polymer molecular imaging agent, incorporating the 
fluorophore Cy5 and desferrioxamine B. 
Hyperbranched polymer PEGMA (HBP 5-1) was synthesised using RAFT polymerisation techniques 
similar to what was described previously in chapter three and four. The polymerisation feed ratio 
was 20 PEGMA: 1 EGDMA: 1 RAFT agent: 0.2 ACVA. The RAFT agent used in this polymer was the 
butyl Z-group analogue of the one used previously: 1 prop-2-yn-1-yl 4-
(((butylthio)carbonothioyl)thio)-4-cyanopentanoate (BTCVAlk). The physical properties of this 
hyperbranched polymer were analysed via 1H NMR and GPC as described previously in Chapter 3, 
and are summarised in Table . 
 The trithiocarbonate groups were removed using a radical deprotection strategy that has 
been described in the literature.70 The azo-initiator used was 4,4′-azobis(4-cyanovaleric acid) 
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(ACVA), where the carboxylic acid groups had been activated as pentafluorophenol esters (AVCA-
PFP) as per literature protocols.69 150 mg HBP 5-1 (4.1 × 10-6 mol, 1 eq) was dissolved with 200 mg 
ACVA-PFP (3.3 × 10-4, 80 eq) in 2 mL THF and reacted at 70 C for 16 h. The solution was 
concentrated under vacuum and precipitated into 50% hexane in diethyl ether. The solution was 
centrifuged and the supernatant was decanted, the pellet was resuspended in the minimal 
amount of THF and precipitated again. This process was repeated twice to yield HBP 5-2. (Yield 50 
%) δH (700 MHz, DMSO-d6, ppm) 4.69 (2 H), 4.01 (60 H), 3.50 (670 H), 3.42 (66 H), 3.31 (678 H), 
3.23 (72 H), 0.95 (34 H), 0.78 (46 H). δF (700 MHz, DMSO-d6, ppm) -152.70 – -153.88 (m), -158.03 
(d), -162.72 (m). UV-Vis characterisation of the absorbance peak at 309 nm showed 97% loss of 
trithiocarbonate groups. 
 36 mg of HBP 5-2 (9.8×10-7 mol, 1eq) was dissolved in 450 μL of dry DMSO. A 50 μL solution 
of DMSO containing 0.5 mg of Cy5-NH2 (7 × 10
-7 mol, 0.7 eq) and 1 μL triethylamine (6.5 × 10-6 
mol, 6 eq) was added and allowed to react for 6 h at 25 C, protected from light. Then a 50 μL 
solution of DMSO containing 3.0 mg DFO (4.3 × 10-6 mol, 4.5 eq) and 2 μL of triethylamine (2.0 × 
10-5 mol, 10 eq) was added to the reaction and allowed to react for 16 h at 25 C, protected from 
the dark. When complete, the reaction was diluted with water and lyophilised to remove bulk 
DMSO. The polymer was then purified using automated size exclusion chromatography to yield 25 
mg of HBP 5-3. (Yield 70 %)δ H (500 MHz, DMSO-d6, ppm) 7.89 – 7.64 (2 H), 7.63 – 7.50 (1 H), 7.48 
– 7.29 (2 H), 4.76 – 4.59 (6 H), 4.23 – 3.87 (83 H), 3.68 – 3.35 (2915 H), 3.20 (330 H), 3.04 – 2.88 
(12 H), 2.64 – 2.47 (6 H), 2.30 – 2.12 (7 H), 1.92 (4 H), 1.56 – 1.40 (8 H), 1.40 – 1.25 (11 H), 1.25 – 
0.80 (23 H), 1.03 – 0.82 (22 H), 0.84 – 0.61 (43 H).  
 105 
 
5.3.2. Synthesis of heterobifunctional N3-OEG4-COO-PFP (5-5) linker for CuAAC 
conjugation  
 
Scheme 2. Synthetic strategy for the production of a bifunctional OEG linker for CuAAC conjugation reactions. 
1.5 g sodium hydride (0.7 eq, 3.8 × 10-2 mol, 60% in mineral oil) was stirred to a suspension in 48 
mL anhydrous THF under a nitrogen atmosphere. 10.4 g tetraethylene glycol (1 eq, 5.3 × 10-2 mol) 
in 24 mL anhydrous THF was added drop-wise over an hour, with the aid of a syringe pump, and 
left to react for a further hour at 25 C. Then 6.1 mL ethyl bromoacetate (1 eq, 5.5 × 10-2 mol) in 48 
mL of THF was added drop-wise over an hour at 25 C (syringe pump) and allowed to react for a 
further 2 h, before the reaction mixture was heated to 60 C and allowed to react for 16 h. The 
reaction was quenched with methanol, until all insoluble precipitate had dissolved. The reaction 
was dried to oil under vacuum and then dissolved in 3% hydrochloric acid (250 mL). The aqueous 
layer was extracted with three separate fractions of DCM (300 mL), which were each back 
extracted with brine (200 mL). The organic fractions were collected together and dried with 
magnesium sulfate and dried under vacuum. NMR analysis showed the presence of undesired OEG 
side products, with possible structures proposed in Scheme 4. Flash chromatography was 
performed with silica gel-60 as the stationary phase, and a gradient of 100 % DCM to 7% methanol 
in DCM. 1.5 g was collected as a mixture of the mono-functionalised product 5-1 (~50 %) and side 
products (~50 %). This mixture was used as is in the following step. 
 1.5 g 5-1 (1 eq 5.3 × 10-3 mol) was dissolved in 50 mL of DCM with 1.5 mL of triethylamine (2 
eq, 1.1 × 10-2 mol) and stirred on ice, under nitrogen atmosphere, for 15 min. 650 μL mesyl 
chloride (1.5 eq, 8.0 × 10-3 mol) dissolved in 25 mL DCM was added over 15 min and allowed to 
react for a further 90 min while on ice, before it was allowed to heat to room temperature and 
reacted for a final two hours. The reaction mixture was concentrated to an oil under vacuum and 
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then dissolved in 3% hydrochloric acid (100 mL), extracted with three portions of DCM (120 mL) 
and the organic layer was back extracted with three portions of brine (100 mL). The DCM solution 
was dried with magnesium sulfate and concentrated to an oil under vacuum. 1.9 g of 5-2 was 
recovered and used without further purification in the next step.  
 1.9 g 5-2 (5.3 × 10-3 mol) and 1.7 g sodium azide (5 eq, 2.6 × 10-2 mol) were dissolved in 50 
mL DMF and reacted at 65 C for 16 h. The DMF was then removed under vacuum, leaving a dry, 
off white powder. The powder was suspended in 200 mL of diethyl ether and filtered through 
Celite to remove excess sodium azide. The solution was dried to a yellow oil, under vacuum. Flash 
chromatography was performed twice, to remove side products, with silica gel-60 and a gradient 
of 100 % DCM to 50 % acetonitrile in DCM. It was still not possible to resolve the desired 5-3 from 
all of the OEG side products using this technique. The collected fractions contained a mixture of 
the desired product 5-3 (55 %) and of side product 5-3b (45 %). Purification of these two species 
was achieved with preparative reverse phase HPLC, running a gradient from 30% acetonitrile in 
water to 80% acetonitrile in water. Recovered 136 mg of 5-3 at greater than 95% purity.  δH (500 
MHz, Chloroform-d, ppm (J Hz)) 4.21 (1 H, q, J 7.1), 4.14 (1 H, s), 3.75 – 3.72 (1 H, m), 3.72 – 3.68 (1 
H, m), 3.66 (4 H, s), 3.39 (1 H, t, J 5.1), 1.28 (2 H, t, J 7.1). δC (700 MHz, Chloroform-d, ppm) 170.08 
, 70.46 , 70.27 , 70.25 , 70.23 , 70.22 , 70.19 , 69.65 , 68.27 , 68.17 , 60.39 , 50.31 , 13.85.ESI-MS: 
323 m/z [M + NH4]
+, 328 m/z [M + Na]+  
 136 mg of 5-3 was dissolved in 10 % hydrochloric acid (1 mL) and refluxed for 2 h. The 
reaction was quenched by neutralising to pH 7 with sodium hydroxide and lyophilised to a 
powder. The powder was suspended in 100 mL of DCM and dried with anhydrous magnesium 
sulfate. Insoluble sodium chloride and magnesium sulfate was removed with fluted filter paper 
and dried under vacuum. Recovered 110 mg of pure compound 5-4. (Yield: 88%) δH (500 MHz, 
Chloroform-d, ppm (J Hz)) 3.87 (1 H, s), 3.72 – 3.58 (3 H, m), 3.40 (1 H, dd, J 5.5, 4.5). δC (700 MHz, 
Chloroform-d, ppm) 173.21, 71.09, 70.58, 70.53, 70.52, 70.47, 70.40, 70.28, 70.24, 70.02, 69.96, 
69.93, 68.51, 50.59. ESI-MS: 300 m/z [M + Na]+ 
 50 mg 5-4 (1.8 × 10-4 mol), 130 mg pentafluorophenol (2 eq, 3.6 x 10-4 mol) and 4 mg 4-
dimethylaminopyridine (0.2 eq, 3.6 × 10-5 mol) were dissolved in 1 mL DCM and stirred on ice for 
15 min. To this, a solution of 74 mg N,N′-dicyclohexylcarbodiimide (2 eq 3.6 × 10-4 mol) in 1 mL 
DCM was added drop-wise, while on ice. The reaction was allowed to proceed at 0 C for 1 h, then 
at 25 C for 16 h. Insoluble side products were filtered off and the reaction mixture dried, under 
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vacuum. The residual oil was dissolved in 3 mL acetonitrile and divided into three 1 mL portions. 
Two of these portions were purified by preparative HPLC, using an isocratic mobile phase of 
acetonitrile. After collecting and drying the desired fractions, 9 mg of the activated linker 5-5 was 
recovered. (Yield 12%) δH (500 MHz, Chloroform-d, ppm (J Hz)) 4.55 (2 H, s), 3.85 – 3.79 (2 H, m), 
3.76 – 3.70 (2 H, m), 3.72 – 3.63 (11 H, m), 3.38 (2 H, t, J 5.1). δC (700 MHz, Chloroform-d, ppm) 
166.65, 141.73, 140.37, 138.77, 137.18, 124.48, 71.26, 70.70, 70.66, 70.64, 70.04, 67.87, 50.68. δF 
(700 MHz, Chloroform-d, ppm (J Hz)) -151.32 – -153.74 (m), -157.37 (t, J 21.7), -161.93 (td, J 22.3, 
4.9). 
5.3.3. Synthesis of heterobifunctional N3-OEG4-Gly3 (5-10) linker for sortase 
conjugation  
 
Scheme 3. Synthetic strategy for the production of a bifunctional OEG linker for sortase mediated conjugation. 
A solution of 300 mg of N-(tert-butoxycarbonyl) glycine (1.7 × 10-3 mol, 1 eq), 390 mg N,N’-
dicyclohexycarboxyl carbodiimide (DCC, 1.9 × 10-3 mol, 1.1 eq) and 220 mg N-hydroxysuccinimide 
(1.9 × 10-3 mol, 1.1 eq) in 15 mL of anhydrous DMF was reacted for 16 h at 25 C. Insoluble 
dicyclohexylurea was filtered from the solution, before 300 μL of 11-azido-3,6,9-trioxaundecan-1-
amine (1.2 × 10-3 mol, 0.7 eq) dissolved in 1.2 mL of DMF was added drop-wise over 10 min and 
allowed to react for 6 h at 25 C. The reaction mixture was concentrated to an oil under vacuum 
and purified with flash chromatography (silica gel-60, 5% methanol in DCM). The purified oil was 
dried under vacuum to yield 270 mg of 5-6. (Yield 42%) δH (700 MHz, Chloroform-d, ppm (J Hz)) 
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6.80 (1 H, t, J 5.7), 5.43 (1 H, t, J 5.7), 3.75 (2 H, d, J 5.5), 3.70 – 3.53 (11 H, m), 3.52 (2 H, dd, J 5.7, 
4.7), 3.42 (2 H, q, J 5.3), 3.38 – 3.34 (2 H, m), 1.40 (8 H, s).  
 70 mg of 5-6 (1.9 × 10-4 mol) was dissolved in 1 mL of DCM. 100 μL of trifluoroacetic acid 
(TFA) was added to the solution and allowed to react for 5 h at 25 C. The solution was dried to an 
oil under vacuum. To remove TFA bound to the free amine of the glycine, a lyophilisation strategy 
was employed. The oil was dissolved in an excess of 3% hydrochloric acid solution, frozen with 
liquid nitrogen and lyophilised to a solid. This was repeated three times. The process was then 
repeated three further times with pure water to remove excess hydrochloric acid to yield 50 mg 5-
7. (Yield 95%) δH (700 MHz, Chloroform-d, ppm (J Hz)) 8.42 (1 H, s), 8.04 (3 H, s), 3.99 (2 H, s), 3.72 
– 3.64 (3 H, m), 3.63 (2 H, d, J 6.0), 3.52 – 3.46 (3 H, m), 3.45 (2 H, t, J 4.9). Removal of TFA was 
confirmed by the loss of the TFA peak at -76 ppm in 19F NMR. 
 0.2 g of glycylglycine (1.5 × 10-3 mol, 1 eq) was dissolved in 2 mL of saturated sodium 
bicarbonate solution and cooled on ice for 15 min. 0.65 g of di-tert-butyl dicarbonate (3 × 10-3 mol, 
2 eq) was dissolved in 2 mL and added drop-wise to the chilled solution. The solution was left on 
ice for a further 15 min, before allowing to gradually warm to 25 C and to react for 16 h. The pH 
of the reaction was neutralised with 10% hydrochloric acid solution, and then dried to an oil under 
vacuum. The oil was dissolved in 50 % acetonitrile in water and purified with preparative reverse-
phase HPLC, running a gradient from 20% to 100% acetonitrile over 30 min. 150 mg of pure 5-8 
recovered. (Yield 43%) δH (700 MHz, DMSO-d6, ppm (J Hz)) 7.40 (1 H, s), 7.09 (1 H, t, J 6.2), 3.50 (2 
H, d, J 6.2), 3.41 (2 H, d, J 4.7), 1.38 (9 H, s).  
 50 mg of 5-8 (2.2 × 10-4 mol, 1.2 eq), 53 mg of pentafluorophenol (2.9 × 10-4 mol, 1.6 eq) and 
5 mg 4-dimethylaminopyridine (4 × 10-5 mol, 0.2 eq) were dissolved in 2 mL of DMF and chilled on 
ice for 15 min. 59 mg of DCC (2.9 × 10-4 mol, 1.6 eq) dissolved in 1 mL of DMF was added drop-wise 
over 5 min and allowed to react on ice for 15 min, before warming to 25 C and reacting for a 
further 5 h. 50 mg of 5-7 (1.8 ×10-4 mol, 1 eq) was dissolved in 400 μL of DMF, added to the 
reaction mixture and allowed to react at 25 C for 48 h. The insoluble side products were filtered 
off, and the yellow solution was concentrated to an oil under vacuum. Purification of the product 
was achieved by size exclusion chromatography with LH-20 Sephadex and acetonitrile as the 
mobile phase. 35 mg of pure 5-9 recovered. (75% purity by NMR, yield 32%) δH (500 MHz, 
Chloroform-d, ppm (J Hz)) 7.12 (1 H, s), 7.03 (2 H, s), 6.75 (1 H, s), 5.37 (1 H, s), 3.99 (2 H, d, J 5.6), 
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3.94 (2 H, d, J 5.6), 3.83 (2 H, d, J 5.8), 3.70 – 3.60 (15 H, m), 3.57 (2 H, t, J 5.1), 3.45 (2 H, q, J 5.2), 
3.41 (3 H, q, J 5.0), 1.45 (9 H, s).  
 5-9 was deprotected to the free amine using the same reaction and purification conditions 
as 5-7. Recovered 27 mg of 5-10. (Yield 98%) δ H (700 MHz, DMSO-d6) 8.70 (1 H, t, J 5.7), 8.27 (3 H, 
t, J 5.9), 8.02 (11 H, s), 7.93 (3 H, t, J 5.7), 3.83 (6 H, d, J 5.6), 3.68 (6 H, d, J 5.9), 3.61 – 3.59 (2 H, 
m), 3.58 (2 H, s), 3.57 – 3.49 (9 H, m), 3.44 – 3.38 (11 H, m), 3.39 (1 H, d, J 4.7). δC (700 MHz, 
DMSO-d6) 168.67, 168.53, 166.63, 155.08, 69.79, 69.75, 69.68, 69.58, 69.24, 68.95, 49.99, 42.00, 
41.89, 40.36, 38.53. ESI-MS: 390 m/z [M + H]+, 412 m/z [M + Na]+, 431 m/z [M + MeCN + H]+. 
To validate that the OEG linker 5-10 could undergo sortase coupling to an LPETG modified 
scFv, a fluorescent analogue was made to allow for detection via PAGE and FACS analysis. 1 mg of 
5-10 (3 × 10-6 mol) and 1 mg FITC-DBCO (1.5 × 10-6 mol) was dissolved in 350 μL of DMSO and 
allowed to react at 25 C for 16 h, protected from light. Attachment of the fluorophore to the 
linker was confirmed by LCMS and the linker 5-11 was used as is for conjugation reactions. ESI-MS: 
1055 m/z [M + H]+,1077 m/z [M + Na]+ 
5.3.4. Attachment of N3-OEG-Gly3 (5-10) linker to hyperbranched polymer for 
sortase coupling 
5 mg of HBP 5-3 was dissolved in 400 μL ultrapure water (1.4 × 10-7 mol HBP, 5 × 10-7 mol of alkyne 
end groups: 1 eq) and 34 μL of 5-10 (8.5 mg/mL, 7.5 10-7 mol, 1.5 eq to alkyne) dissolved in DMSO 
was added. The aqueous copper catalyst solution was prepared prior to addition to the reaction. 
10 μL sodium ascorbate (125 mM, 1.25 10-6 mol, 2.5 eq), 10 μL (BimC4A)3 (25 mM, 2.5 × 10
-7 mol, 
0.5 eq) and 8 μL copper sulfate (31 mM, 2.5 × 10-7 mol, 0.5 eq) were mixed together in that order 
and added to the reaction mixture. The reaction was allowed to proceed for 16 h at 25 C, 
protected from light. The reaction mixture was diluted to 2 mL with ultrapure water and purified 
using automated size exclusion chromatography to yield 4.5 mg of HBP 5-4. (% alkyne end group 
functionalised: 60 %, Yield of polymer: 90%) δH (700 MHz, DMSO-d6, ppm) 8.12 (5 H), 7.40 (1 H), 
5.14 (5 H), 4.70 (3 H), 4.53 (10 H), 4.25 – 3.87 (263 H), 3.76 – 3.33 (7851 H), 3.25 (906 H), 3.05 – 
2.93 (5 H), 2.00 – 1.66 (25 H), 1.41 – 1.09 (61 H), 1.08 – 0.48 (178 H). 
5.3.5. Azide functionalisation of anti-EGFR scFv 
EGFR scFv was provided as a stock solution at 6.2 × 10-6 M in PBS. 3 mL of solution was 
concentrated to 0.5 mL (3.1 × 10-5 M) using an Amicon Ultra centrifugal filter (Merck-Millipore) 
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with a 10 kDa MWCO membrane. To this solution 5 equivalents of 5-5 in anhydrous DMSO (7 μL, 
5.5 mg/mL, 7.5 × 10-8 mol) was added and allowed to react at 25 C for 3 h, then 4 C for 16 h. A 
200 μL aliquot of this solution was taken out of the reaction and kept (5-12). To the remaining 300 
μL of reaction mixture another 3 μL of 5-5 (5.5 mg/mL, 3.7 × 10-8 mol) was added to give 10 
equivalents, and allowed to react at 25 C for 3 h before being stored at 4 C (5-13). Attachment of 
OEG linker was confirmed by MALDI-TOF analysis. 
 Purification of free OEG linker from 5-12 and 5-13 was achieved by size exclusion 
chromatography with PD MiniTrap G10 columns (GE Healthcare). Solutions were concentrated to 
4.8 × 10-5 M with Amicon Ultra centrifugal filter (Merck-Millipore), prior to CuAAC conjugation 
reactions. 
5.3.6. Preliminary CuAAC conjugation reactions between hyperbranched polymer 
multimodal imaging agent and scFv targeting ligand. 
A range of experimental conditions for CuAAC conjugation have been explored. A sequential set of 
experiments were performed to investigate how a number of the key parameters could affect the 
degree of coupling. The rationale behind each set of experiments is described in Figure 5-8. The 
actual experimental conditions for each reaction are tabulated in  Appendix 5.7.3. . A 
demonstrative experimental protocol is described in detail for reaction CuAAC-27. An aqueous 
solution of 1.8 μL of HBP 5-3 (270 μM, 2 eq, 4.8 × 10-10 mol) and 5 μL of 5-12 (48 μM, 1 eq, 2.4 × 
10-10 M) were mixed together in an Eppendorf tube. In a separate tube an aqueous catalyst 
solution was prepared by mixing 1.0 μL of sodium ascorbate (12.5 mM, 50 eq, 1.2 × 10-8 mol), 1.0 
μL of (BimC4A)3 (2.5 mM, 10 eq, 2.40 × 10
-9 mol) and 0.8 μL copper sulfate (3.1 mM, 10 eq, 2.4 × 
10-9 mol), in that order. The catalyst solution was then added to the reaction mixture and allowed 
to react at 4 C for 16 h. Characterisation of conjugation was performed by SDS-PAGE.  
 To validate that the OEG linker was able to undergo CuAAC conjugation to HBP 5-3, a small 
test reaction was performed. An aqueous solution of 80 μL of HBP 5-3 (380 μM, 1 eq, 3.0 × 10-8 
mol) and 13.5 μL of 5-5 (15 mM, 6 eq, 2.0 × 10-7 mol) was prepared, to which was added 2 μL 
sodium ascorbate (125 mM, 2.5 eq, 2.5 × 10-7 mol), 2 μL (BimC4A)3 (25 mM, 0.5 eq, 5 × 10
-8 mol) 
and 1.6 μL copper sulfate (31 mM, 0.5 eq, 5 × 10-8 mol). The reaction was allowed to proceed at 25 
C for 16 h, protected from light. The solution was dissolved up directly in 500 μL DMSO-d6 and 
conjugation was assessed by 1H NMR with a 98% diffusion gradient to suppress water peaks. 
 111 
 
5.3.7. Preliminary sortase conjugation reactions between hyperbranched 
polymer multimodal imaging agent and scFv targeting ligand. 
A range of conditions were investigated for sortase conjugation reactions, summarised in 
Appendix:Table 7 and Table 9. 10 X sortase buffer was prepared as 50 mM tris-
(tris(hydroxymethyl)aminomethane (Tris), 150 mM sodium chloride and 10 mM calcium chloride 
in ultrapure water. TBS buffer was prepared as 50 mM Tris and 150 mM sodium chloride in 
ultrapure water. All reagents were prepared at the concentrations recorded in Appendix 0. 
TAMRA-GGG and HBP 5-4 were prepared in ultrapure water and 5-11 was prepared in 30 mM 
phosphate solution (pH 8.5) due to insolubility in pure water. Reactions were performed by 
pipetting the required volumes (given in Appendix 0) of each reagent into an Eppendorf tube, 
ensuring the solutions are well mixed. Reactions were then incubated at 37 C for 3 h. 
Characterisation of conjugation was achieved using either SDS-PAGE or a cell binding assay. 
The sortase mediated conjugation of HBP 5-4, FITC-OEG-GGG (5-11) and TAMRA-GGG to 
the anti-EGFR scFv via a sortase recognition epitope LPETG was evaluated by flow cytometry using 
the breast cancer cell line MDA MB 468 cells that over express EGFR.  The binding of the anti EGFR 
scFv labeled with fluorescently labeled triglycine substrate (Cy5-HBP, FITC-OEG-GGG, TAMRA-
GGG) to MDA cells was indicative of a sortase mediated labeling event.  MDA MB 468 cells (ATCC® 
HTB-132™) were cultured in 10% FCS (Hyclone) in advanced RPMI (Invitrogen) with 2mM glutamax 
(Invitrogen) at 37 C in 5% CO2.  For flow cytometry experiments, cells were removed from tissue 
culture flasks using a cell scraper, centrifuged at 700rpm for 5 mins and the cell pellet was 
resuspended in 10 % FCS-PBS to give 2x106 cells/mL.  100 uL of the cell suspension was aliquoted 
into 1.5 mL tubes and stored on ice.   
Different dilutions of the sortase reactions were added to the 100 μL cell suspension and 
incubated for 60 mins on ice. Following incubation, the cells were centrifuged gently at 1000 rpm 
for 5 mins, the supernatant was pipetted off and 200 uL of 10 % FCS-PBS added.  This wash step 
was repeated two more times.  After the third and final wash, the supernatant was removed from 
the cells and the pellet was resuspended in 100 uL of 10 % FCS-PBS. Fluorescence binding to the 
cells was analysed via flow cytometry.  
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5.4. Results and discussion 
5.4.1. Synthesis of hyperbranched polymer multimodal molecular imaging agent  
Table 1. Summary of physical and chemical properties of HBP 5-3 
 Monomer 
conversion 
Mn (ÐM) 
(SEC-MALLS) 
Mn (
1H 
NMR) 
Alkyne 
groups 
Branch 
points 
Dh 
Number Avg 
(± St Dev) 
Cy5 
dyes 
DFO 
HBP 
5-3 
99% 37 kDa (1.5) 11 kDa 3.6 2.6 5.5 ± 0.2 nm 0.9 1.8 
 
The first aim of this chapter was to synthesise a hyperbranched polymer multimodal molecular 
imaging agent, building on what has been learnt in the previous two chapters. While the same 
imaging modalities are intended to be utilised (fluorescence and PET), there have been some key 
changes to the selection of the imaging moieties. Firstly the NIR infrared fluorophore favoured in 
Chapter 3, was replaced with the far-red dye Cy 5. This was done because far-red dyes can be 
detected and visualised with many in vitro instruments, such as confocal microscopy and flow 
cytometry; very few of these instruments are set up for NIR fluorescence. The trade-off is that far-
red dyes such as Cy 5 are not as effective for in vivo imaging as the near infrared dyes, as 
demonstrated in Figure 3, Chapter 3. This use of in vitro instruments can allow for improved ex 
vivo analysis of these hyperbranched polymers, following in vivo imaging studies. Histological and 
microscopic analysis can provide extremely high resolution distribution of the polymeric materials 
within a tissue of interest, while flow cytometry can be used to evaluate cell-by-cell binding of the 
materials.71 These ex vivo techniques can provide complementary information to the in vivo 
imaging experiments, in assessing the performance of the targeted conjugates used in this work.  
In vivo imaging techniques can show accumulation of our materials within the tumour tissues, but 
flow cytometery can be used to visualise binding of the targeted polymers to the tumour cells and 
confocal microscopy could be used to visualise internalisation The bifunctional chelator for PET 
imaging was also changed to desferrioxamine-B (DFO), to provide for the use of zirconium-89 as 
the radioisotope for imaging. 89Zr has a half-life of 78 hours, allowing for imaging studies to be 
performed for up to two weeks, which is well suited to the slow pharmacokinetics of antibodies 
and other large, long-circulating materials.72 DFO has been the most widely utilised ligand for 89Zr-
PET, due to good labelling properties (1:1 chelate:metal ratio) and high stability (<2% 
demetallation in serum, 7 days).73 While the hyperbranched polymers were synthesised in the 
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same manner as previously described, a new approach to incorporating these imaging ligands was 
undertaken, to improve the conjugation efficiency and simplify the synthesis of these materials. 
 In the previous chapters, the alkyne end groups of the hyperbranched polymer were 
modified with an amino-OEG-azide bifunctional ligand, via thermally assisted Huigsen 
cycloadditions. This provided for amine functionality for attachment of imaging and targeting 
ligands via isothiocyanate and activated acid chemistry. This approach was limited in that the 
trithiocarbonate groups had to first be removed prior to introduction of the amine functionalised 
OEG, and that the conditions for cycloaddition were harsh and had to be carefully controlled, to 
prevent degradation of the material. Also all of the imaging and targeting ligands were being 
attached to the same α-polymer chain end. A new approach was employed to generate ω-chain 
ends with activated pentafluorphenyl (PFP) ester groups, which are highly reactive towards 
primary amines and have been widely used in the literature for amide formation.74 This was 
achieved by using an initiator, which had been activated as the pentafluorophenyl ester, to 
perform radical deprotection of the trithiocarbonate groups (Scheme 1).69 This approach is 
advantageous because it combines the two steps of trithiocarbonate group removal and end 
group activation, into one step. PFP activated initiator was synthesised by the esterification of 
4,4’-azobis(4-cyanovaleric acid) with pentafluorophenol using carbodiimide coupling chemistry. A 
large excess of initiator compared to trithiocarbonate end groups (20 equivalents) was used to 
ensure complete removal and substitution. Purification of these materials was achieved via 
repetitive precipitation from 50% diethyl ether in hexane. Purification methods which utilised 
aqueous conditions were avoided, to prevent hydrolysis of the PFP ester groups. After reaction for 
16 hours at 70 C and purification, UV-Vis spectroscopy of the characteristic peak at 309 nm 
showed 97% removal of trithiocarbonate groups. ( Appendix Figure 5-17) 19F NMR was used to 
confirm attachment of the pentafluorophenol ester to the purified polymer (Appendix: Figure 
5-18). This approach provided a high level of reactive functionality, ready for ligation with 
bifunctional imaging molecules. 
 Once activation of the chain ends with PFP had been completed, ligation of imaging 
molecules could be readily achieved by reaction with the pendant primary amine. Sequential 
addition, firstly of the Cy-5-amine and then an excess of DFO-amine, was performed to yield the 
multimodal imaging agent HBP 5-3. An excess of organic base (either triethylamine or pyridine) 
was added to the reaction mixture to ensure that the amine was in its secondary, neutral form, 
which is the most nucleophilic and therefore most reactive towards the activated acid. 
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Quantification of the attachment of the ligands was achieved by UV-Vis and 1H NMR spectroscopy, 
following purification by size exclusion chromatography. (Summarised in Table ) The attachment of 
the ligands was further confirmed by running a 95 % diffusion gradient during a 1H DOSY NMR 
scan. Under these conditions, NMR signal from small molecules that are freely diffusing within the 
sample are suppressed. Only 1H resonances which are attached to large, slowly diffusing molecules 
will remain.75 The characteristic peaks for Cy5 and DFO can still be seen in the spectrum under 
these conditions, along with all of the characteristic polymer peaks.(Figure 5-5) This means that 
these nuclei are diffusing at a similar rate and so implies that the ligands are most likely attached 
to the polymer. This now provides a hyperbranched polymer imaging agent, which can be used for 
fluorescence and PET imaging, with alkyne-functional α-end groups that can be exploited for 
conjugation reactions. 
 
Figure 5-5. Assigned 
1
H NMR spectrum for HBP 5-3, showing conjugation of Cy5 and DFO. Quantification of DFO and Cy5 is 
achieved by comparing the integral of the peaks at 2.5 ppm and 7.30 respectively, to the methylene adjacent to the alkyne of the 
polymer chain end at 4.7 ppm. 
20, 57, 129, 130, 133, 134
132, 136
7-8
4
2
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5.4.2. Synthesis of bifunctional OEG linker for CuAAC conjugation 
Two heterobifunctional OEG ligands have been synthesised in this work to allow for CuAAC and 
sortase coupling of the hyperbranched polymers to the desired scFv. The first OEG ligand 
combines azide functionality with an activated pentafluorophenol ester (5-7). The PFP-ester end 
group will allow for easy conjugation to almost any protein based targeting molecule, as they 
generally contain an abundance of primary amine groups in the form of lysine side chains.76 This 
linker will then provide azide functionality, which will allow for CuAAC conjugation to the alkyne 
end groups of HBP 5-3. The synthetic strategy for this linker is summarised in Scheme 2, which has 
been adapted from strategies utilised by Goswami et al.77  
 While this strategy did provide the required heterobifunctional linker, there were 
significant difficulties during synthesis. The most significant issue was the formation of a number 
of side products during the Williamson ether synthesis in step 1. Scheme 4 proposes chemical 
structures for possible side products for this reaction. Due to the similarity of these structures, 
NMR spectra of the impure products were convoluted, making it difficult to characterise exactly 
which of these species were present. During the repeated purifications that were attempted, 
these side products were characterised if isolated, to aid in understanding what side-reactions 
were occurring during the reaction where the primary goal was to isolate and characterise the 
desired product (5-5). The similarities in chemical structure of these compounds also made 
isolation of the desired product by flash chromatography extremely difficult. Repetitive flash 
columns following substitution by sodium azide was eventually able to provide a mixture of 
predominantly 5-3 and 5-3b. (Appendix: Figure 5-20) Formation of the diacetate structure of 5-3b 
is likely to have occurred during the first synthetic step. After formation of the ether, it is 
hypothesised that the ester underwent base catalysed hydrolysis, possibly due to the presence of 
trace quantities of water in the reaction. This would have yielded a carboxylate anion that could 
then react with a second molecule of ethyl bromoacetate, forming the diacetate structure 
(Scheme 5). These two products were eventually resolved using preparative HPLC (Appendix: 
Figure 5-19). This provided the desired product, as confirmed by NMR analysis (Appendix: Figure 
5-21 and Figure 5-22) and mass spectrometry, at >95 % purity. The structure of the side product 
was confirmed to be 5-3b, and not 5-3a, by 1H NMR of the isolated fraction (Appendix: Figure 
5-23). This was confirmed since the diacetate structure would not exhibit a peak for the methylene 
adjacent to the azide group at 3.3 ppm. There is also no singlet at 4.1 ppm for the β-methylene of 
the acetate, but there are two singlets at 4.2 and 4.6 ppm. This suggests that there are two non-
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equivalent β-methylene species in the structure, which is explained by structure 5-3b. If the side 
product was 5-3a, these peaks should be chemically equivalent in the 1H NMR spectrum. These 
two peaks are also shifted downfield, due to the presence of two esters in close proximity, which 
act as electron withdrawing species. While a small amount of this impurity remained in the desired 
product, it is expected that the second acetate group should be cleaved during acid hydrolysis in 
the next step providing the same free acid product.  
 
Scheme 4. Proposed chemical structures for the possible side products of 5-3. The side products are expected to have formed 
during the initial Williamson ether synthesis, and during subsequent reactions the hydroxyl groups were substituted for an 
azide. 
 
Scheme 5. Proposed mechanism for the formation of diacetate OEG side product 5-3b 
 Once a pure compound had been isolated, deprotection of the ester to the free acid was 
easily achieved by reflux in aqueous hydrochloric acid solution.78 Forcing conditions were required 
due to the ethyl group being a poor leaving group, and were able to be used due to the lack of 
other labile bonds in the molecule. Deprotection was again confirmed by NMR spectroscopy by 
loss of the proton (1.3 ppm, 4.2 ppm) and carbon signals (13 ppm, 60 ppm) of the ethyl ester 
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group, and the shift upfield of the β-methylene protons (4.1 ppm to 3.9 ppm). (Appendix: 1H NMR: 
Figure 5-24, 13C NMR: Figure 5-25). After deprotection, the final step in this synthesis was 
formation and purification of the activated ester. 
 A range of coupling conditions were explored for formation of the PFP activated ester of 5-5, 
where it was found that quantitative conversion to the ester could be achieved by using a twofold 
excess of the carbodiimide and pentafluorophenol. This left a large concentration of undesired 
free pentafluorophenol and coupling agents  in the final crude product. A range of standard 
purification methods were explored. Firstly, precipitation and recrystallization from aprotic 
solvents was attempted, which selectively solubilised either the OEG product or the impurities. 
These methods proved inefficient, while extensive and repetitive handling of the product would 
lead to near complete hydrolysis of the activated ester. Liquid extraction of the reaction mixture 
with small amounts of water also led to complete hydrolysis. It is hypothesised that this reaction 
was base catalysed by the presence of DMAP from the reaction, which greatly enhanced the 
degradation. Flash chromatography on silica gel and aluminum oxide was also attempted. While a 
silica gel column (mobile phase: isoctratic 50% hexane in ethyl acetate) was able to provide a pure 
product, there was once again significant hydrolysis of the ester leading to a very low yield of pure 
material being recovered. It is hypothesised that hydrolysis was caused by the activated hydroxyl 
groups on the surface of the stationary phase. Finally, preparative reverse phase HPLC running an 
isocratic mobile phase of dry acetonitrile provided an efficient method for isolating the OEG linker, 
from dicyclohexylcarbodiimide, dicyclohexylurea and DMAP. Free PFP co-eluted with the linker, 
but could be easily removed under high vacuum. This finally provided the pure OEG linker 5-5 
(Appendix: 1H NMR: Figure 5-26, 13C NMR: Figure 5-27, 19F NMR: Figure 5-28). Before conjugation 
reactions were attempted, the reactivity of the bifunctional ligand with both the scFv and the 
hyperbranched polymer were independently validated. 
 To validate the reactivity of 5-5 with the alkyne end groups of HBP 5-3, a small test reaction 
was performed, and analysed via 1H NMR. A 95% diffusion gradient was applied to the 
experiment, to reduce the intensity of the H2O peak from the reaction solution. Conjugation of the 
OEG linker to the polymer and formation of the triazole was confirmed by the characteristic 
disappearance of the peak at 4.7 ppm and the appearance of two new peaks at 4.5 and 5.2 ppm 
(Figure 5-6). This phenomenon was previously described in Chapter 3 as the loss of the methylene 
adjacent to the alkyne group and the formation of two new methylene species adjacent to either 
side of the triazole ring. There is also the appearance of the peak representing the proton on the 
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triazole ring at 8.1 ppm (Figure 5-6). This confirmed that the synthesised OEG linker 5-5 could 
undergo CuAAC conjugation to the hyperbranched polymer imaging agent, with the conjugation of 
the linker to the scFv left to be validated. 
 
Figure 5-6. 
1
H NMR spectrum with a 95 % diffusion gradient showing the conjugation of 5-5 to HBP 5-3 via CuAAC conjugation 
  
7-8
m n
o
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5.4.3. Azide functionalisation of EGFR scFv with 5-10 for CuAAC conjugation.  
Owing to the small amount of EGFR scFv available for use in this study and its complex chemical 
nature, validation of the conjugation of 5-5 was non-trivial. Many of the commonly utilised 
spectroscopic techniques (e.g. NMR, infrared spectroscopy) are not sensitive enough to detect 
single-bond changes in the small quantity of material used in these reactions. Mass spectrometry 
is a highly sensitive technique suitable for working at these concentration ranges. Matrix-assisted 
laser desorption/ionisation-time-of-flight (MALDI-TOF) mass spectrometry is a technique suitable 
for use with large biomolecules and organic macromolecules. The MALDI process is a soft 
ionisation technique that prevents fragmentation of the fragile macromolecules and produces far 
fewer multiply charged species, which simplifies analysis.79, 80 Time-of-flight mass spectrometry is 
well suited for the analysis of macromolecules as it covers a large mass range, and is well suited 
for use with MALDI due to the use of a pulsed laser providing a timing mechanism. An experiment 
was devised where the EGFR scFv was reacted with 5 equivalents of 5-5 (5-12), then half of this 
reaction mixture was reacted with a further 5 equivalents of the linker (referred to as 10 
equivalents, 5-13). The normalised MALDI spectra for both reactions and the unreacted scFv are 
shown in Figure 5-8. The peak for the unconjugated EGFR scFv appears as a broad multiplet, which 
is caused by the presence of buffer salts and non-optimal matrix conditions. Despite this, it can be 
seen that there is a shift to higher molar mass from the control scFv following reaction with the 
OEG linker. When 5 equivalents of 5-5 are used (5-12) there are now two major peaks in the 
MALDI-TOF spectrum, the original peak at 26220 m/z and a higher peak at 24680 m/z. For the 
resolution of this spectrum, this mass shift of 260 m/z is in good agreement with the expected 
mass shift of 277 m/z from the attachment of one OEG unit(Figure 5-8). This confirms attachment 
of 5-5 to the scFv , though the peak for the free scFv (26220 m/z) is still very intense, suggesting 
there is a significant amount of free scFv left in the reaction. When the extra 5 equivalents of 5-5 
are added to the reaction (5-13), the spectrum shows two peaks centred around 26480 m/z and 
26690 m/z, with the peak for the free scFv being greatly reduced in intensity. The difference 
between these two peaks of 210 m/z does not correlate as well with the expected mass shift from 
an additional OEG linker. This analysis is being confounded by the low resolution of the spectrum, 
the multiplicity caused by buffer salts and the multiple species of scFv conjugate present due to 
the lack of site specificity for OEG attachment. Despite this, these results suggest that the amount 
of conjugation is related to the feed of the linker and that there is now much less free scFv 
remaining in the sample. This analysis could be improved by using an enzymatic digestion of the 
conjugated scFv, and then analysing the fragments for OEG attachment.81, 82 These smaller 
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fragments (<5 kDa) would be much more sensitive to mass changes caused by attachment of the 
small linker (277 Da), compared to the intact scFv(26 kDa), and this analysis could allow for 
identification of the lysine residues that are being conjugated. This experiment provided validation 
for successful reaction of linker 5-5 with the EGFR scFv targeting molecule allowing for conjugation 
to hyperbranched polymers in subsequent steps. 
 
Figure 5-7. Normalised MALDI-TOF spectrum for the conjugation VEGF-R2 scFv with varying quantities of OEG linker 5-5.  
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5.4.4. Preliminary CuAAC conjugation reactions between hyperbranched polymer 
multimodal imaging agent and scFv targeting ligand. 
 
Figure 5-8. Flow diagram explaining the rationale behind each set of experimental conditions examined for subsequent attempts 
at CuAAC bioconjugationconjugation of HBP 5-3 and 5-12. 
As was described in the experimental section, a range of coupling conditions for CuAAC have been 
explored, in order to try and achieve conjugation between HBP 5-3 and the EGFR scFv (5-13). The 
rationale behind each set of experimental conditions is summarised in Figure 5-8, but will be 
discussed in detail with reference to results from characterisation. Characterisation of each set of 
reactions was performed with polyacrylamide gel electrophoresis (PAGE). SDS-PAGE is a particular 
electrophoresis technique, where samples are first reacted with a solution containing a reducing 
Experiment 1
• The catalyst ratio from literature sources was used as a starting point. It was desirable to 
optimise the reaction such that the minimum amount of copper required for effective 
catalysis was used. In this experiment, a twentyfold concentration range was used to try and 
find the minimum of copper required for this system. A slight excess of scFv was used to 
simplify purification of the desired conjugate from free HBP. 
• Table 2, Appendix 5.4.3
Experiment 2
• Hypothesis: reaction kinetics in experiment 1 are too slow due to the low temperature 
used for reaction. Increasing the temperature will increase the reaction rate.
• The same ratios of reagents were used as for Experiment 1. The reaction temperature 
was increased to 37 C, for 3 h.
• Table 3, Appendix 5.4.3
Experiment 3
• Hypothesis: the concentration of scFv and hyperbranched polymer are too low for 
effective conjugation
• The concentration of scFv stock solution was increased three fold, and a twofold molar 
excess of HBP relative to scFv was used to improve the kinetics of the reaction.
• Table 4, Appendix 5.4.3
Experiment 4
• Hypothesis: the Cy5 fluorescence seen with the protein band after destaining could be 
due to non-specific interaction of the polymer with the scFv, rather than covalent 
conjugation.
• Reaction conditions identical to experiment 3, with an additional control of scFv and HBP 
mixed together without any catalyst. 
• Table 5, Appendix 5.4.3
Experiment 5
• Hypotheses: the concentration of available copper catalyst is too low and is being 
decreased due to sequestration of copper by the protein. The molar ratio of polymer of to 
scFv is too low for the low concentration of protein in solution (less than 20 μM).
• The concentration of sodium ascorbate, chelator and copper sulfate was increased 
greatly. A tenfold molar excess of HBP to scFv was used
• Table 6, Appendix 5.4.3
No conjugation detected by SDS-PAGE
No conjugation detected by SDS-PAGE
ScFv band is fluorescent after coomassie destaining in reaction 
mixtures. No fluorescence detected in protein only control.
Fluorescence of scFv band after coomassie staining is due to non-
specific interaction between scFv and HBP. No conjugation detected
No conjugation detected by SDS-PAGE
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agent (dithiothreitol) and a surfactant (sodium dodecyl sulfate). The reducing agent will cleave any 
disulfide bonds, while the surfactant will denature the protein and give an even distribution of 
negative charge per unit of mass. Therefore, as the proteins are fractionated by size on the cross 
linked gel, this size should be approximately equivalent to molecular mass.83, 84 SDS-PAGE is 
commonly utilised to evaluate protein-polymer conjugation reactions.65, 85 
First attempts at CuAAC conjugation utilised a slight excess of scFv to polymer. The 
rationale behind this decision was to favour quantitative conjugation of the hyperbranched 
polymer, simplifying purification prior to use for in vivo studies. If a small amount of the unlabelled 
scFv remained, it would not affect the imaging results greatly, because it would not be detectable. 
Alternatively, if free polymer was left it would greatly affect the results because it possessed 
imaging moieties and so would be visualised during the experiments. The biodistribution of the 
unconjugated polymer would be expected to be different from the targeted conjugate and so 
would give spurious results when imaged in an animal. The catalyst ratio from literature sources 
were used as a starting point.86, 87 It was desirable to try and find the minimum amount of copper 
required for effective catalysis, to minimise contaminating metal ions that could affect the binding 
of PET isotopes during radiolabelling. As such, a range of copper concentrations were investigated 
from 6 μM to 120 μM. The first two sets of experiments were identical in quantities of reagents, 
but only differed in the choice of reaction temperature and time of reaction. The results from the 
SDS-PAGE are shown in Figure 5-9 and Figure 5-10.  The gel was stained with coomassie blue (stain 
for protein Figure 5-9.a), which shows two bands in all lanes with protein present (including scFv 
only control, lane 6). The higher band is likely due to a dimer of the scFv, formed by crosslinking of 
the free cysteine on the N-terminus. There is no shift in any bands of the reaction mixtures (lanes 
2-5) when compared to the control sample (lane 6). The presence of the Cy5 fluorophore allows 
for direct detection of the polymer on the gel. When the Cy5 image is acquired (prior to coomassie 
staining there are some broad bands that appear just below the protein band, amongst a smear of 
signal through all lanes with polymer present.  It is expected that the mass of the conjugate would 
be approximately double that of the free protein (EGFR scFv: 26 kDa, HBP 5-3: 37 kDa). While 
polymers do not necessarily run at their expected molar mass during PAGE analysis, a visible 
increase in retention is expected for the conjugates.65, 85 These results suggest there is no 
conjugation of the hyperbranched polymer to the scFv. 
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Figure 5-9. SDS-PAGE gel of experiment 1. a) coomassie blue stained gel image, b) Cy5 image prior to coomassie blue staining, c) 
overlay of Cy5 fluorescent image with coomassie stained image. (Lane 1: EGFR only, 2: CuAAC-1, 3: CuAAC-2, 4: CuAAC-3, 5: 
CuAAC- 4, 6: molecular weight ladder (bands marked in kDa)) 
 
Figure 5-10. SDS-PAGE gel of experiment 2. a) coomassie blue stained gel image, b) Cy5 image prior to coomassie blue staining, c) 
overlay of Cy5 fluorescent image with coomassie stained image. (Lane 1: CuAAC-5, 2: CuAAC-6, 3: CuAAC-7, 4: CuAAC-8, 5: 
CuAAC- 9, 6: CuAAC-10 7: molecular weight ladder (bands marked in kDa)) 
In the third set of experiments the concentration of the scFv stock was increased three fold 
and the HBP 5-3 was used in a two-fold excess to scFv. These changes were made to try and 
increase the reaction kinetics. While this is counter to the original rationale for wanting to use an 
excess of scFv, it was deemed necessary in order to achieve optimal conjugation. If necessary, an 
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excess of free polymer can be purified from the conjugate using His-trap chromatography, using 
the His-tag that has been engineered on the scFv.88 Once again, in the Cy5 image acquired 
immediately after the gel has been run, there is the diffuse band that appears below the protein 
band and significant signal smeared throughout the lane (Figure 5-11.a). There are no new bands 
appearing at an increased retention time. The coomassie blue stained gel again shows no changes 
in scFv migration in the reaction mixtures compared to the controls (Figure 5-11.b). Interestingly, 
when a Cy5 image is acquired after coomassie staining, the smearing of Cy5 signal along the lane 
has been decreased, possibly due to polymer being washed out of the gel during the destaining 
procedure. There is now a distinct fluorescence band that co-localises with the coomassie band for 
the scFv (lanes 2-5), which is much more intense when compared to the scFv only control (lane 6) 
and shows no band for the polymer by itself (lane 7, Figure 5-11). It is possible that this result 
arises from the conjugated polymer not affecting the migration of the scFv at all. While this is 
unexpected, there is some support for this claim since in the original Cy5 image the polymer 
seemed to smear through the whole lane. It is possible though that this is a non-specific 
interaction, and so an additional control was included in the next set of experiments to test this 
hypothesis. 
 
Figure 5-11. SDS-PAGE gel of experiment 3. a) Cy5 image prior to coomassie blue staining, b) coomassie blue stained gel image, c) 
Cy5 image after coomassie staining. (Lane 1: molecular weight ladder (bands marked in kDa), 2: CuAAC-13, 3: CuAAC-14, 4: 
CuAAC-15, 5: CuAAC-16, 6: CuAAC-17, 7: CuAAC-18) 
Experiment 4 was a direct repeat of experiment 3, with the only change being the addition 
of a control experiment, where HBP 5-3 and scFv 5-13 were reacted together without any catalyst 
solution. The results from PAGE analysis are shown in Figure 5-12. The initial Cy5 image shows no 
obvious bands, with the most intense regions not correlating to the protein bands in the 
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coomassie image (Figure 5-12.a). Again the coomassie image shows no shift in the bands between 
the reactions (lanes 2-4) and the controls (lanes 5-6) (Figure 5-12.b). When the Cy5 image is again 
acquired post-coomassie blue staining, the same fluorescent scFv bands can be seen as before. 
This is also true for the lane containing polymer and scFv without catalyst solution (lane 6), 
implying that this phenomenon is not caused by polymer-scFv conjugation. It is hypothesised that 
while the free polymer is being washed out of the gel during the destaining process, there is some 
physical interaction between the polymer and the scFv. This prevents the polymer from being 
washed out in areas where the scFv is also present, thus creating these fluorescent bands. This 
explains the unexpected result seen in the previous experiment and suggests that conjugation is 
not occurring under these conditions. This is somewhat unexpected because it was demonstrated 
above that the free linker will readily react with the polymer in a model reaction.  
 
Figure 5-12. SDS-PAGE gel of experiment 4. a) Cy5 image prior to coomassie blue staining, b) coomassie stained gel image, c) Cy5 
image after coomassie staining. (Lane 1: molecular weight ladder (bands marked in kDa), 2: CuAAC-19, 3: CuAAC-20, 4: CuAAC-
21, 5: CuAAC-22, 6: CuAAC-23, 7: CuAAC-24) 
 Further optimisation of reaction conditions based on literature reports, suggested using a 
much larger excess of the other substrate when the concentration of protein is less than 20 μM.89 
The final concentrations of scFv in all of the experiments in this work range between 8 μM and 18 
μM, so for the final experiment a tenfold excess of HBP5-3 was used. The ratio of sodium 
ascorbate and chelator were also recommended to be increased greatly, due to side reactions that 
can occur with oxygen and other radical species present within the reaction. Another 
consideration is the concentration of copper ions in the reaction. It has been shown that there is a 
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minimum required copper concentration of 50 μM, and that maximal activity is reached by 250 
μM.90 There can also be issues with copper ions being sequestered by the protein substrate, which 
lowers the concentration available for reaction. This effect is compounded by the presence of the 
His-tag on the scFv, which is a good ligand for copper. As such a range of copper concentrations 
were used in this set of experiments, from 77 μM up to 400 μM. Finally, the reactions were heated 
to 37 C for 3 h, because it was suggested in the literature that mild heating may help to free 
sequestered copper and also improve the reaction rate.89 The reaction time was kept short at 
these temperatures, because the instability in solution of the scFv was a concern. Despite all of the 
recommended modifications being utilised in experiment 5, it can be seen in the PAGE result that 
there was still no detectable levels of conjugation (Figure 5-13).  
 
Figure 5-13. SDS-PAGE gel of experiment 5. a) coomassie blue stained gel image, b) Cy5 image prior to coomassie blue staining, c) 
overlay of Cy5 fluorescent image with coomassie stained image. (Lane 1: CuAAC-25, 2: CuAAC-26, 3: CuAAC-27, 4: molecular 
weight ladder) 
While these results are disappointing, the impediments to conjugation are not expected to 
be terminal. It has been demonstrated that the free linker (5-5) will independently undergo CuAAC 
conjugation to the hyperbranched polymers, and that it has been successfully attached to the 
scFv. Further optimisation of the reaction conditions is required to obtain hyperbranched polym-
scFv conjugates. There are still a number of key parameters that can be explored. Firstly, an 
increase in the concentration of scFv will improve the kinetics of the reaction. This will require the 
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solution stability of the scFv at higher concentrations and at the relevant reaction temperatures to 
be determined. It may also be advantageous to remove the His-tag prior to conjugation, due to its 
ability to bind copper ions. There are a number of classes of chelators that can be used for CuAAC, 
which are suitable for a range of reaction conditions. Therefore it is has been shown in the 
literature to be very important to select the right chelator for the desired reaction conditions, and 
then to carefully optimise the reaction conditions to ensure successful conjugation.91 Finally, it 
may be advantageous to move to a copper free strategy by modifying the hyperbranched polymer 
with a ring strained alkyne (e.g. Dibenzocyclooctyne). This should overcome issues of copper 
sequestration and reduce the number of molecular components that need to come together for 
successful reaction, which may increase the likelihood of conjugation occurring in dilute systems, 
or with bulky substrates.92, 93 The length of the OEG linker could also be investigated, in order to 
overcome issues of steric hindrance caused by conjugating two bulky substrates. 
5.4.5. Synthesis of triglycine functionalised hyperbranched polymers for sortase 
conjugation 
As discussed in the introduction to this chapter, the Sortase A enzyme recognises the peptide 
motif NLPETGc, which it can then cross couple with the free N-terminus of oligoglycine to form a 
covalent linkage. In this work, the EGFR scFv was bioengineered to be expressed with a C-terminal 
LPETG motif. This meant that the corresponding triglycine moiety had to be incorporated into the 
hyperbranched polymer structure. To achieve this, another heterobifunctional OEG linker was 
designed and synthesised. It also possessed an azide functional group to allow for attachment to 
HBP 5-3, but the ω-end carried a short triglycine peptide sequence. This was achieved by firstly 
reacting 11-azido-3,6,9-trioxaundecan-1-amine with N-Boc protected glycine. Boc protected 
glycine was used to prevent oligomerisation of the amino acids during amide coupling. 
Attachment was confirmed with 1H-1H COSY NMR spectroscopy showing that the terminal 
methylene of OEG (Appendix Figure 5-30 correlated with the newly formed amide peak (Appendix 
Figure 5-30 Peak 7, 6.8 ppm). Selective removal of the N-Boc protecting group was achieved by 
reaction with an excess of TFA, which can be confirmed by the loss of the t-butyl peak at 1.4 ppm 
and the shift of the α-methylene from 5.5 ppm to 8.0 ppm (Appendix Figure 5-32). The normalised 
integral of this peak also increased from one to three, which is consistent with the change from a 
secondary amide to a protonated primary amine. The TFA salt of the primary amine was removed 
by exchange with the chloride anion of hydrochloric acid and repeated lyophilisation, which is a 
technique commonly employed in peptide synthesis.94  
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 The desired triglycine OEG linker was synthesised by reaction of the mono-glycine OEG (5-7) 
with N-Boc protected glycylglycine (5-8). 5-8 was synthesised by the reaction of glycylglycine with 
di-tert-butyl dicarbonate (Boc2O) in basic conditions. The nucleophilic amine of the terminal 
glycine is able to undergo a substitution reaction onto one of the carbonyl groups of Boc2O, with 
carbonic acid acting as a leaving group. This carbonic acid undergoes degradation into carbon 
dioxide and t-butanol (or isobutylene), with evaporation of the carbon dioxide driving the reaction 
forward.78 Boc-Gly2 (5-8) was attached to 5-7 via carbodiimide coupling chemistry to yield 5-9. 
Deprotection was again achieved with TFA and purified by lyophilisation against dilute 
hydrochloric acid, to yield the desired bifunctional linker 5-10 ready for use with sortase 
conjugation. (1H NMR Appendix Figure 5-34, 13C NMR Figure 5-35). There was some residual 
dicyclohexylurea (~25%) in the final OEG product, which was used as is in the next step. The DCU 
was not expected to affect the reaction conditions and could then be purified more easily from the 
polymer product via size exclusion chromatography. 
 In order to prepare a sortase ready hyperbranched polymer, linker 5-10 was attached using 
CuAAC to the alkyne end groups of the polymer. 1H NMR of the SEC purified product showed that 
70% of the alkyne end groups were conjugated with the OEG linker 5-10 (Figure 5-14). This gives 
on average 2.5 triglycine moieties per hyperbranched polymer for sortase conjugation (HBP5-4). In 
order to validate that the linker itself was able to undergo sortase conjugation, 5-10 was reacted 
with FITC-DBCO to provide a fluorescent tag for characterisation. The ring strained alkyne of the 
DBCO functionalised dye is able to undergo spontaneous reaction with the azide of 5-10 without 
the presence of catalyst. This provided two materials which could potentially undergo sortase 
conjugation to the scFv targeting molecule, including a multimodal molecular imaging agent. 
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Figure 5-14.
 1
H NMR with a 95% diffusion gradient of HBP5-4, highlighting peaks used to measure number of attached triglycine 
linkers 
5.4.6. Preliminary sortase conjugation reactions between hyperbranched 
polymer multimodal imaging agent and scFv targeting ligand. 
 The scFv that was used for the sortase conjugation reactions was a variant of the EGFR scFv 
used above, but which had been bioengineered to possess a LPETG motif expressed on its C-
terminus. The experimental conditions utilised for the first trial are summarised in the appendix: 
Table 7. Figure 5-15 shows the SDS-PAGE results from the first set of sortase conjugation reactions 
attempted. The coomassie blue stained images in Figure 5-15.a show the corresponding bands for 
the EGFR scfv (~26 kDa) and the sortase enzyme (~19 kDa) for the negative control Srt-2, where no 
oligoglycine substrate was included in the reaction. The faint band at 12 kDa was believed to arise 
from trace quantities of a degradation product from sortase. Figure 5-15.b shows the three colour 
fluorescent images of reactions Srt-2 through to Srt-11 (Cy5 shown in blue, rhodamine shown in 
red, fluorescein shown in green). The lanes representing reactions with TAMRA-GGG and FITC-
OEG-GGG (5-11) show the appearance of a new, very well defined band that is not present in the 
negative controls. This band shows the same retention as the coomassie band for the scFv. The 
molecular weight of both of these molecules is only approximately 1 kDA, so conjugation is not 
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expected to significantly affect the migration of the scFv. The other fluorescent bands present in 
these lanes arise from unconjugated oligoglycine substrates and trace quantities of other side 
products present in these materials. The conjugate bands are much less intense than these bands, 
due to the large excess of oligoglycine substrate used in these reactions (80 fold excess). The 
formation of the TAMRA-scFv conjugate validates our reaction protocol, as it replicates the results 
from the literature using the same substrate.57 The formation of the conjugate with 5-11 confirms 
that the free OEG linker synthesised in this work is able to undergo sortase mediated conjugation. 
The next step was to evaluate conjugation to the hyperbranched polymer. 
 Lanes 2, 5 and 8 of Figure 5-15.b) show the sortase conjugation reactions between the scFv 
and the triglycine modified hyperbranched polymer (HBP 5-4). All lanes show a smearing of the 
fluorescent signal, similar to what was seen previously with the CuAAC reactions. There is no 
visible difference between the negative controls (lanes 2 and 5) and the reaction with all of the 
necessary components (lane 8). If conjugation between the scFv and the polymer was successful, a 
new band would be expected, with a molecular weight of approximately 50-60 kDa. There is no 
evidence for this species in lane 8. This result is unexpected, as it was shown that the free 
triglycine linker could undergo sortase mediated conjugation to the scFv. To confirm the results in 
this experiment, a cell binding assay and flow cytometry were used as a secondary technique. This 
technique was chosen because it would also provide predictive information about the suitability of 
these materials for imaging experiments in the future. 
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Figure 5-15. SDS-PAGE gel characterisation of sortase conjugation reactions. a) Protein bands imaged by coomassie blue staining, 
Lane 1: molecular weight standards (mass of bands labelled in kDa), Lane 2: mixture of sortase enzyme and EGFR scFv only (Srt-
2). b) fluorescent images of sortase conjugation reaction (Cy5 shown in blue, rhodamine shown in red, fluorescein shown in 
green) Lane 1: Srt-2, Lane 2: Srt-3, Lane 3: Srt-4, Lane 4: Srt-5, Lane 5: Srt-6, Lane 6: Srt-7, Lane 7: Srt-8, Lane 8: Srt-9, Lane 10: Srt-
11. 
  A cell binding assay was performed where the reaction mixtures Srt-3 through to Srt-11 
were incubated at 4 C with MDA MB468 breast cancer cells, to measure ligand binding to the 
EGFR receptor over expressed on the cell surface.95, 96 The results from the reaction with TAMRA-
GGG are shown in Figure 5-16.a. It can be seen in the histogram that the peak for the negative 
control reactions (blue and green) aligned with the peak for cells incubated with PBS only (black). 
This suggests that there is no non-specific interaction between TAMRA-GGG and the cells. When 
the cells were incubated with Srt-10, where conjugation was shown in the SDS-PAGE analysis, 
there is a significant shift to higher fluorescence intensity in the histogram (red cruve). This 
suggests that the TAMRA-GGG is conjugated to the scFv, which is facilitating binding to the EGFR 
receptor on the cell’s surface. When the same analysis is performed for the FITC-OEG-GGG (Figure 
5-16b), there is a shift in the histogram for the negative controls compared to the cell only 
controls. This suggests there is some non-specific binding of the fluorophore to the cells. When the 
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complete reaction mixture is used though, there is a much greater shift in the fluorescence 
intensity of the histogram, once again suggesting receptor mediated binding of the conjugated 
fluorophore. Finally the results from the reactions with HBP 5-4 (Figure 5-16c), show a very large 
shift in the histogram from the cell only control to the negative sortase controls, due to significant 
non-specific interactions. When this peak is compared to the reaction mixture with all of the 
necessary components (Srt-9) there is no shift in this peak. This suggests that there is no receptor 
mediated binding and so no conjugation. All of these results confirm the results from the SDS-
PAGE analysis above, demonstrating successful conjugation of TAMRA-GGG and FITC-OEG-GGG (5-
11) to the EGFR scFv, with no conjugation evident for HBP 5-4. 
 
Figure 5-16. Analysis of cell binding assay by FACS to qualitatively assess sortase conjugation reactions. (Black line: cell only 
control, green line: cells + oligoglycine substrate + sortase, blue line: cells + oligoglycine substrate + EGFR scFv, solid red curve: 
cells + oligoglycine substrate + EGFR scFv + sortase (positive reaction mixture)) 
 The larger size of the hyperbranched polymer, compared to the free linker 5-11, could affect 
the interaction of the substrate with the enzyme and thus the conjugation to the scFv. The comb-
like nature of the polymer could also be causing additional steric hindrance around the triglycine 
end group, preventing reaction. Though as was discussed in the introduction, there are many 
examples in the literature of successful sortase conjugations to a wide range of much larger 
substrates (eg. nanoparticles and cells). In a number of these examples the concentration of 
sortase enzyme used was much higher than was used here.57, 59, 60 In light of this, a second set of 
experiments was undertaken using a more concentrated stock of sortase enzyme (100 μM), and 
also reducing the concentration of hyperbranched polymer in the reaction (Appendix: Table 9). 
Once again the SDS-PAGE results suggest there was no conjugation occurring in any of these 
reactions, due to the lack of any new bands appearing in the fluorescent images. In this 
experiment the gel was stained with coomassie blue and imaged. Only the bands for the sortase 
enzyme and the scFv are visible in the negative control and all of the reaction mixtures. There 
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were no new bands for a conjugated material appearing at higher molecular weights.  It is 
apparent from the literature that while this reaction can work with a wide range of systems, it is 
necessary to optimise the reaction conditions for each individual system. There have been a 
number of reported issues with sortase conjugation, including the formation of undesired 
intermediates and having to control the equilibrium between the forward and reverse 
transpeptidase reactions.57, 97Therefore, further optimisation of reaction conditions may still 
provide for successful conjugation. While further changes in the concentration of hyperbranched 
polymer and sortase enzyme should be further optimised, some of the other conditions yet to be 
investigated include the final concentration of the scFv and calcium ions, as well as the pH of the 
reaction. 
 
5.5. Conclusions 
This chapter aimed to develop and compare CuAAC and sortase conjugation strategies for the 
synthesis of scFv targeted hyperbranched polymer molecular imaging agents. The hyperbranched 
polymers synthesised for this work were modified from the previous designs in this thesis. Firstly, 
the NIR fluorophore was exchanged for a far red fluorophore (Cy5) to allow for in vitro and ex vivo 
analysis. The PET ligand DFO was used in this material to allow for the use of 89Zr as the 
radioisotope. The half-life of 89Zr (78 h) is much longer than 64Cu, and better matches the expected 
half-life of the scFv-hyperbranched polymer conjugates intended to be synthesised in this work. A 
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new strategy for introduction of these imaging moieties was utilised, by modifying the ω-chain 
ends with pentafluorophenol activated ester. These reactive groups allowed for facile reaction 
with amine functionalised imaging molecules. The α-chain ends carried an alkyne group from the 
RAFT agent used for polymerisation. This alkyne group allowed for this material to be used with 
CuAAC conjugation reactions. 
 Copper-catalysed azide-alkyne cycloaddition was explored as a route to produce scFv-
hyperbranched polymer imaging agents. In order to achieve this goal a short oligoethylene glycol 
linker was designed and synthesised, which carried both azide functionality and a 
pentafluorophenol activated ester. It was demonstrated through MALDI-TOF analysis that the PFP-
ester moieties allows for facile attachment of this linker to the scFv antibody. This introduced the 
necessary azide functionality to allow for CuAAC conjugation to the hyperbranched polymers. 
Preliminary CuAAC conjugation reactions between the modified scFv and the synthesised 
hyperbranched polymer imaging agents were attempted. Despite exploring an extensive range of 
experimental conditions, no successful conjugation was achieved. Since it was shown that the 
synthesised OEG linker can react with the alkyne functional groups of the hyperbranched 
polymers, it is believed that with further optimisation of the reaction condition, the desired 
conjugate could be synthesised. 
 Sortase enzyme catalysed conjugation was proposed as an alternative methodology, which 
could provide site specific attachment of the hyperbranched polymer to the scFv. In order to 
achieve this goal, an alternative OEG linker with triglycine functionality was synthesised. This linker 
also possessed an azide functional group, to allow attachment to the alkyne functional groups of 
the hyperbranched polymer. The triglycine modified hyperbranched polymer and a fluorescent 
analogue of the OEG linker were used in preliminary conjugation reactions. It was shown that 
successful conjugation could be achieved with the fluorescent analogue of the OEG linker, but no 
conjugation was seen with the hyperbranched polymer. It was hypothesised that this could be due 
to the large size of the hyperbranched polymers, and steric crowding of the triglycine end groups 
inhibiting interaction with the sortase enzyme. Sortase has been used to conjugate a wide range of 
substrate in the literature, so it is believed that with further optimisation of the reaction 
conditions, conjugation with this methodology can be achieved.  
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5.7. Appendix 
5.7.1. Protein parameters for the two anti-EGFR scFvs used in this work 
Anti-EGFR-cysteine used for CuAAC conjugations 
        10         20         30         40         50         60  
QLQLQESGPG LVKPSETLSL TCTVSGGSVS SGDYYWTWIR QSPGKGLEWI GHIYYSGNTN  
 
        70         80         90        100        110        120  
YNPSLKSRLT ISIDTSKTQF SLKLSSVTAA DTAIYYCVRD RVTGAFDIWG QGTMVTVSSG  
 
       130        140        150        160        170        180  
GGGSGGGGSG GGGSDIQMTQ SPSSLSASVG DRVTITCQAS QDISNYLNWY QQKPGKAPKL  
 
       190        200        210        220        230        240  
LIYDASNLET GVPSRFSGSG SGTDFTFTIS SLQPEDIATY FCQHFDHLPL AFGGGTKVEI  
 
KHHHHHHC  
Number of amino acids: 248 
Molecular weight: 26434.2 
Theoretical pI: 6.52 
Extinction coefficients: Ext. coefficient: 44140. Abs 0.1% (=1 g/l)   1.670, assuming all pairs of Cys 
residues form cysteines (extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water). 
 Anti-EGFR-LPETG used for sortase conjugations 
        10         20         30         40         50         60  
QLQLQESGPG LVKPSETLSL TCTVSGGSVS SGDYYWTWIR QSPGKGLEWI GHIYYSGNTN  
 
        70         80         90        100        110        120  
YNPSLKSRLT ISIDTSKTQF SLKLSSVTAA DTAIYYCVRD RVTGAFDIWG QGTMVTVSSG  
 
       130        140        150        160        170        180  
GGGSGGGGSG GGGSDIQMTQ SPSSLSASVG DRVTITCQAS QDISNYLNWY QQKPGKAPKL  
 
       190        200        210        220        230        240  
LIYDASNLET GVPSRFSGSG SGTDFTFTIS SLQPEDIATY FCQHFDHLPL AFGGGTKVEI  
 
       250        260  
KLPETGGAAA DYKDDDDKAA AHHHHHH  
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Molecular weight: 28307.1 
Theoretical pI: 5.80 
Extinction coefficients: Ext. coefficient: 45630. Abs 0.1% (=1 g/l)   1.612, assuming all pairs of Cys 
residues form cysteines (extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water). 
5.7.2. Additional spectral data 
 Synthesis of hyperbranched polymer as a multimodal molecular imaging 
agent 
 
Figure 5-17. UV-Vis spectrum showing the characteristic absorbance of the trithiocarbonate group at 309 nm for HBP 5-1 and and 
loss of this peak following reaction with an excess of PFP-ACVA (HBP5-2) 
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Figure 5-18. Assigned 
19
F NMR spectrum for HBP 5-2 showing attached PFP peaks (DMSO-d6) 
Synthesis of heterobifunctional N3-OEG4-COO-PFP (5-5) linker for CuAAC 
conjugation   
 
Figure 5-19. Preparative HPLC profie for the purification of 5-3. (Gradient from 30 % to 80 % acetonitrile in water, Sunfire C-18 
OBD column) 
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Figure 5-20. 
1
H NMR spectrum of 5-3 prior to purification by LCMS (CDCl3) 
 
Figure 5-21. Assigned 
1
H NMR spectrum for 5-3 (CDCl3) 
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Figure 5-22. Assigned 
13
C NMR spectrum for 5-3 (CDCl3) 
 
 
Figure 5-23. Assigned 
1
H NMR spectrum for 5-3b (CDCl3) 
 144 
 
 
Figure 5-24. Assigned 
1
H NMR spectrum for 5-4 (CDCl3) 
 
Figure 5-25. Assigned 
13
C NMR spectrum for 5-4 (CDCl3) 
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Figure 5-26. Assigned 
1
H NMR spectrum for 5-5. (CDCl3) 
 
Figure 5-27. Assigned 
13
C NMR spectrum for 5-5 (CDCl3) 
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Figure 5-28. Assigned 
19
F NMR spectrum for 5-5. (CDCl3) 
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Synthesis of heterobifunctional N3-OEG4-Gly3 linker for sortase conjugation 
(5-10) 
 
Figure 5-29. Assigned 
1
H NMR spectrum for 5-6. (CDCl3) 
 
Figure 5-30. 
1
H-
1
H COSY NMR spectrum of 5-6, highlighting the correlation between the terminal methylene of the OEG linker 
(3.42 ppm) and the newly formed amide bond (6.8 ppm). (CDCl3) 
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Figure 5-31. Assigned 
1
H NMR spectrum for 5-7. (CDCl3) 
 
Figure 5-32. 
1
H NMR spectra of a) 5-7 and b) 5-6. Removal of the N-Boc protecting group by TFA was confirmed by loss of t-Bu 
methyl peak at 1.4 ppm in a) and shift of amide peaks 3 (5.5 ppm) and 7 (6.8 ppm) in b) to peaks 1 (8.0 ppm) and 4 (8.4 ppm) b). 
(CDCl3) 
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Figure 5-33. Assigned 
1
H NMR spectrum for 5-8. (DMSO-d6) 
 
Figure 5-34. Assigned 
1
H NMR spectrum for 5-10. (Star marks peaks for DCU impurity) (DMSO-d6) 
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Figure 5-35. Assigned 
13
C NMR spectrum for 5-10. (Star marks peaks for DCU impurity). (DMSO-d6) 
5.7.3. Summary of experimental conditions for preliminary CuAAC conjugation 
reactions. 
A range of experimental conditions have been attempted for CuAAC conjugation of the 
hyperbranched polymer molecular imaging agent (HBP 5-3) and the azide functionalised EGFR scFv 
(5-12). In this supplementary section, these conditions have been summarised and tabulated by 
experimental generation. The rationale behind the changes in conditions for each set of 
experiments was summarised in Experimental Section 5.3.6. . As has been discussed in the 
discussion section, none of these conditions yielded HBP-scFv conjugates. 
  
 151 
 
 
Table 2. Summary of experimental conditions for first set of CuAAC conjugation reactions between HBP5-3 and 5-12 
Experiment 1 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 16.5 μM 1250 μM 250 μM 310 μM 
  
CuAAC-1 
Equivalents 1 1.1 2.5 0.5 0.5 
 4 C Volume (μL) 10.8 200.0 5.8 5.8 4.7 16.3 
[Final] (μM) 12 13 30 6 6 
 
CuAAC-2 
Equivalents 1 1.1 5 1 1 
 4 C Volume (μL) 10.8 200.0 11.6 11.6 9.4 
 [Final] (μM) 12 13 60 12 12 
 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 16.5 μM 12.5 mM 2.5 mM 3.1 mM 
  
CuAAC-3 
Equivalents 1 1.1 12.5 2.5 2.5 
 4 C Volume (μL) 10.8 200.0 2.9 2.9 2.3 24.5 
[Final] (μM) 12 13 149 30 30 
 
CuAAC-4 
Equivalents 1 1.1 50 10 10 
 4 C Volume (μL) 10.8 200.0 11.6 11.6 9.4 
 [Final] (μM) 12 13 598 120 120 
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Table 3. Summary of experimental conditions for second set of CuAAC conjugation reactions between HBP5-3 and 5-12. 
(Controls are highlighted in grey) 
Experiment 2 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 16.5 μM 1250 μM 250 μM 310 μM 
  
CuAAC-5 
Equivalents 1 1.1 2.5 0.5 0.5 
 37 C Volume (μL) 2.7 50.0 1.5 1.5 1.2 4.1 
[Final] (μM) 12 13 30 6 6 
 
CuAAC-6 
Equivalents 1 1.1 5 1 1 
 37 C Volume (μL) 2.7 50.0 2.9 2.9 2.3 
 [Final] (μM) 12 13 60 12 12 
 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 16.5 μM 12.5 mM 2.5 mM 3.1 mM 
  
CuAAC-7 
Equivalents 1 1.1 12.5 2.5 2.5 
 37 C Volume (μL) 2.7 50.0 0.7 0.7 0.6 6.1 
[Final] (μM) 12 13 149 30 30 
 
CuAAC-8 
Equivalents 1 1.1 50 10 10 
 37 C Volume (μL) 2.7 50.0 2.9 2.9 2.3 
 [Final] (μM) 12 13 598 120 120 
 
CuAAC-9 
Equivalents 0 1.1 50 10 10 
 37 C Volume (μL) 0.0 50.0 2.9 2.9 2.3 2.7 
[Final] (μM) 0 13 597 119 119 
 
CuAAC-
10 
Equivalents 1 0 50 10 10 
 
37 C 
Volume (μL) 2.7 0.0 2.9 2.9 2.3 50.0 
Final concn 
(μM) 12 0 598 120 120 
 
CuAAC-
11 
[Final] (μM) 0 1.1 0 0 0 
 37 C Volume (μL) 0.0 10.0 0.0 0.0 0.0 2.6 
[Final] (μM) 0 13 0 0 0 
 
NRB42-
12 
Equivalents 1 0 0 0 0 
 37 C Volume (μL) 2.7 0.0 0.0 0.0 0.0 58.1 
[Final] (μM) 12 0 0 0 0 
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Table 4. Summary of experimental conditions for third set of CuAAC conjugation reactions between HBP5-3 and 5-12. (Controls 
are highlighted in grey) 
Experiment 3 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 48 μM 1250 μM 250 μM 310 μM 
  
CuAAC-13 
Equivalents 2 1 2.5 0.5 0.5 
 4 C Volume (μL) 3.6 10.0 1.0 1.0 0.8 10.8 
[Final] (μM) 36 18 44 9 9 
 
CuAAC-14 
Equivalents 2 1 12.5 2.5 2.5 
 4 C Volume (μL) 3.6 10.0 4.8 4.8 3.9 0.0 
[Final] (μM) 36 18 222 44 44 
 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 48 μM 12.5 mM 2.5 mM 3.1 mM 
  
CuAAC-15 
Equivalents 2 1 25 5 5 
 4 C Volume (μL) 3.6 10.0 1.0 1.0 0.8 10.8 
[Final] (μM) 36 18 444 89 89 
 
CuAAC-16 
Equivalents 2 1 50 10 10 
 4 C Volume (μL) 3.6 10.0 1.9 1.9 1.5 8.1 
[Final] (μM) 36 18 888 178 178 
 
CuAAC-17 
Equivalents 0 1 50 10 10 
 4 C Volume (μL) 0.0 10.0 1.9 1.9 1.5 11.6 
[Final] (μM) 0 18 888 178 178 
 
CuAAC-18 
Equivalents 2 0 50 10 10 
 4 C Volume (μL) 3.6 0.0 1.9 1.9 1.5 18.1 
[Final] (μM) 36 0 888 178 178 
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Table 5. Summary of experimental conditions for fourth set of CuAAC conjugation reactions between HBP5-3 and 5-12. (Controls 
are highlighted in grey) 
Experiment 4 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 48 μM 1250 μM 250 μM 310 μM 
  
CuAAC-19 
Equivalents 2 1 2.5 0.5 0.5 
 4 C Volume (μL) 1.8 5.0 0.5 0.5 0.4 5.4 
[Final] (μM) 36 18 44 9 9 
 
CuAAC-20 
Equivalents 2 1 12.5 2.5 2.5 
 4 C Volume (μL) 1.8 5.0 2.4 2.4 1.9 0.0 
[Final] (μM) 36 18 222 44 44 
 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 48 μM 12.5 mM 2.5 mM 3.1 mM 
  
CuAAC-21 
Equivalents 2 1 50 10 10 
 4 C Volume (μL) 1.8 5.0 1.0 1.0 0.8 4.0 
[Final] (μM) 36 18 888 178 178 
 
CuAAC-22 
Equivalents 0 1 50 10 10 
 4 C Volume (μL) 0.0 5.0 1.0 1.0 0.8 5.8 
[Final] (μM) 0 18 888 178 178 
 
CuAAC-23 
Equivalents 2 0 50 10 10 
 4 C Volume (μL) 1.8 0.0 1.0 1.0 0.8 9.0 
[Final] (μM) 36 0 888 178 178 
 
CuAAC-24 
Equivalents 2 1 0 0 0 
 4 C Volume (μL) 1.8 5.0 0.0 0.0 0.0 6.7 
[Final] (μM) 36 18 0 0 0 
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Table 6. Summary of experimental conditions for fifth set of CuAAC conjugation reactions between HBP5-3 and 5-12. (Controls 
CuAAC-22, CuAAC-23 and CuAAC-24 were used from experiment four and diluted to match the final concentration of protein.) 
Experiment 5 
  
HBP 5-3 EGFR 5-13 NaAsc (BimC4A)3 CuSO4 Water Temperature 
  
270 μM 18 μM 50 mM 20 mM 3.1 mM 
  
CuAAC-25 
Equivalents 10 1 
 
50 10 
 37 C Volume (μL) 9 11.5 3.1 0.6 0.8 5.9 
[Final] (μM) 80 8 5000 387 77 
 
CuAAC-26 
Equivalents 10 1 
 
160 32 
 37 C Volume (μL) 9 11.5 3.1 1.9 2.5 2.9 
[Final] (μM) 80 8 5000 1250 250 
 
CuAAC-27 
Equivalents 10 1 
 
260 52 
 37 C Volume (μL) 9 11.5 3.1 3.1 4.0 0.2 
[Final] (μM) 80 8 5000 2000 400 
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5.7.4. Summary of experimental conditions for preliminary sortase conjugation 
reactions. 
Table 7. Summary of experimental conditions used for first set of sortase conjugation reactions. (Control samples, table 
continues on page 154)  
 
Sortase 
EGFR 
scFv 
TAMRA-GGG HBP 5-4 
FITC-OEG-
GGG (5-11) 
10X Sortase 
Buffer 
TBS 
 
Concentration 
(μM) 10 14 200 540 200 
  
Srt-1 
Ratio 1 0 0 0 0 
  Moles 2E-11 
      Volume (μL) 2 
    
2 16 
Srt-2 
Ratio 1 4.2 0 0 0 
  Moles 2E-11 8.4E-11 
     Volume (μL) 2 6 
   
2 10 
Srt-3 
Ratio 1 0 0 67.5 0 
  Moles 2E-11 
  
1.35E-09 
   Volume (μL) 2 
  
2.5 
 
2 13.5 
Srt-4 
Ratio 1 0 80 0 0 
  Moles 2E-11 
 
1.6E-09 
    Volume (μL) 2 
 
8 
  
2 8 
Srt-5 
Ratio 1 
   
80 
  Moles 2E-11 
   
1.6E-09 
  Volume (μL) 2 
   
8 2 8 
Srt-6 
Ratio 
 
4.2 
 
67.5 
   Moles 
 
8.4E-11 
 
1.35E-09 
   Volume (μL) 
 
6 
 
2.5 
 
2 9.5 
Srt-7 
Ratio 
 
4.2 80 
    Moles 
 
8.4E-11 1.6E-09 
    Volume (μL) 
 
6 8 
  
2 4 
Srt-8 
Ratio 
 
4.2 
  
80 
  Moles 
 
8.4E-11 
  
8E-10 
  Volume (μL) 
 
6 
  
4 2 8 
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Table 8. Summary of experimental conditions used for first set of sortase conjugation reactions. (Positive reaction samples, table 
continued from page 153)  
 
 
Sortase 
EGFR 
scFv 
TAMRA-GGG HBP 5-4 
FITC-OEG-
GGG (5-11) 
10X Sortase 
Buffer 
TBS 
 
Concentration 
(μM) 
10 14 200 540 200 
  
Srt-9 
Ratio 1 4.2 
 
67.5 
   
Moles 2E-11 8.4E-11 
 
1.35E-09 
   
Volume 2 6 
 
2.5 
 
2 7.5 
Srt-10 
Ratio 1 4.2 80 0 0 
  
Moles 2E-11 8.4E-11 1.6E-09 
    
Volume 2 6 8 
  
2 2 
Srt-11 
Ratio 1 4.2 0 0 80 
  
Moles 2E-11 8.4E-11 
  
1.6E-09 
  
Volume 2 6 
  
8 2 2 
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Table 9. Summary of experimental conditions for second set of sortase reactions, with increased sortase enzyme concentration. 
The molar ratio of oligoglycine bearing hyperbranched polymer (HBP 5-4) to LPETG-EGFR scFv was also varied. 
  
Sortase 
EGFR 
scFv 
HBP 5-4 HBP 5-4 
10X 
Sortase 
Buffer 
TBS 
 
Concentation (μM) 100 14 540 77 
  
Srt-12 
Ratio 2.4 1.0 
    
Moles 2.00E-10 8.40E-11 
    
Volume (μL) 2 6 
  
2 10 
Srt-13 
Ratio 2.4 1.0 8.0 
   
Moles 2.00E-10 8.40E-11 6.75E-10 
   
Volume (μL) 2 6 1.25 
 
2 8.75 
Srt-14 
Ratio 2.4 1.0 
 
2.3 
  
Moles 2.00E-10 8.40E-11 
 
1.93E-10 
  
Volume (μL) 2 6 
 
2.5 2 7.5 
Srt-15 
Ratio 2.4 1.0 
 
1.1 
  
Moles 2.00E-10 8.40E-11 
 
9.63E-11 
  
Volume (μL) 2 6 
 
1.25 2 8.75 
Srt-16 
Ratio 2.4 1.0 8.0 
   
Moles 2.00E-10 8.40E-11 6.75E-10 
   
Volume 2 6 1.25 
 
2 8.75 
Srt-17 
Ratio 2.4 1.0 
 
2.3 
  
Moles 2.00E-10 8.40E-11 
 
1.93E-10 
  
Volume 2 6 
 
2.5 2 7.5 
Srt-18 
Ratio 2.4 1.0 
 
1.1 
  
Moles 2.00E-10 8.40E-11 
 
9.63E-11 
  
Volume (μL) 2 6 
 
1.25 2 8.75 
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Chapter 6. Conclusions  
This PhD project has expanded the knowledge in various aspects required for designing polymeric 
materials as multimodal molecular imaging agents and their use in vivo. This knowledge is 
intended to aid in development of polymeric materials as theranostics. Specifically, this thesis 
aimed to synthesise biocompatible hyperbranched polymers with controlled size and architecture 
and to chemically modify these materials to introduce the desired imaging moieties. 
Hyperbranched polymers were selected as the nanomaterial platform due to the high density of 
functional end groups available for attachment of imaging and targeting molecules, as well as their 
unique physicochemical properties that can be modified to impart favourable responses to 
biological systems. Once these imaging agents were synthesised, the second aim of this thesis was 
to use molecular imaging techniques to better understand the relationship between the 
physicochemical properties of the hyperbranched polymers and their performance in vivo. In 
particular, a primary aim was to visualise the biodistribution and pharmacokinetics of these 
materials in mouse models for cancer. In order to achieve these overarching goals, three specific 
objectives were outlined in Chapter 1. 
Objective 1: To design and synthesise hyperbranched polymers, for use as 
multimodal molecular imaging agents. 
The synthesis of hyperbranched polymers with controlled size and architecture from 
biocompatible polyethylene glycol based monomers was first demonstrated in Chapter 3. It was 
shown through in depth chemical characterisation that RAFT polymerisation exerted control over 
the polymerisation kinetics and provided soluble hyperbranched polymers. The reaction 
conditions were controlled to produce two hyperbranched polymers with significantly different 
hydrodynamic diameters and number of branches. The trithiocarbonate RAFT agent used 
throughout this thesis possessed an R-group with terminal alkyne functionality, which provided 
hyperbranched polymers with multiple terminal alkyne groups at the α-chain ends and 
trithiocarbonate functional groups at the ω-chain ends. The synthesised hyperbranched polymers 
provided the necessary framework for building multimodal molecular imaging agents in this thesis. 
 In order to incorporate the desired imaging moieties, this thesis has explored a range of 
different approaches for the chemical modification of the polymer end groups. Far-red 
fluorophores, near-infrared fluorophores and chelators of radioisotopes were incorporated to 
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allow for in vivo fluorescence and PET imaging. The first approach described in Chapter 3 was to 
modify the alkyne end groups with a heterobifunctional OEG linker, which possessed an azide and 
primary amine on either end group. Following formation of the triazole via Huisgen-type click 
chemistry, hyperbranched polymers with terminal amine groups resulted, which upon reaction 
with NHS-activated ester fluorophores or isothiocyanate bearing chelators yielded multimodal 
molecular imaging agents.  
  A different approach was utilised in Chapter 5 to provide ω-labelled hyperbranched 
polymers. This approach used a radical initiator to replace the trithiocarbonate end groups with 
PFP-activated esters. These groups were then able to react with amine bearing imaging probes to 
once again yield multimodal molecular imaging agents. This approach provided hetero-telechelic 
polymers with the imaging molecules attached to the ω-chain end, and an alkyne on the α-chain 
end, ready for targeting molecule conjugation. This provided a greater number of functional end 
groups compared to the previous strategy, where all the imaging molecules and the targeting 
ligand were no longer confined to the same α- chain end. 
Objective 2: To study the properties of hyperbranched polymers, in vivo, utilising 
the complimentary information provided by multimodal molecular imaging 
techniques  
In Chapter 3, molecular imaging techniques were used to visualise the differences in 
pharmacokinetics of the two hyperbranched polymers that were synthesised. It was shown that 
the larger, more highly branched material was retained longer within the mouse. The smaller 
material underwent very rapid clearance over the first 24 hours. Due to the long circulation time 
of the larger hyperbranched polymer, its ability to accumulate within a melanoma tumour through 
the EPR effect was then explored. It was shown using both PET and fluorescence imaging that the 
material was able to accumulate within the cancerous tissue, and was retained for at least 72 
hours.  
 The next step to progress the development of these imaging molecules into theranostics was 
to include targeting moieties, to provide disease specificity. The first generation of these targeted 
materials were reported in Chapter 4, where folic acid was attached to a hyperbranched polymer 
functionalised with a PET ligand. The distribution of these materials within the targeted melanoma 
tumour was then investigated using PET-CT and PET-MRI. Through the use of PET-MRI it was 
shown that the distribution of these nanomaterials was heterogeneous across the tumour tissue, 
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with the highest concentration being localised to areas of high vascularity. Areas of the tumour 
that were not well vascularised contained significantly lower concentrations of the material. This 
has important implications for the use of these materials for the delivery of therapeutics. This 
heterogeneity in accumulation can lead to areas of the tumour not being treated effectively, 
which can lead to disease relapse and increased resistance to therapy. This was the first time that 
whole animal imaging techniques have been used to demonstrate this phenomenon in a live 
animal. 
Objective 3: To develop novel strategies for conjugation of polymeric molecular 
imaging agents and biomolecules for use as targeted systems. 
To further develop the hyperbranched polymers into theranostics, it was necessary to be able to 
incorporate highly specific targeting molecules into the nanomaterial. ScFvs were identified as one 
class of targeting molecule that could be used to achieve this goal. In Chapter 5 two different 
approaches for the conjugation of scFvs to the hyperbranched polymers was investigated: copper 
catalysed Huigsen 1,3-dipolar cycloadditions and enzyme catalysed cross coupling by the sortase 
enzyme. While successful conjugation between the hyperbranched polymers and scFvs was not 
achieved in this thesis, a number of key developments were made and significant insight into the 
potential use of these methodologies was achieved.  
 Firstly, two OEG linkers were designed, synthesised and characterised, which provide the 
necessary chemical functionality for these two conjugation strategies. Both linkers possessed α-
azide groups as demonstrated by NMR spectroscopy allowing attachment to the alkyne end 
groups of the hyperbranched polymers. For CuAAC conjugation, the OEG linker possessed an ω-
PFP ester for reaction to the pendant primary amine group that was engineered into the scFv. 
Through the use of MALDI-TOF characterisation, it was shown that the scFv could be readily 
modified with this linker, to provide the desired azide functionality.  
 The second OEG linker possessed an ω-triglycine oligopeptide. By attaching this linker to the 
hyperbranched polymer with CuAAC conjugation, it provided a hyperbranched polymer that could 
be recognised by the sortase enzyme. To validate the coupling mechanism, this linker was also 
attached to a fluorophore, which through SDS-PAGE and FACS analysis demonstrated that this 
linker could undergo sortase mediated conjugation to a scFv. However, no conjugation was 
achieved with the polymer, presumably due to steric effects which inhibited enzyme coupling. 
Further optimisation of reaction conditions is anticipated to yield polymer-scFv conjugates for 
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both strategies. With optimisation it is anticipated that OEG linkers synthesised in this thesis can 
be used for the conjugation of a wide range of biomolecules (eg. scFvs, antibodies, peptides or 
aptamers) to hyperbranched polymers to provide targeted molecular imaging agents for a wide 
range of diseases. It is also believed that these linkers can be used more generally, to conjugate 
biomolecules to a wide range of polymer and nanoparticle substrates, for other advanced material 
applications outside of molecular imaging.  
Summary  
This thesis has explored aspects of design, synthesis and characterisation of hyperbranched 
polymers as novel multimodal molecular imaging agents. A range of synthetic strategies have been 
combined for the production of hyperbranched polymers with controlled architecture, and for the 
incorporation of imaging moieties and targeting molecules. The imaging agents synthesised in this 
thesis have been used to gain a better understanding of the behaviour of these hyperbranched 
polymer materials in vivo. All of these insights will greatly progress the development of these 
materials into nanomedicines. After optimisation of conjugation of scFv targeting ligands has been 
achieved, the next stage in the development process is to look at ways to incorporate therapeutic 
agents into these materials, to generate a true theranostic. This could be achieved by chemical 
incorporation of pharmaceuticals, peptides, oligonucleotides or proteins, or by chelation of 
therapeutic radioisotopes as well as imaging isotopes. This thesis has combined the synthesis of 
novel theranostic agents through the use of macromolecular chemistry, alongside the preclinical 
evaluation of these new materials via molecular imaging. It is believed that the information gained 
from this unique approach will lead to improved development of the next generation of 
theranostics. 
 
 
